Characterization of the Casz1-Dependent Mechanisms Essential for Cardiomyocyte Development by Dorr, Kerry
 
 
CHARACTERIZATION OF THE CASZ1-DEPENDENT MECHANISMS ESSENTIAL 
FOR CARDIOMYOCYTE DEVELOPMENT 
Kerry M. Dorr 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill 
in partial fulfillment of the requirements for the degree of Doctor of Philosophy in 
Genetics and Molecular Biology in the School of Medicine. 
Chapel Hill 
2015  
 Approved by: 
 Frank Conlon 
 Terry Magnuson 
 Li Qian 
 Joan Taylor 
 Andy Wessels 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 
Kerry M. Dorr 
ALL RIGHTS RESERVED 
iii 
 
ABSTRACT 
Kerry M. Dorr: Characterization of the Casz1-Dependent Mechanisms 
Essential for Cardiomyocyte Development 
(Under the direction of Frank L. Conlon) 
 
The heart is one of the first structures to form during development and is required 
for embryonic growth and survival. The four-chambered mammalian heart arises from a 
series of complex processes during embryonic development that includes the 
specification and differentiation of the different cardiac cell types within the heart, 
proliferation, and morphological movements of the early heart fields. Early development 
of the heart is governed by hyperplastic growth in which cardiac cells undergo mitogen-
dependent activation during the G1-phase of the cell cycle. Though numerous growth 
factor signals have been shown to be required for cardiomyocyte proliferation, genetic 
studies have only identified a limited number of transcription factors that act to regulate 
the entry of cardiomyocytes into S-phase. Casz1 is an evolutionarily conserved 
transcription factor that is essential for heart development; however, there are vast 
deficiencies in our understanding of the mechanism by which Casz1 regulates aspects 
of cardiac development. 
Here we report that Casz1 is expressed in, and gives rise to, cardiomyocytes in 
the first and second heart fields. We show through the generation of a cardiac 
conditional null mutation that Casz1 is required for the proper development and growth 
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of the cardiac chambers. We further demonstrate that Casz1 is essential for the 
proliferation of cardiomyocytes in both heart fields and that loss of Casz1 leads to 
severe cardiac hypoplasia, ventricular septal defects, and a decrease in cardiomyocyte 
cell number. Additionally, we report that the loss of Casz1 leads to a prolonged or 
arrested S-phase, a decrease in DNA synthesis, an increase in phosphorylated-Rb, and 
a concomitant decrease in the cardiac mitotic index. Taken together these studies 
establish a role for Casz1 in mammalian heart development and cardiomyocyte cell 
cycle progression.
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Chapter 1: Introduction 
 
The heart is one of the first structures to form during development, and heart 
precursor cells are among the first cells of the epiblast to undergo gastrulation (Lawson 
et al., 1991; DeRuiter et al., 1992; Parameswaran and Tam, 1995; Tam et al., 1997; 
Saga et al., 1999; Saga et al., 2000; Buckingham et al., 2005; Devine et al., 2014; 
Lescroart et al., 2014). In murine development, following ingression in the early to mid-
primitive streak stages, mesodermal heart precursor cells begin to migrate 
anterolaterally as a sheet, and by the late primitive streak stages, they are localized as 
identifiable bilateral fields that lie on either side of the ventral midline forming a structure 
known as the cardiac crescent (Parameswaran and Tam, 1995; Tam et al., 1997; Saga 
et al., 2000; Shenje et al., 2014). Heart precursor cells that form the cardiac crescent 
are derived from two mesodermal populations: termed a first heart field (FHF) and a 
second heart field (SHF). Cardiac precursors of the first heart field undergo 
differentiation and assemble into a primitive heart tube by embryonic day 8.5 (E8.5) 
(Tam et al., 1997; Saga et al., 1999; Meilhac et al., 2004; Buckingham et al., 2005; 
Tzouanacou et al., 2009; Devine et al., 2014; Lescroart et al., 2014). This tube is 
lengthened by the addition of newly differentiated myocardium derived from the SHF, 
giving rise to the arterial and venous poles (Kelly et al., 2001; Mjaatvedt et al., 2001; 
Waldo et al., 2001; Cai et al., 2003; Meilhac et al., 2003; Meilhac et al., 2004; Zaffran et 
al., 2004; Buckingham et al., 2005; Tzouanacou et al., 2009).  
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During the early stages of heart development, cardiomyocytes of the FHF and 
SHF are highly proliferative, resulting in substantial growth of the embryonic heart (Tam 
et al., 1997; Buckingham et al., 2005; Tzouanacou et al., 2009; van den Berg et al., 
2009; Dominguez et al., 2012; Meilhac et al., 2014). In both rodents and humans, the 
overall rate of cardiomyocyte proliferation gradually declines concomitant with the onset 
of terminal cardiomyocyte differentiation (Soonpaa et al., 1996; Christoffels et al., 2000; 
Pasumarthi and Field, 2002; Sedmera et al., 2003; Toyoda et al., 2003; Walsh et al., 
2010; Ikenishi et al., 2012). After this period, the mammalian heart continues to grow, 
largely through hypertrophy and recruitment of cells from extra-cardiac sources 
including the neural crest and epicardium (Viragh and Challice, 1981; Gorza et al., 
1988; Kirby, 1990; Kirby and Waldo, 1995; Li et al., 1996; Creazzo et al., 1998; Manner 
et al., 2001; Brown and Baldwin, 2006; Ahuja et al., 2007; Winter and Gittenberger-de 
Groot, 2007; Zhou and Pu, 2008; van Wijk et al., 2009; Kelly, 2012; Maillet et al., 2013). 
All animal life is dependent upon the sustained function of the heart. It is 
therefore not surprising that genetic and acquired cardiac diseases can result in 
devastating consequences with congenital heart defects representing the number one 
type of human birth defect, and cardiovascular disease accounting for the most 
common cause of adult death worldwide (Hoffman, 1995; Hoffman and Kaplan, 2002; 
Lopez et al., 2006; Heron et al., 2009; Dolk et al., 2010a; Dolk et al., 2010b; van der 
Linde et al., 2011; Fahed et al., 2013; Pediatric Cardiac Genomics et al., 2013). The 
mammalian heart has limited regenerative potential, which is in stark contrast to the fish 
or amphibian heart, which retains robust capacities for regeneration via the activation of 
cardiomyocyte proliferation (Oberpriller and Oberpriller, 1974; Poss et al., 2002; Laube 
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et al., 2006; Jopling et al., 2010; Kikuchi et al., 2010; Jopling et al., 2012; Piatkowski et 
al., 2013). Cardiomyocyte loss is the causal etiology of many forms of heart disease; 
therefore, strategies aimed at repopulating the damaged heart with replacement 
cardiomyocytes could potentially restore cardiac structure and more importantly, cardiac 
function.   
 
The cardiomyocyte cell cycle 
The eukaryotic cell cycle consists of four coordinated processes that include cell 
growth, DNA replication, distribution of duplicated chromosomes into daughter cells, 
and cell division. The cycle of most eukaryotic cells is composed of four distinct phases: 
S-phase, where DNA synthesis occurs; M-phase, where karyokinesis and cytokinesis 
occur; and G1-phase and G2-phases, where cells continue to grow and prepare for entry 
into their respective, subsequent phase. The central core of the cell cycle machinery 
comprises the cyclin-dependent kinases (Cdks) and cyclins. In most eukaryotes, there 
are different Cdks that control different stages of the cell cycle. Cdks are activated via 
complex formation with phase-specific cyclins, leading to changes in the 
phosphorylation of intracellular proteins that both regulate cell cycle events and 
advance the cell cycle through the stage that the particular Cdk controls (Mitchison, 
1971; Baserga, 1985; Murray and Hunt, 1993; Sherr, 1993; Morgan, 1997; Pavletich, 
1999; Nurse, 2000; Hochegger et al., 2008; Lim and Kaldis, 2013; Alberts, 2015). Cdk 
activity is terminated by either cyclin protein degradation or by Cdk inhibitors, such as 
INK family members (p15, p16, p18 and p19) and Cip/Kip family members (p21, p27 
and p57) (Serrano et al., 1993; Guan et al., 1994; Hannon and Beach, 1994; Polyak et 
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al., 1994; Roberts et al., 1994; Chan et al., 1995; Hirai et al., 1995; Russo et al., 1996; 
Brotherton et al., 1998; Russo et al., 1998; Pavletich, 1999; Sherr and Roberts, 1999; 
Lim and Kaldis, 2013). Cyclin protein synthesis and degradation determine the timing of 
the activation of the cyclin’s partner Cdk. The Cdks are critical for cell cycle progression 
because their inactivation prevents mitosis (Figure 1.1) (Devault et al., 1991; van den 
Heuvel and Harlow, 1993; Morgan, 1997; Nurse, 2000; Lim and Kaldis, 2013; Alberts, 
2015). There are four classes of cyclins that are defined by the cell cycle stage during 
which they complex with Cdks: G1-cyclins, which promote passage through the start of 
the cell cycle; G1/S-cyclins, which commit the cell to DNA replication; S-cyclins, which 
initiate DNA replication; and M-cyclins, which promote mitosis (Sherr, 1993; Morgan, 
1997; Hochegger et al., 2008; Alberts, 2015). 
Cell cycle activity is an essential component of cardiac differentiation and 
morphogenesis. Detailed analyses of cyclins and Cdks have revealed dramatic changes 
in cell cycle patterns during embryonic and postnatal stages of cardiac development. 
Positive cell cycle regulators are highly expressed in the embryonic heart and 
downregulated in the adult heart while cell cycle inhibitors show the opposite expression 
pattern (Soonpaa and Field, 1998; Pasumarthi and Field, 2002; Goetz et al., 2006; 
Ahuja et al., 2007; Walsh et al., 2010; Ikenishi et al., 2012).  Protein expression 
analyses by western blot for cyclin E, cyclin A, cyclin D1, and cyclin B1 in heart 
ventricles demonstrate a synchronous change in expression during embryonic and 
postnatal stages. Cyclin levels are high during early embryonic stages (E12) and 
gradually decrease as embryogenesis proceeds with minimal levels detected at birth. 
Interestingly, a surge in expression occurs at postnatal day 5 (P5), followed by a rapid 
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decline, and cyclins are undetectable in adult ventricles. Concomitant with these data, 
western blot analyses of the cyclin E-Cdk2, cyclin A-Cdk1/2, and cyclin B1-Cdk1 
complexes also demonstrated a similar synchronous pattern with high levels present in 
early embryogenesis (E12), followed by a gradual decline, a surge at P5, and a rapid 
decline to undetectable levels in adult ventricles (Ikenishi et al., 2012). Terminally 
differentiated cardiomyocytes show repression of cell cycle activators such as the 
Cyclin/Cdk complexes (described above), Myc, and E2F transcription factors. 
Conversely, negative cell cycle regulators such as INK4, p21, p27, retinoblastoma 
protein (Rb), and cyclin-dependent kinase inhibitors are increased (Table 1.1) (Kim et 
al., 1994; Flink et al., 1998; Li et al., 1998; Pasumarthi and Field, 2002).  
 
Cardiomyocyte cell cycle control and growth 
Mammalian cardiomyocytes exhibit three developmentally determined forms of 
cell cycle control and growth: proliferation, binucleation and hypertrophy. During 
embryonic development, the heart primarily grows via hyperplasia or cell proliferation, 
which is defined as an increase in cell number by cell division. Shortly after birth, 
proliferation ceases and cardiomyocytes undergo cell-cycle withdrawal, following an 
additional round of DNA synthesis and mitosis without cytokinesis, which leads to the 
formation of binucleated cardiomyocytes. The postnatal heart primarily grows via 
hypertrophy, or an increase in cell size (Figure 1.2) (Erokhnia, 1968a; Erokhnia, 1968b; 
Dowell and McManus, 1978; Clubb and Bishop, 1984; Oparil et al., 1984; Goldspink et 
al., 1986; Li et al., 1996; Soonpaa et al., 1996; Bergmann et al., 2009; Walsh et al., 
2010; Maillet et al., 2013). The transition from hyperplastic to hypertrophic growth is 
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required for normal heart morphogenesis and determines the appropriate heart size 
necessary for pumping a large volume of blood.  
Proliferation 
Tritiated thymidine analyses (Erokhnia, 1968a; Erokhnia, 1968b) that measure 
DNA synthesis demonstrate that cardiomyocyte proliferation is high during early murine 
embryogenesis at E8, with labeling indices of approximately 70% of precardiac 
mesodermal cells. These levels start to decrease around E10-12, with labeling indices 
plunging to 45%. This decrease is concomitant with the onset of cardiomyocyte 
differentiation (Erokhnia, 1968a; Erokhnia, 1968b). As embryogenesis proceeds, 
cardiomyocyte proliferation gradually declines (Erokhnia, 1968a; Erokhnia, 1968b; 
Soonpaa et al., 1996; Toyoda et al., 2003; Walsh et al., 2010; Zeng et al., 2014). 
Fluorescence-activated cell sorting (FACS) analyses of purified populations of E14 
cardiomyocytes treated with  5’-bromo-2’-deoxyuridine (BrdU) revealed cardiomyocyte 
DNA synthesis levels of 22.95% (Walsh et al., 2010). This work is further supported by 
5-ethynyl-2’deoxyuridine (EdU) analyses, an alternative thymidine analog, of sectioned 
cardiac tissue at E10, E17, P7, P21 and in the adult, demonstrating a decrease in 
cardiomyocyte proliferation as embryogenesis proceeds, with no EdU incorporation 
observed after P21 (Zeng et al., 2014).  
The proliferative capacity of adult cardiomyocytes is quite limited; the frequency 
and source of new cardiac cells is somewhat controversial, as different labs have 
reported dissimilar results, most likely due to differences in experimental techniques and 
analyses (Li et al., 1996; Soonpaa et al., 1996; Soonpaa and Field, 1997; Soonpaa and 
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Field, 1998; Bergmann et al., 2009; Walsh et al., 2010; Mollova et al., 2013; Senyo et 
al., 2013; Ali et al., 2014; Naqvi et al., 2014). Tritiated thymidine analyses of α-cardiac 
myosin heavy chain-positive ventricular myocardium revealed DNA synthesis levels of 
0.0006% in wild-type 12 week-old adult murine cardiomyocytes (Soonpaa and Field, 
1997). Additionally, DNA synthesis levels increased to 0.0083% in 12 week old mice 
subjected to a myocardial injury, in which the myocardium was cauterized midway 
between the apex and base of the heart (Soonpaa and Field, 1997).  FACS analysis of 
cardiomyocyte populations treated with BrdU revealed DNA synthesis levels of 9.6% for 
P3 neonates, which dropped to 0.94% by P7, 0.02% at P14, and was undetectable by 3 
weeks of age (Walsh et al., 2010). More recently, using genetic fate-mapping with 
stable isotope labeling and multi-isotope imaging mass spectrometry (MIMS), it was 
shown that cardiomyocytes proliferate at a low rate by the division of pre-existing 
cardiomyocytes during normal aging. This process increases 4-fold in areas adjacent to 
myocardial injury (Senyo et al., 2013). MIMS is a technique that utilizes a rare stable 
isotope of nitrogen (15N) and allows for high-resolution quantitation (Steinhauser et al., 
2012). Treatment with 15N-thymidine for 8 weeks at three different timepoints beginning 
at P4 (neonates), and in 10 week (young adult) and 22 month-old (old adult) adults 
followed by MIMS analysis revealed dramatic changes in DNA synthesis throughout 
aging (Senyo et al., 2013). The percentage of 15N-labeled cardiomyocytes per day in the 
neonatal heart was 1.00%; percentages in the young adult heart were 0.015% and 
0.007% in the old adult heart (Senyo et al., 2013). In line with these observations, 
recent mouse studies revealed that mammals possess the ability to regenerate heart 
tissue immediately after birth (by P2), but lose this ability by P7 (Porrello et al., 2011). 
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Interestingly, a recent mouse study confirmed the previously identified postnatal time 
window during which cardiomyocyte cell numbers increased during P1-4, and 
suggested the existence of a second tight, transient, proliferative time window at P15, 
leading to a 40% increase in predominantly binucleated cardiomyocytes (Naqvi et al., 
2014). 
In humans, cardiomyocyte proliferation can be observed until 20 years of age, 
which is much longer than anticipated, based on the data detailed above for mice and 
rats. Of particular significance and in contrast with mice, myocardial growth in humans 
occurs through the simultaneous cycles of cardiomyocyte proliferation and cell 
enlargement. However, similar to mice, cardiomyocyte cycling and division decreases 
with age (Li et al., 1996; Soonpaa and Field, 1997; Soonpaa and Field, 1998; Bergmann 
et al., 2009; Mollova et al., 2013). A novel 14C-based, birth-dating technique, which can 
establish the age of cardiomyocytes based on the integration of 14C into human DNA, 
demonstrated that cardiomyocytes renew with an annual turnover rate of 1.9% for a 19 
year-old individual, decreasing to 1% between the ages of 21 and 40 years, with levels 
decreasing to 0.45% by 75 years of age (Bergmann et al., 2009). A more recent study 
supporting these results utilized a combined approach that first determined the 
percentage of cardiomyocytes in M-phase by laser-scanning cytometry (LSC) of 
myocardial sections that stained positive for phosphorylated histone H3 (pHH3), an M-
phase marker, followed by a stereological quantification technique to quantify the 
number of cardiomyocytes present in the myocardium. LSC is a highly sensitive, 
microscopy-based cytofluorometry method that measures fluorescence emitted from 
individual cells at several wavelength ranges (Pozarowski et al., 2006). The optical 
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dissection method is a stereological technique that obtains quantitative information 
about three-dimensional tissues from two-dimensional sections (Muhlfeld et al., 2010). 
This study identified 0.8–1.1 ͯ 109 newly generated cardiomyocytes during the first year 
of life; 0.9 ͯ 109 new cardiomyocytes during years 1–10; and 0.6 ͯ 109 new 
cardiomyocytes during years 10–20 (Mollova et al., 2013). Consistent with these data, 
morphometric analyses revealed that during physiological hypertrophy, the 
cardiomyocyte nuclear DNA content remains constant. However, as the heart grows in 
size and when the weight of the myocardium reaches approximately 210 grams, there 
appears to be a linear increase in the percentage of cardiomyocyte nuclear DNA 
content as cardiac mass increases. Because human hearts do not change nuclear 
number with hypertrophy, this observation indicates that new cardiomyocytes are 
generated during this period of growth (Adler, 1975; Adler and Costabel, 1975; Adler 
and Friedburg, 1986; Herget et al., 1997; Laflamme and Murry, 2011).  
Binucleation 
The cell cycle ends in the division of the cytoplasm by cytokinesis. In a typical 
cell, cytokinesis accompanies every round of mitosis. However, some cells undergo 
mitosis without cytokinesis, resulting in a multinucleated cell (Rappaport, 1996; Glotzer, 
1997; Field et al., 1999). This type of endoreduplication generally occurs in tissues with 
high metabolic activity and in cells that are terminally differentiated (MacAuley et al., 
1998; Larkins et al., 2001; Gonzalez et al., 2006; Zielke et al., 2013). In the heart, the 
transition from hyperplastic to hypertrophic growth is associated with the formation of 
binucleated cardiomyocytes (Oparil et al., 1984), resulting from incomplete cell division 
in which karyokinesis becomes uncoupled from cytokinesis. During the murine 
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embryonic burst of proliferation (E10–12), karyokinesis and cytokinesis are matched, 
resulting in cardiomyocyte proliferation. In contrast, during early neonatal stages (P4–6), 
karyokinesis occurs in the absence of cytokinesis, resulting in binucleation of 
cardiomyocytes (Li et al., 1996; Soonpaa et al., 1996; Li, F. et al., 1997b; Walsh et al., 
2010). In mice and rats, binucleation begins around P4; by 3 weeks of age, 85–90% of 
cardiomyocytes are binucleated with normal diploid DNA content in each nucleus 
(Clubb and Bishop, 1984; Li et al., 1996; Soonpaa et al., 1996; Porrello et al., 2011). In 
humans, these percentages range from 25–57% (Schmid and Pfitzer, 1985; Olivetti et 
al., 1996). Notably, humans do not display a transition to predominantly binucleated 
cardiomyocytes, maintaining relatively high levels (~64%) of mononucleated 
cardiomyocytes up to 20 years of life. However, cardiomyocyte cytokinesis ceases after 
this time point, resulting in mononucleated cells with tetraploid (4n) or higher DNA 
content (Adler and Costabel, 1975; Olivetti et al., 1996; Mollova et al., 2013).  
The mechanism by which binucleation occurs remains unclear. However, the 
actin-myosin contractile ring, the structure that generates the force necessary to 
separate the daughter cells after mitosis, forms during the binucleation process 
indicating that the molecules involved in later stages of cytokinesis are responsible for 
binucleation (Li, F. et al., 1997b; Miller, 2011). One possible explanation is that the 
presence and incomplete disassembly of myofibrils in the equator region where 
cleavage furrows normally form could physically impede cytokinesis (Li, F. et al., 
1997a). In muscle, for example, contractile myofibrils are organized into sarcomeres. 
Recent evidence suggests that during karyokinesis, the sarcomeric Z-disks and M-
bands disassemble in the midzone region. Interestingly, during cytokinesis, the 
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sarcomeric structure is absent, indicating that cardiomyocyte division involves 
sarcomeric disassembly (Figure 1.3) (Bersell et al., 2009). Interestingly, recent studies 
suggest that multinucleation could result from defects in the recruitment of the 
contractile ring protein, anillin (Straight et al., 2005; Smith et al., 2013). Anillin binds to 
myosin II heavy chain and helps to focus myosin at the contractile ring (Straight and 
Field, 2000). Depletion of anillin leads to disorganized contractility and cytokinesis 
failure (Field and Alberts, 1995; Straight et al., 2005; Smith et al., 2013).  
The physiological significance of possessing binucleated cells also remains to be 
elucidated. There are few examples of multinucleated cells in higher-level vertebrates; 
however, most examples of multinucleation occur in highly metabolically active cells 
such as osteoclasts, hepatocytes and muscle cells (Holtzer et al., 1957; Okazaki and 
Holtzer, 1966; Kahn and Simmons, 1975; Hall and Ralston, 1989; Manolagas and Jilka, 
1995; Rossi et al., 2000; Miyaoka et al., 2012). Multinucleated cells often occur in 
pathological conditions due to aberrant cell cycle control (Gillespie and Stevens, 1972; 
Most et al., 1997; Sagona and Stenmark, 2010; Weihua et al., 2011). It has been 
hypothesized that multinucleation is advantageous, generating twice the amount of RNA 
for greater protein synthesis. Indeed, transcriptional activity that influences specialized 
cellular functions has been implicated in other multinucleated cell types (Boissy et al., 
2002). Another advantage specific to muscle cells could be adaptation to the 
physiological process of contraction, which requires myofibrils to maintain their 
organization along their entire lengths. An increase in cross-sectional area could lead to 
an increase in the force of contraction (Ahuja et al., 2007).  
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Hypertrophy 
The size of an organ depends both on the number and size of the cells it 
contains. In mammals, nutritional status, growth factors, and hormones play important 
roles in the control of organ size (Conlon and Raff, 1999). The heart is an essential 
pump and its size is tightly regulated across species to ensure proper function. The 
heart must be large enough to generate a physiological cardiac output, but not so large 
as to block cardiac output, which is common in cardiomyopathies (Seidman, 2000; 
Seidman and Seidman, 2001; Heallen et al., 2011). During the postnatal period, the 
cardiomyocytes of both rodents and humans undergo a period of physiological growth, 
increasing in size by 30–40-fold (Adler and Costabel, 1975; Li et al., 1996). 
Between preadolescence (P10) and puberty (P35), mouse body weight (in 
grams) increases by 3.8-fold, whereas mouse heart weight (in milligrams) increases by 
3.5-fold. At the cellular level, cardiomyocyte length increases by 46 µm with little change 
in diameter. During this period of growth, the left ventricle increases in weight 3.47-fold, 
and cardiomyocyte volume increases 1.7-fold (Adler, 1975; Adler and Costabel, 1975; 
Laflamme and Murry, 2011; Naqvi et al., 2014). This interesting discrepancy, suggests 
that an increase in cardiomyocyte number also occurs during this time period (Naqvi et 
al., 2014). A similar trend is observed in humans, where the cellular volume of 
cardiomyocytes increases by 8.6-fold between birth and 20 years of age; this increase 
is concomitant with an increase in the number of cardiomyocytes (Mollova et al., 2013) 
as well as an increase in the number of non-cardiomyocytes including fibroblasts and 
endothelial cells (Adler and Costabel, 1975). Physiological hypertrophy is initiated by 
multiple signaling pathways including the vascular endothelial growth factor B (VEGFB) 
13 
 
and receptor (VEGFR1), insulin and insulin-like growth factor 1 (IGF1). These trigger 
intracellular signalling pathways that regulate protein synthesis, metabolism and energy 
production (Reiss et al., 1996; Bellomo et al., 2000; Karpanen et al., 2008; Bry et al., 
2010). Growth signals are controlled by ERK1/2, PI3K, AKT and mTOR complex 1 
(mTORC1), whereas AMP-activated protein kinase (AMPK) governs metabolic adaptive 
reprogramming (Maillet et al., 2013) (Bueno et al., 2000; Lips et al., 2004; Purcell et al., 
2007; Kehat and Molkentin, 2010; Kehat et al., 2011; Horman et al., 2012).    
One very important distinction with regard to hypertrophy is to highlight the 
difference between normal hypertrophy during heart growth and pathological 
hypertrophy. Cardiomyocytes increase in size in response to biomechanical stress, a 
process known as pathological hypertrophy (Seidman and Seidman, 2001). 
Pathological hypertrophy is functionally, mechanistically, and histologically distinguished 
from normal embryonic and postnatal myocardial growth by characteristic changes in 
cardiac myocyte shape and volume (Bishop, 1990; Dorn, 2007). In humans, 
hypertrophic cardiomyopathy (HCM) is a genetic condition caused by mutations in 
genes that encode sarcomeric proteins, including cardiac β-myosin heavy chain 
(MYH7), cardiac myosin-binding protein C (MYBPC3), cardiac troponin T (TNNT2), 
cardiac troponin I (TNNI3), essential myosin light chain (MYL3), regulatory myosin light 
chain (MYL2), α-tropomyosin (TPM1), cardiac actin (ACTC), and titin (Bettencourt-Dias 
et al.) (Poetter et al., 1996; Kimura et al., 1997; Mogensen et al., 1999; Satoh et al., 
1999). HCM often presents as sudden death during exertion in a formerly asymptomatic 
individual. Increased awareness and echocardiographic screening have improved 
detection and shown that HCM is more common than previously thought. At the cellular 
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level, the major features of HCM are cardiomyocyte and myofibrillar disarray, 
hypertrophy, and myocardial fibrosis. Genetic causes of HCM, which are autosomal 
dominant, are now estimated to account for at least 50% of sporadic childhood onset 
cases (Seidman, 2000; Seidman and Seidman, 2001; Morita et al., 2008). 
Consequently, the need for genetic screens for HCM could greatly impact human 
health.  
Adult onset pathological hypertrophy is also induced by acquired cardiac 
deficiencies such as hypertension, valvular disease, myocardial infarction (MI), and 
endocrine disorders. In these types of cardiac pathologies, chronic pressure overload 
results in concentric hypertrophy with a small, thick-walled left ventricle that is 
associated with significantly increased risk of heart failure and malignant arrhythmia 
(Grossman et al., 1975; Levy et al., 1990b; Levy et al., 1990a; Koren et al., 1991; Morita 
et al., 1996; Dorn et al., 2003; Frey et al., 2004; Heineke and Molkentin, 2006; Dorn, 
2007; van Berlo et al., 2013). Genes upregulated in adult onset pathological 
hypertrophy include brain natriuretic peptide, angiotensin-converting enzyme, the 
endothelin receptor, and the β-adrenergic receptor kinase (Iemitsu et al., 2001; Dorn 
and Force, 2005). In addition, studies have implicated the calcium–calcineurin–NFAT 
and protein kinase A pathways in regulating the pathological growth of the heart. Other 
examples of mediators of pathological cardiac hypertrophy are the p38 and c-Jun N-
terminal kinase (JNK) branches of the MAPK cascade. Sustained p38 or JNK activation 
in the heart leads to cardiomyopathy and heart failure (Heineke and Molkentin, 2006; 
Maillet et al., 2013; van Berlo et al., 2013).  
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Growth factors that regulate cardiomyocyte proliferation 
Cardiomyocytes from both FHF and SHF undergo hyperplastic growth in 
response to input from a large network of growth factor signaling pathways; such 
pathways integrate a suite of transcription factors and microRNAs (miRNAs), which are 
proposed to directly regulate the cardiac cell cycle (Lavine et al., 2005; Ahuja et al., 
2007; Bersell et al., 2009; Heallen et al., 2011; Porrello et al., 2011; Xin et al., 2011; 
Eulalio et al., 2012; von Gise et al., 2012; Wadugu and Kuhn, 2012; Xin et al., 2013). 
Many of these growth factors are secreted by the epicardium, an epithelial sheet of cells 
that forms over the heart, and several lines of evidence suggest that cardiomyocyte 
proliferation in the developing myocardium is influenced by these secreted factors 
(Rumyantsev, 1977; Chen et al., 2002; Sengbusch et al., 2002; Kang and Sucov, 2005; 
Sun et al., 2007; Sucov et al., 2009; Shen et al., 2015). Additionally, in cell culture, 
many mitogens have been shown to stimulate the proliferation of fetal cardiomyocytes 
(Figure 1.4) (Armstrong et al., 2000).   
Hippo pathway 
First identified in Drosophila melanogaster, the Hippo signaling pathway is a 
conserved regulator of organ size (Pan, 2010). Hippo signaling mediates contact 
inhibition of cell proliferation by cell to cell interactions that control tissue growth 
(Fagotto and Gumbiner, 1996; Zhao, B. et al., 2007; McClatchey and Yap, 2012). 
Genetic loss-of-function mutations of Hippo pathway members in Drosophila lead to 
tissue overgrowth, characterized by increased proliferation and decreased cell death 
(Wu et al., 2003; Wei et al., 2007). The mammalian core Hippo signaling components 
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include the Ste-20-like protein kinases Mst1 and Mst2, which form a complex with the 
WW-repeat scaffolding protein Salv that phosphorylates Lats1 and Lats2. These Lats 
kinases complex with Mob, which phosphorylates and inactivates Yap and Taz. Yap 
and Taz partner with transcription factors, such as Tead, to regulate gene expression 
(Chan et al., 2005; Callus et al., 2006; Dong et al., 2007; Zhao, B. et al., 2007; Lei et al., 
2008; Praskova et al., 2008; Pan, 2010).  
The conditional depletion of the Salv gene using Nkx2.5-Cre (Moses et al., 
2001), an early cardiac marker, leads to perinatal lethality due to heart enlargement 
(cardiomegaly) (Heallen et al., 2011). Furthermore, phenotypic analysis at E14.5 
revealed that cardiac expression of a Salv mutant caused expansion of trabecular and 
subcompact ventricular myocardial layers, thickened ventricular walls, and enlarged 
ventricular chambers, but showed no change in myocardial cell size (Heallen et al., 
2011). In addition, conditional mutants of Lats2 and Mst1/2 showed similar myocardial 
expansion phenotypes in the heart (Heallen et al., 2011). 
 Yap1 is a major target of the Hippo signaling pathway and is inactivated by 
Hippo kinase activity (Dong et al., 2007; Zhao, B. et al., 2007). Conditional depletion of 
the Yap1 gene in the embryonic heart, utilizing either the Tnnt2-Cre (Jiao et al., 2003) or 
the Nkx2.5-Cre driver (Moses et al., 2001), results in cardiac abnormalities and 
embryonic lethality by E16.5 due to myocardial hypoplasia (Xin et al., 2011; von Gise et 
al., 2012). Yap1-null mutants showed a significant reduction in the cardiomyocyte 
mitotic index by pHH3 staining as well as reduced DNA synthesis by EdU analysis, 
indicating that Yap1 is required for cardiomyocyte proliferation (Xin et al., 2011). 
Conversely, Yap1 gain-of-function mutants stimulate cardiomyocyte proliferation both in 
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vitro and in vivo. Treatment of embryos at E8.5 with a doxocycline-inducible Yap1 
transgene results in embryonic lethality by E15.5, with embryos exhibiting cardiomegaly 
(von Gise et al., 2012). Histological examination revealed dramatic myocardial 
overgrowth with moderate thickening of the compact myocardium and marked 
expansion of the trabecular myocardium. Furthermore, Yap1 gain-of-function mutants 
showed enhanced cardiomyocyte proliferation (von Gise et al., 2012). 
The above-mentioned studies, demonstrate that Hippo signaling inhibits 
cardiomyocyte proliferation. A recent study found that depletion of Hippo signaling in the 
adult myocardium is an endogenous repressor of cardiomyocyte renewal and 
regeneration. Inactivating either the Salv or Lats1/2 genes with a tamoxifen-inducible 
Cre, the Myh6CreERT2 transgene (Sohal et al., 2001), in the adult heart leads to cell cycle 
re-entry and a significant induction of DNA synthesis, measured by EdU and Ki67 
analyses (Heallen et al., 2011). Moreover, Hippo deficiency promoted efficient heart 
regeneration in both postnatal cardiac apex resection and adult myocardial infarction 
models, revealing a crucial, inhibitory role for Hippo signaling in cardiomyocyte renewal 
and regeneration (Heallen et al., 2013).  
Wnt pathway 
Wnt proteins compose a large family of secreted signaling molecules that 
regulate critical aspects of development, including cell-fate specification, proliferation, 
survival, migration and adhesion (Cohen et al., 2008). The Wnt signaling pathway is an 
evolutionarily conserved pathway that encompasses two major signaling branches: the 
canonical or Wnt-β-catenin-dependent pathway and the noncanonical or β-catenin-
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independent pathway (Komiya and Habas, 2008). The canonical Wnt signaling pathway 
begins with Wnt proteins binding to a coreceptor complex composed of the frizzled 
(Fzd) family, seven-pass transmembrane proteins and lipoprotein receptor-related 5/6 
(Lrp5/6) proteins. Wnt receptor binding activates the intracellular effector protein 
dishevelled, which in turn inactivates a protein complex that includes the constitutively 
active serine-threonine kinase glycogen synthase kinase 3 (Gsk3), as well as the 
scaffolding proteins axin and adenomatosis polyposis coli (APC). This complex normally 
phosphorylates β-catenin and targets it for degradation (He et al., 2004; Gordon and 
Nusse, 2006; Komiya and Habas, 2008; MacDonald et al., 2009; Rao and Kuhl, 2010). 
The hallmark of the canonical Wnt pathway is the accumulation and translocation of the 
adherens junction associated-protein β-catenin into the nucleus (He, 2004; Gordon and 
Nusse, 2006). In contrast, the noncanonical pathway is further divided into two distinct 
branches: the planar cell polarity pathway, known for its role in epithelial cell orientation, 
and the Wnt/Ca2+ pathway, known for its role in cell movement during gastrulation 
(Strutt, 2002; Klein and Mlodzik, 2005; Barrow, 2006; Green et al., 2008; Komiya and 
Habas, 2008; De, 2011) .  
Wnt signaling is essential for cardiogenesis and regulates many aspects of 
cardiac morphogenesis as well as the self-renewal and differentiation of cardiac 
progenitor cells (Cohen et al., 2008). Several components of the canonical Wnt pathway 
are required for proper heart and vascular formation (Brade et al., 2006; Eisenberg and 
Eisenberg, 2006; Tzahor, 2007; Cohen et al., 2008; Rochais et al., 2009; Bergmann, 
2010; Rao and Kuhl, 2010; Zelarayan et al., 2010). Recently, Wnt signaling was shown 
to play a critical role in regulating cardiomyocyte proliferation. Treatment of 
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cardiomyocytes with the small molecule 6-bromoindirubin-3′-oxime (BIO), a specific 
inhibitor of Gsk3 promoted proliferation in vitro (Meijer et al., 2003). Stimulation of both 
neonatal and adult rat cardiomyocytes with BIO induced S-phase entry, upregulated 
positive cell cycle regulators, and increased the cardiomyocyte mitotic index. In addition, 
BIO treatment elevated β-catenin activity in cardiomyocytes, suggesting that the 
increase in proliferative ability may be due, in part, to the activation of the canonical Wnt 
pathway (Tseng et al., 2006).  
Interestingly, a recent study (Heallen et al., 2011) revealed that Hippo signaling 
inhibits Wnt/β-catenin to regulate heart size. Gene expression profiling in Salv-cardiac 
null mice revealed a dramatic upregulation of canonical Wnt target genes, including 
Sox2, Snai2/Slug, and Birc5/Survivin in the heart (Heallen et al., 2011). Immunostaining 
using β-catenin-specific antibodies revealed a 4-fold increase in nuclear β-catenin, 
which is normally localized to the cytosol. Genetic interaction studies with Salv-null mice 
combined with a conditional β-catenin-null allele (Hippo-deficient embryos with reduced 
β-catenin dosage) resulted in suppression of the Hippo cardiomyocyte overgrowth 
phenotype and returned gene expression profiles to wild-type levels (Heallen et al., 
2011). These findings indicate that Wnt signaling is required for the upregulation of 
cardiomyocyte proliferation and cardiomegaly in Hippo mutants. Furthermore, the 
authors demonstrated by chromatin immunoprecipitation (ChIP) studies that Yap and β-
catenin are contained within a common regulatory complex on Sox2 and Snai2. 
Therefore, in cardiomyocytes, Hippo signaling restricts Yap from the nucleus, resulting 
in the diminution of Hippo/Wnt–regulated gene expressions. The Yap and β-catenin 
interaction with Snai2 and Sox2 reveals a nuclear mechanism for the antagonistic 
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control of cardiomyocyte growth by Hippo and canonical Wnt signaling (Heallen et al., 
2011).  
Insulin-like Growth Factor (IGF) pathway 
 Insulin-like growth factors 1 and 2 (IGF1 and 2) are secreted ligands that are 
important for embryonic growth (Le Roith, 1997). IGF2 signaling is mediated by the 
type-1 IGF receptor (IGF1R), whereas receptor-mediated endocytosis of type-2 IGF 
receptor (IGF2R) causes the degradation of excess IGF2 (Ludwig et al., 1995). In cell 
culture, both IGFs stimulate the proliferation of primary fetal ventricular cardiomyocytes 
(Liu et al., 1996; Hertig et al., 1999), and both are expressed in the epicardium during 
myocardial compact zone expansion (Fraidenraich et al., 2004; Li et al., 2011). Notably, 
combined treatment of cultured whole mouse embryos with NRG1 and IGF1 results in a 
substantial increase in DNA synthesis, as well as the expansion of the ventricular 
compact zone leading to chamber growth and maturation (Hertig et al., 1999). 
Interestingly, injection of exogenous IGF1 leads to a partial rescue of cardiac defects 
observed in Id-null embryos (Fraidenraich et al., 2004). Id proteins inhibit cell lineage-
specific gene expression and differentiation of several different bHLH transcription 
factors required for development (Norton and Atherton, 1998; Norton et al., 1998; Sikder 
et al., 2003). Id-null mice exhibit severe cardiac abnormalities leading to embryonic 
lethality. Treatment of Id-null mice with IGF1 results in enhanced myocardial 
proliferation and a rescue of embryonic lethality (Fraidenraich et al., 2004). The role of 
IGF1 in cardiomyocyte proliferation is further enhanced by the transgenic 
overexpression of IGF1 in the postnatal myocardium with the α-myosin-heavy chain 
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promoter (α-MHC), leading to a significant increase in cardiomyocyte cell number and 
cardiomegaly (Reiss et al., 1996).  
IGF2 is encoded by the imprinted gene Igf2 and is expressed only from the 
paternal allele in most tissues (DeChiara et al., 1991). Genomic imprinting affects 
several mammalian genes and results in the expression of those genes from only one of 
the two parental chromosomes (Reik and Walter, 2001). Depletion of IGF2R, also 
encoded by an imprinted gene, in mice leads to excess IGF2, causing severe 
hyperplasia, with heart size 2–5 times larger than that of a wild-type littermate. In 
addition to heart failure, these mice exhibit respiratory abnormalities and die at birth 
(Lau et al., 1994; Wang et al., 1994; Eggenschwiler et al., 1997). Igf2-null embryos 
exhibit a substantial decrease in ventricular wall cardiomyocyte proliferation leading to 
severe hypoplasia. Furthermore, the conditional depletion of both IGFRs in embryonic 
hearts also leads to a significant decrease in myocardial compact zone proliferation at 
E12.5 (Li et al., 2011).  
Neuregulin/ErbB pathway 
Neuregulin1 (NRG1) is a cell-cell signaling protein that is a ligand for receptor 
tyrosine kinases (RTKs) of the epidermal growth factor receptor family (ErbB1 – 4) 
(Falls, 2003). Binding of NRG1 to ErbB4 leads to heterodimerization with ErbB2 or 
homodimerization with ErbB4 (Fuller et al., 2008). Deletion of NRG1, ErbB2, or ErbB4 
leads to myocardial hypoplasia and embryonic lethality in mice, indicating that each of 
these genes is essential for cardiac development (Gassmann et al., 1995; Lee et al., 
1995; Meyer and Birchmeier, 1995). Interestingly, NRG1 induces mononucleated 
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cardiomyocytes to proliferate. Following NRG1 stimulation, cardiomyocytes re-enter the 
cell cycle from S-phase and disassemble sarcomeres, enabling cytokinesis. 
Furthermore, the conditional deletion of ErbB4 in the adult myocardium leads to a 
complete ablation of DNA synthesis as measured by EdU incorporation and a 20% 
reduction in the number of cardiomyocyte nuclei. Conversely, overexpression of ErbB4 
in the adult heart leads to a 3-fold increase in EdU incorporation. Together these data 
demonstrate that NRG1 induces proliferation of differentiated cardiomyocytes in vivo. 
Most strikingly, NRG1-treated animals show significant improvements in cardiac 
function and structure following myocardial infarction (Bersell et al., 2009). However, a 
recent study contradicted these findings, demonstrating that nine consecutive daily 
injections of NRG1β1 did not result in an increase in DNA synthesis in either the normal 
or infarcted adult mouse heart (Reuter et al., 2014). Therefore, the potential for NRG1 to 
be used as a therapeutic regimen for cardiac regeneration remains unclear. Notably, 
during embryogenesis NRG1 does not play a role in proliferation, but participates in 
signaling between the endocardium and myocardium that is required for differentiation 
and maturation (Grego-Bessa et al., 2007).     
Periostin 
Cardiomyocytes in the border zone of a myocardial infarction have a transient 
increase in cell-cycle activity. Based on these findings, it was hypothesized that it may 
be possible to apply extracellular factors to induce cardiomyocyte proliferation (Kuhn et 
al., 2007). Periostin (Postn) is a secreted extracellular matrix protein that is associated 
with the epithelial-to-mesenchymal transition during cardiac development where it is 
localized to the subendocardial region of atrioventricular cushions and along the 
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mesenchyme myocardium interface (Norris et al., 2004; Litvin et al., 2005; Butcher et 
al., 2007). It is re-expressed in adult life following cardiac injury (Stanton et al., 2000; 
Wang et al., 2003). Postn-null mice are viable and show very mild phenotypes, none of 
which are cardiovascular (Rios et al., 2005). However, following myocardial infarction, 
Postn-null mice show reduced scar formation, but no change in rates of cardiomyocyte 
proliferation (Shimazaki et al., 2008; Lorts et al., 2009). Overexpression of full-length 
periostin via the α-MHC promoter in differentiated cardiomyocytes also did not increase 
cardiomyocyte cell cycle activity (Lorts et al., 2009). Conversely, the local delivery of a 
periostin peptide in rats immediately after myocardial infarction increased 
cardiomyocyte proliferation, reduced scar formation, and improved both ventricular 
remodeling and myocardial function. In addition, periostin stimulates mononucleated 
cardiomyocytes to enter a full mitotic cell cycle (Kuhn et al., 2007). The discrepancy 
between these findings has yet to be explained but could be due to either the molecular 
mechanisms involved (peptide vs. gene) or the timing of delivery (acute vs. chronic 
overexpression (Senyo et al., 2014).   
  Fibroblast Growth Factor (FGF) pathway   
Fibroblast growth factors (FGFs) encoded by a large family of genes are 
polypeptide signaling proteins with many important functions during development. FGFs 
activate cell surface FGF receptors (FGFRs) which are trans-membrane RTKs. During 
embryonic development, FGFs play diverse roles in regulating cell proliferation, 
migration, and differentiation. In the adult organism, FGFs are homeostatic factors and 
function in tissue repair and response to injury.  There are at least 22 FGF ligands and 4 
FGFRs. Alternative mRNA splicing of FGFRs is tissue specific, producing epithelial 
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variants (b-splice forms) and mesenchymal variants (c-splice forms) (Miki et al., 1992; 
Chellaiah et al., 1994; Naski and Ornitz, 1998; Ornitz and Itoh, 2001; Pownall and 
Isaacs, 2010). Binding of FGF ligands leads to the autophosphorylation of the FGFR, 
allowing interaction of the FRS2 docking protein, followed by activation of the 
GRB2/SOS complex.  Activated SOS then activates RAS and triggers a phosphorylation 
cascade leading to the activation of RAF, MEK, and mitogen-activated protein kinase 
(ERK) (Kouhara et al., 1997; Rochais et al., 2009; Pownall and Isaacs, 2010). FGFR 
signals are also transduced by the phospholipase C-γ pathway and the 
phosphoinositide-3 kinase (PI3K) pathway (Bottcher and Niehrs, 2005; Thisse and 
Thisse, 2005; Beenken and Mohammadi, 2009; Knights and Cook, 2010; Pownall and 
Isaacs, 2010).  
A role for FGF signaling in cardiomyocyte proliferation has been demonstrated 
from flies to humans (Beiman et al., 1996; Ornitz and Itoh, 2001; Moon, 2006; Lavine 
and Ornitz, 2008; Moon, 2008). Several studies have demonstrated that FGFs are 
mitogenic for cardiomyocytes in culture (Speir et al., 1992; Engelmann et al., 1993; 
Pasumarthi et al., 1996). In addition, overexpression of FGFR1 in rat cardiomyocytes 
leads to increased proliferation (Sheikh et al., 1999). Fgf8 depletion in cardiac 
mesoderm leads to embryonic lethality due to proliferative defects in the SHF and a 
failure to properly elongate the developing heart tube (Ilagan et al., 2006; Park et al., 
2006). Fgf10 was the first identified marker of the SHF (Kelly et al., 2001). However, 
embryos lacking Fgf10 exhibit abnormal ventricular morphogenesis and malpositioning 
of the heart in the thoracic cavity, but no outflow tract (OFT) alignment defects 
(Marguerie et al., 2006). Conditional ablation of Fgfr1 and Fgfr2 in SHF cells (using 
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Islet1-Cre) (Srinivas et al., 2001) results in a substantial reduction in proliferation (Park 
et al., 2008). FGFs can be classified within subfamilies, which share similar receptor-
binding properties and overlapping patterns of expression (Ornitz and Itoh, 2001). Fgf9, 
Fgf16 and Fgf20 compose one subfamily and are all expressed in the epicardium and 
endocardium of the developing heart (Colvin et al., 1999; Lavine et al., 2005). Fgf9-null 
mice die at birth due to lung hypoplasia and an enlarged dilated heart (Colvin et al., 
2001). However, during embryonic development, Fgf9-null hearts are hypoplastic and 
exhibit decreased cardiomyocyte proliferation (Colvin et al., 2001; Lavine et al., 2005). 
Interestingly, double-knockout mice for Fgfr1 and Fgfr2 also display cardiac hypoplasia 
and decreased proliferation. Further work has demonstrated that FGF9 signals to the 
myocardium from the epicardium through Fgfr1c and Fgfr2c (Lavine et al., 2005). In line 
with these studies, mice lacking Fgf16 also show decreased cardiomycoyte proliferation 
(Hotta et al., 2008).  
FGF signaling has also been shown to play a role in adult cardiomyocyte 
proliferation. Mammalian cardiomyocytes control the cell cycle via p38 MAP kinase, 
which regulates the expression of genes required for mitosis, including cyclin A and 
cyclin B. p38 activity is inversely correlated with cardiac growth during development, 
and its overexpression blocks fetal cardiomyocyte proliferation. Cardiac-specific p38α 
knockout mice show enhanced cardiomyocyte proliferation and pronounced cytokinesis 
(Engel et al., 2005; Engel et al., 2006). In contrast, genetic activation of p38 in a 
dominant-negative transgenic mouse model led to reduced proliferation in the adult 
heart (Engel et al., 2005). Treatment with a p38 MAP kinase inhibitor coupled with 
recombinant FGF1 following acute myocardial injury enhanced cardiomyocyte 
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proliferation and improved cardiac function. The addition of FGF1 alone or in 
combination with the p38 inhibitor also improved angiogenesis around the scar area, 
possibly contributing to the survival of newly generated cardiomyocytes (Engel et al., 
2006). Furthermore, the apoptosis observed with ischemia-reperfusion injury is 
attenuated by FGF-1 in the adult myocardium (Cuevas et al., 1997). 
 
MicroRNAs regulate cardiomyocyte proliferation 
The regulatory pathways that govern heart development and growth are 
modulated by several miRNAs. miRNAs, 21–25 nucleotides in length, are noncoding 
RNAs that play important regulatory roles in biology by targeting mRNAs for cleavage or 
repressing translation (Bartel, 2004; Liu and Olson, 2010; Small and Olson, 2011; Xin et 
al., 2013). miRNAs can be classified into three categories: intergenic, intronic, and 
exonic. Intergenic miRNAs are derived from their own transcriptional units in the 
intergenic regions of the genome. Intronic and exonic miRNAs are located within the 
introns and exons of host genes (protein-coding or nonprotein-coding genes) and are 
usually cotranscribed and coexpressed with their host genes (Bartel, 2004). Nucleotides 
2–8 of the miRNA, termed the “seed” sequence located at the 5’ end, are essential for 
target recognition and binding. Based on the seed sequence, miRNAs can suppress 
collections of mRNAs that encode proteins participating in similar biological networks 
(Bartel, 2009). 
Many miRNAs are implicated in the regulation of many aspects of cardiovascular 
biology (Figure 1.5). miR-1 and miR-133 promote mesoderm differentiation early in 
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development. By contrast, they have opposing roles later in the cardiac lineage when 
miR-1 promotes and miR-133 inhibits cardiomyocyte differentiation (Zhao, Y. et al., 
2007; Ivey et al., 2008; Small and Olson, 2011). However, only a few have been 
identified that specifically regulate cardiomyocyte proliferation (Liu and Olson, 2010; Xin 
et al., 2013). To identify pathways involved in cardiomyocyte proliferation, a high-
throughput miRNA screen was conducted, and 40 miRNAs were identified that induced 
DNA synthesis and increased cytokinesis in neonatal rat cardiomyocytes (Eulalio et al., 
2012). Of these, miR-590-3p and miR-199a-3p were subsequently implicated in 
cardiomyocyte proliferation during injury repair (Shin et al., 2002; Kook and Epstein, 
2003; Eulalio et al., 2012). Interestingly, these miRNAs contain different seed 
sequences, but have several of the same predicted targets. Both were found to target 
the Homer1 gene, which modulates Ca2+ signaling in the heart through its interaction 
with the Ca2+ release channel ryanodine receptor (RyR). Also, both target the Hopx 
gene, which encodes a homeodomain protein that inhibits cardiomyocyte proliferation 
(Kook and Epstein, 2003; Trivedi et al., 2010; Grubb et al., 2012). In vivo, 
overexpression of miR-590-3p and miR-199a-3p in neonatal mice results in increased 
cardiomyocyte proliferation. Of particular note, the presence of these two miRNAs in 
cardiomyocytes reduces fibrotic scar size and improves cardiac function following 
myocardial infarction, suggesting a potential therapeutic use. Interestingly, miR-590-3p 
but not miR-199a-3p, was found to target Clic5, a cell proliferation inhibitor, 
demonstrating a unique specificity for certain targets (Eulalio et al., 2012). However, 
despite evidence for roles of the mir-590-3p and mir-199a-3p in cardiomyocyte 
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proliferation in neonatal mice and rats, what role, if any, they play in embryonic 
cardiomyocyte proliferation, remains to be established. 
In addition, miR-15 and miR-195 (members of the miR-15 family) have been 
shown to regulate the cardiomyocyte cell cycle. miR-195 is highly upregulated in 
neonatal mouse ventricles at P10 after cardiomyocytes have exited the cell cycle 
(Porrello et al., 2011; Porrello et al., 2013). Overexpression of miR-195 in the 
developing heart leads to severe hypoplasia and cell cycle arrest during G2-phase. 
Further work showed that miR-195 targets Chek1, a cell cycle checkpoint kinase that 
promotes G2-to-M-phase transition and thus mitotic progression (Porrello et al., 2011). 
Conversely, inhibition of miR-15 leads to an increase in cardiomyocyte proliferation in 
neonatal and adult mice, and improved cardiac function following injury (Hullinger et al., 
2012; Porrello et al., 2013).   
 
Transcription factors that regulate cardiomyocyte proliferation 
Cardiomyocyte proliferation is an intrinsic component of normal cardiac 
morphogenesis and is dependent upon cardiac-specific transcriptional regulators as 
well as exogenous signals, as described above (Dunwoodie, 2007; Smith and Bader, 
2007; Lavine and Ornitz, 2008; Ikenishi et al., 2012). 
Foxp1 
Foxp1 is a transcriptional repressor protein that binds to DNA via its highly 
conserved forkhead DNA-binding domain (Li and Tucker, 1993; Shu et al., 2001; Li et 
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al., 2004). Foxp1 is expressed in cardiomyocytes, in the endocardium, and in cells 
underlying the cushion mesenchyme (Lu et al., 2002; Wang et al., 2004). Global loss of 
the Foxp1 gene results in a complex, and slightly confusing, cardiac phenotype 
characterized by defects in outflow tract septation, increased myocardial proliferation, 
and thinning of ventricular myocardium (Wang et al., 2004). The observations of 
increased cell proliferation and loss of ventricular mass in Foxp1 mutants suggest that 
Foxp1 may regulate cardiomyocyte proliferation in a complex manner. Loss of Foxp1 in 
endothelial cells using Tie2-Cre (Kisanuki et al., 2001) results in embryonic lethality that 
correlates with decreased ventricular mass and reduced cardiomyocyte proliferation. 
This finding contrasts with the increased proliferation observed in global loss-of-function 
mice (Zhang et al., 2010), which is the result of decreased Fgf3/16/17/20 expression in 
the endocardium. Loss of Foxp1 specifically in the myocardium using the Nkx2.5-Cre 
(Moses et al., 2001) leads to increased proliferation (particularly in the trabecular zone) 
increased ventricular wall thickness, and ventricular septation defects. Interestingly, 
Foxp1 directly represses Nkx2.5 in the myocardium, and loss of Foxp1 leads to 
increased Nkx2.5 expression (Zhang et al., 2010). Moreover, transgenic overexpression 
of Nkx2.5 results in increased cardiomyocyte proliferation and ventricular wall thickness, 
similar to that in myocardial-deficient Foxp1 mutants. Together, these data indicate that 
Foxp1 regulates the balance of myocardial growth in development, resulting in the 
controlled exit of cardiomyocytes from the cell cycle (Zhang et al., 2010). 
Jumonji  
Jumonji is a member of the JMJ transcription factor family that features an AT-
rich interaction domain and is highly expressed in the myocardium throughout 
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embryonic development (Gregory et al., 1996; Kortschak et al., 2000; Jung et al., 
2005a). Jumonji mutant mice exhibit hyperproliferation and overexpression of cyclin D1 
(Takeuchi et al., 1995; Takeuchi et al., 1999; Toyoda et al., 2003; Jung et al., 2005b; 
Jung et al., 2005a). Interestingly, jumonji downregulates growth via an interaction with 
the cell cycle regulator, retinoblastoma protein (Rb) (Jung et al., 2005b). Further 
studies, revealed that enhanced expression of cyclin D1 in mutant mice decreased 
GATA4 protein levels and inhibited the differentiation of cardiomyocytes in a Cdk4/6-
dependent manner (Nakajima et al., 2011).  
Hopx 
 Hopx is a transcriptional corepressor that is essential for the normal development 
of the mammalian heart. It is expressed in the embryonic and postnatal myocardium, 
and functions downstream of the early cardiac-specific transcription factor, Nkx2-5. 
Hopx modifies the expression of cardiac-specific genes and thereby finely regulates 
heart development (Kook and Epstein, 2003; Kook et al., 2006). Hopx inhibits the 
transcriptional activity of serum response factor (SRF) in cardiomyocytes, and, by doing 
so, modulates cardiac growth and proliferation. Hopx inhibits SRF-dependent 
transcriptional activation by recruiting and forming a complex with histone deacetylase 
(HDAC), forming a complex that includes HDAC2. Transgenic mice that overexpress 
Hopx develop severe cardiac hypertrophy, cardiac fibrosis, and premature death due to 
a shift in the balance of pro and antihypertrophic pathways. Conversely, a mutant form 
of the Hopx gene, which does not recruit HDAC, does not induce hypertrophy (Kook et 
al., 2003). Furthermore, HDAC2 and Hopx mediate the deacetylation of GATA4, a 
critical cardiac transcription factor. In the absence of Hopx and HDAC2 in mouse 
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embryos, GATA4 hyperacetylation is associated with a substantial increase in 
cardiomyocyte proliferation, upregulation of GATA4 target genes, and subsequent 
lethality. These data suggest that HDAC2, Hopx and GATA4 coordinately regulate 
cardiomyocyte proliferation during embryonic development (Trivedi et al., 2010). 
Meis1 
Meis1 is a homeodomain transcription factor that is required for normal cardiac 
development and hematopoiesis (Imamura et al., 2002; Hisa et al., 2004; Azcoitia et al., 
2005). siRNA-mediated knockdown of Meis1 in neonatal rat cardiomyocytes results in a 
3-fold increase in cardiomyocyte proliferation. Cardiac-specific deletion of Meis1 
induces cardiomyocyte proliferation and most notably, extends the postnatal 
proliferative time window without any deleterious effects on cardiac function. 
Conversely, the overexpression of Meis1 in cardiomyocytes decreases proliferation. 
Furthermore, Meis1 is required for the transcriptional activation of the Cdk inhibitors 
p15ink4b, p16ink4a, and p21Cip1, suggesting that Meis1 is a critical regulator of the 
cardiomyocyte cell cycle, prompting cell cycle exit (Mahmoud et al., 2013). 
  T-box genes 
T-box (Tbx) transcription factors are highly conserved across species, expressed 
in a wide variety of tissue types, and are required for the development of several organs 
and tissues (Agulnik et al., 1996; Kiefer, 2004; Showell et al., 2004; Naiche et al., 2005). 
Tbx genes regulate patterning and cell fate, cell survival and/or proliferation (Kispert and 
Herrmann, 1993; Chapman et al., 1996; Bruneau et al., 2001; Papaioannou, 2001; 
Takeuchi et al., 2003; Kiefer, 2004; Showell et al., 2004; Cai et al., 2005; Naiche et al., 
32 
 
2005; Singh et al., 2005; Stennard et al., 2005; Stennard and Harvey, 2005). They are 
also of great clinical relevance as mutations in Tbx genes cause a number of human 
disorders, such as DiGeorge syndrome (Tbx1) and Holt-Oram syndrome (Tbx5) 
(Basson et al., 1994; Li, Q. Y. et al., 1997; Bruneau et al., 2001; Jerome and 
Papaioannou, 2001; Lindsay et al., 2001; Packham and Brook, 2003; Naiche et al., 
2005; Baban et al., 2014). 
The pharyngeal mesodermal progenitor cells of the SHF are situated medially to 
the FHF, that gives rise to the linear heart tube and are distinguished by the expression 
of genes encoding the transcription factors Isl1 and Tbx1 (Kelly et al., 2001; Mjaatvedt 
et al., 2001; Waldo et al., 2001; Cai et al., 2003; Xu et al., 2004). Conditional depletion 
of Tbx1 results in a shortened and narrow outflow tract and severe hypoplasia of the 
SHF due to the requirement for Tbx1 in the pharyngeal mesoderm during cardiac 
looping. Furthermore, Tbx1 positively regulates proliferation in the SHF through the 
transcriptional regulation of Fgf8, Fgf10, and Fgfr1 (Garg et al., 2001; Hu et al., 2004; 
Xu et al., 2004; Zhang et al., 2006; Liao et al., 2008).   
Tbx5 is expressed very early in heart development in the cardiac crescent and 
the early heart tube. As the tube develops, Tbx5 expression becomes restricted to the 
cardiac regions that will form the sinus venosus, atria, and left ventricle (Bruneau et al., 
1999; Liberatore et al., 2000). Tbx5 is required for normal heart development and Tbx5- 
null mice arrest around E10.5 due to severe cardiac defects (Bruneau et al., 2001). 
Furthermore, mice heterozygous for the Tbx5 gene display many of the same cardiac 
abnormalities associated with human patients suffering from Holt-Oram syndrome 
(HOS), an autosomal-dominant condition associated with upper limb and cardiac 
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malformations (Basson et al., 1997; Li, Q. Y. et al., 1997; Bruneau et al., 2001). In 
Xenopus embryos, depletion of the Tbx5 gene results in a dramatic decrease in 
cardiomyocyte number due to defects in cell proliferation. Furthermore, Tbx5 gene 
depletion leads to G1/S-phase arrest and a decrease in the embryonic cardiac mitotic 
index. In contrast, overexpression of Tbx5, which we show also leads to heart-specific 
defects, results in an increase in the cardiac mitotic index and has an inverse effect on 
the timing of the cardiac differentiation program. Collectively, these studies demonstrate 
that Tbx5 is both necessary and sufficient to determine the length of cardiac G1/S-phase 
and the timing of the cardiac differentiation program (Brown et al., 2005; Goetz et al., 
2006). 
Tbx20 is expressed throughout the early cardiac crescent, and later in both the 
myocardium and the endocardium (Iio et al., 2001; Kraus et al., 2001; Cai et al., 
2005). Tbx20-null mutants exhibit severe cardiac hypoplasia and show embryonic 
lethality due to defects in cardiac morphogenesis. Tbx20 directly represses Tbx2 in the 
developing heart; furthermore, Tbx2 itself directly represses Nmyc1 activity (Cai et al., 
2005). Nmyc1 is required for myocardial proliferation, and Nmyc1-null mice show 
pronounced cardiac hypoplasia (Davis and Bradley, 1993). Together, these data 
demonstrate that Tbx20 is a key component of a genetic network that regulates cell 
proliferation and morphogenesis.  
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 Casz1-dependent mechanisms 
Studies investigating the transcriptional regulation of cardiogenesis reveal a role 
for the para-zinc finger transcription factor Casz1 in vertebrate heart development. 
Depletion of Casz1 in Xenopus embryos results in the failure of a subset of progenitor 
cells to differentiate into cardiomyocytes, resulting in aberrant cardiac morphogenesis 
(Christine and Conlon, 2008). There have been relatively few studies of Casz1 in 
mammals. In one of these studies, however, a partial murine Casz1 cDNA was shown to 
be expressed in the developing heart (Vacalla and Theil, 2002), whereas another study 
showed that CASZ1 is expressed in adult human heart tissue (Liu et al., 2006).  
Recently, I demonstrated that Casz1 is expressed in cardiomyocytes during the 
earliest stages of mammalian heart development and used genetic fate mapping to 
show that Casz1-positive cells give rise to derivatives of both the FHF and SHF, 
including cardiomyocytes in the left and right ventricles, and in the left and right atria 
(Dorr et al., in review).  Cardiac-specific depletion of Casz1 using both the Nkx2.5-Cre 
driver (Moses et al., 2001) and the Islet1-Cre driver (Srinivas et al., 2001) results in 
embryonic lethality due to severe cardiac hypoplasia. Furthermore, Casz1 plays an 
essential role in the cardiomyocyte cell cycle. Loss of Casz1 leads to a prolonged or 
arrested G1-phase that is associated with a marked reduction in DNA synthesis, an 
increase in phosphorylated Rb, and a decrease in the cardiac mitotic index. Taken 
together, these results demonstrate a role for Casz1 in the G1-to-S-phase progression 
of cardiomyocytes (Dorr et al., in review).  
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DISSERTATION GOALS 
Our findings in Xenopus imply that cardiomyocytes do not differentiate in a 
uniform manner and suggest that cells located in the ventral region of the heart 
differentiate in response to localized signals. Although those studies demonstrated a 
requirement for Casz1 during development, the genetic requirement for Casz1 remains 
unclear. Xenopus is an excellent model organism for developmental studies. However, 
it is not a genetic model organism, and morpholino knockdown is not suitable for tissue-
specific investigations. Furthermore, unlike the mammalian heart, the Xenopus heart is 
three chambered, featuring two atria and one common ventricle. The laboratory mouse 
is an ideal model organism for cardiovascular genetic studies. Murine cardiac 
development is well characterized and quite similar to that of humans. In addition, the 
mouse genome is quite amenable to modification using the techniques of classical 
transgenesis, gene targeting, and site-specific recombination. For these reasons, I 
sought to determine the genetic requirement for Casz1 during murine cardiac 
development. In chapter 2, I show that cardiac-specific depletion of the Casz1 gene 
results in severe cardiac hypoplasia, and ventricular septal defects leading to embryonic 
lethality. Here, I show that Casz1 regulates cardiomyocyte proliferation and is 
necessary for proper G1-to-S-phase transition of the embryonic cardiac cell cycle.  Next, 
I demonstrate using RNA sequencing technologies that pathways involved in cell growth 
and proliferation are misregulated in hearts depleted of Casz1. Collectively, this work 
will enhance the understanding of Casz1 and provide further insight into the cardiac 
transcriptional network required for proper heart growth. 
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Figure 1.1 The Cardiomyocyte Cell Cycle. Factors involved in cardiomyocyte cell 
cycle progression.  
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Figure 1.2 Control of Cardiomyocyte Growth. Schematic representation of the 
developmentally determined forms of cell cycle control and growth at different 
developmental stages.  
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Figure 1.3. Cardiomyocyte Structure. In muscle cells, contractile myofibrils are 
organized into sarcomeres. During karyokinesis, the sarcomeric Z-disks and M-bands 
disassemble in the midzone region.  
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Figure 1.4. Growth Factors that Regulate Cardiomyocyte Proliferation . Illustration 
showing the core features of the Hippo, Wnt, Igf, Fgf, Periostin, and Nrg signaling 
pathways. This simplified schematic summarizes the key steps from ligand binding to 
target gene transcription for each pathway. 
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Figure 1.5. miRNAs Involved in Cardiomyocyte Proliferation. Regulation of 
cardiomyocyte proliferation by microRNAS (miRNAs). miRNAs can positively or 
negatively regulated cardiomyocyte proliferation. 
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Table 1.1. The Major Cyclins and Cyclin-Dependent Kinases Involved in The 
Cardiomyocyte Cell Cycle 
 
 
GENE FUNCTION CELL CYCLE 
PHASE 
CELL CYCLE MEDIATORS 
Cyclin D1 Cdk4/6 cofactor; positive regulator of 
restriction point transit 
G1/S 
Cyclin D2 Cdk4/6 cofactor; positive regulator of 
restriction point transit 
G1/S 
Cyclin D3 Cdk4/6 cofactor; positive regulator of 
restriction point transit 
G1/S 
Cyclin E Cdk2 cofactor; promotes G1-S transition G1/S 
Cyclin A Cdk1/2 cofactor; positive regulator of S 
and G2-M transition 
G2/M 
Cyclin B Cdk1 cofactor; promotes G2-M transition G2/M 
Cdk1 Promotes G2-M transition G2/M 
Cdk2 Phosphorylates Rb family members; 
promotes G1-S transition 
G1/S 
Cdk4 Phosphorylates Rb family members; 
promotes restriction point transit 
G1/S 
Cdk6 Phosphorylates Rb family members G1/S 
CELL CYCLE INHIBITORS 
INK4 Inhibits Cdk2,4,6 activity; blocks restriction 
point and G1-S transition 
G1/S 
p21 Inhibits Cdk2,4,6 activity; blocks restriction 
point and G1-S transition 
G1/S 
p27 Inhibits Cdk2,4,6 activity; blocks restriction 
point and G1-S transition 
G1/S 
RB Regulates G1-S transition by inhibiting 
E2F activity 
G1/S 
TRANSCRIPTION FACTORS 
E2F Activates cell cycle transcription  G1-S-G2/M 
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CHAPTER 2: Casz1 is required for cardiomyocyte G1-to-S progression during 
mammalian cardiac development1 
 
INTRODUCTION 
Early development of the heart is governed by hyperplastic growth in which 
cardiac cells undergo mitogen-dependent activation during the G1 phase of the cell 
cycle (Ahuja et al., 2007). During early stages of heart development cardiomyocytes of 
the first and second heart fields are highly proliferative, resulting in substantial growth of 
the embryonic heart. The overall rate of cardiomyocyte proliferation gradually declines 
concomitant with the onset of terminal cardiomyocyte differentiation (Soonpaa et al., 
1996; Christoffels et al., 2000; Pasumarthi and Field, 2002; Sedmera et al., 2003; 
Ikenishi et al., 2012). After this period, the vertebrate heart continues to grow largely 
through hypertrophy and by recruitment and proliferation of cells from the neural crest 
and the epicardium (Li et al., 1996; Creazzo et al., 1998; Manner et al., 2001; Ahuja et 
al., 2007; Kelly, 2012; Maillet et al., 2013). 
 
 
______________________ 
1This chapter is an article in press in the journal Development. The citation is as follows: Dorr, 
K.M., Amin, N.M., Kuchenbrod, L.M., Labiner, H., Charpentier, M.S., Pevny, L.H., Wessels, A., 
Conlon, F.L. Casz1 is required for cardiomyocyte G1-to-S progression during mammalian 
cardiac development. Development (2015).
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Understanding the transcriptional mechanisms of cardiomyocyte proliferation is 
critical for uncovering pathologies and treatments for congenital heart disease. Past 
studies have shown that cardiomyocyctes hyperplastic growth occurs in response to 
input from a large network of growth factor signaling pathways (Lavine et al., 2005; 
Ahuja et al., 2007; Bersell et al., 2009; Heallen et al., 2011; Porrello et al., 2011; Xin et 
al., 2011; Eulalio et al., 2012; von Gise et al., 2012; Wadugu and Kuhn, 2012; Xin et al., 
2013). However, many basic questions regarding the mechanisms underlying how 
these growth factors regulate the cardiomyocyte cell cycle remain unanswered. Central 
to this issue, it is unknown which cardiac-specific transcription factors act to drive or 
commit cardiomyocytes into the next round of division.  
 
Casz1 is a para-zinc finger transcription factor that has been shown to be 
expressed in and required for vertebrate heart development, with depletion of Casz1 in 
Xenopus embryos leading to a failure of a small subset of progenitor cells to 
differentiate into cardiomyocytes resulting in aberrant cardiac morphogenesis and 
eventual death (Vacalla and Theil, 2002; Liu et al., 2006; Christine and Conlon, 2008; 
Amin et al., 2014; Sojka et al., 2014). The evolutionary role of Casz1 in heart development 
is further emphasized by genome-wide association studies showing genetic association of 
the CASZ1 locus with blood pressure and hypertension (Levy et al., 2009; Takeuchi et al., 
2010; Lu et al., 2014). Consistently, it has been demonstrated that CASZ1 has an essential 
role in blood vessel assembly and lumen formation (Charpentier et al., 2013b; Charpentier 
et al., 2013a). Together, these studies implicate a potential link between Casz1 and 
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cardiovascular dysfunction. However, the genetic requirement and endogenous role for 
Casz1 in mammalian cardiac development remains to be established.  
 
Here we report that Casz1 is expressed in cardiomyocytes during the earliest 
stages of mammalian heart development, and using genetic fate mapping show Casz1-
positive cells give rise to derivatives of both the first and second heart field including 
cardiomyocytes in the left and right ventricles and the left and right atria. Through the 
generation of a conditional null allele, we demonstrate that Casz1 is essential for early 
mammalian heart development and define a role for Casz1 in the proliferation of 
cardiomyocytes during chamber formation. We go on to demonstrate an essential role 
for Casz1 in the cardiomyocyte cell cycle demonstrating that loss of Casz1 leads to a 
prolonged or arrested G1 phase that is associated with a marked reduction in DNA 
synthesis, an increase in phospho-RB, and a decrease in cardiac mitotic index. Taken 
together, our results demonstrate a role for Casz1 in the G1-to-S phase progression of 
cardiomyocytes.  
 
MATERIALS AND METHODS 
Generation of Casz1 Mutant Mice 
BAC clones containing Casz1 genomic DNA from mouse strain 129 were 
isolated by established methods (Testa et al., 2003). A plasmid, pBS-DTRX-
Casz1Exon6CKO, was constructed that contains the PGKneo expression cassette 
flanked by two FRT sites, and containing a loxP site was inserted into intron 5. loxP 
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sites were introduced into the Casz1 locus flanking exon 6 (Liu et al., 2003). Deletion of 
exon 6 introduces a +2 frameshift in the translational reading frame leading to 
premature stop codons, resulting in the elimination of CASZ1 protein expression. 
Furthermore, alternate splicing to the next three exons all result in proteins that are out 
of frame. The targeting vector contained 2.2 kb of homologous DNA upstream of the 
first loxP and 1.8 kb of homologous DNA (right arm) downstream of the PGKneo 
cassette (Liu et al., 2003). The targeting vector was linearized with NotI and 
electroporated into 1292/Ola embryonic stem cells. G418-resistant colonies were 
picked, expanded, and screened for homologous recombination by Southern blot 
analysis of HindIII digested ES cell gDNA using 5’ and 3’ probes respectively containing 
sequences outside of those in the targeting vector. Homologous recombinant ES cells 
were injected into C57BL6/J blastocysts and chimeric male mice were obtained. Male 
chimeras were mated to C57BL6/J females to establish a mouse line carrying the 
Casz1flox-neo/+ allele. The frt-flanked PGKneo cassette was removed by mating F1 
heterozygous mice to mice expressing the FlpE recombinase (Jackson Labs stock 
#003800) (Rodriguez et al., 2000). The resulting Casz1flox/flox allele was bred to 
homozygosity on a C57BL6 background. Casz1 conditional knockout mice and their 
control littermates were obtained by breeding female Casz1flox/flox mice to male 
Casz1flox/+ mice expressing Nkx2.5Cre/+. Nkx2.5Cre/+ mice were obtained from Robert 
Schwartz (Moses et al., 2001). Sox2Cre/+ mice were obtained from Larysa Pevny 
(Hayashi et al., 2002). Isl1Cre/+ mice were obtained from Li Qian (Srinivas et al., 2001). 
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In Situ Hybridization 
In situ hybridization was carried out as previously described (Wilkinson, 1992). 
Specifically, sense and antisense probes were generated using a digoxigenin (DIG) 
RNA labeling kit (Roche). Probes were hybridized overnight at 65°C onto E8.5 – E10.5 
embryos. DIG-labeled probes were detected by anti-digoxigenin-AP Fab fragments 
(Roche) and precipitated by BM Purple AP substrate (Roche). Embryos and embryonic 
hearts were dissected free from surrounding tissues in PBS. Specimens were fixed 
overnight at 4°C in 4% paraformaldehyde/PBS. In situ probes used were Nkx2.5 (gift 
from Benoit Bruneau), and Casz1 (See primer table for sequences). Tissues were 
photographed, embedded in 4% low melt agarose (Promega) and sectioned by a Leica 
VT1200S vibratome to 30µm thickness. Vibratome sections were mounted on slides 
and imaged on an Olympus BX61 microscope.  
 
RLM-RACE 
5’ RLM-RACE was performed according to the manufacturer's instructions (First 
Choice RLM-RACE kit, Ambion #AM1700). Mouse adult heart RNA was isolated using 
standard Trizol extraction. 
 
Histologic sectioning and Immunohistochemistry 
Embryos were fixed in 4% paraformaldehyde and either paraffin embedded or 
frozen in OCT. Paraffin sections (8 µm) were dewaxed, rehydrated, and stained with 
hematoxylin and eosin using standard methodology. Histology sections were imaged on 
an Olympus BX61 fluorescent microscope. Digital images were utilized for 
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measurement using Image J software. Paraffin sections and cryosections (10 µm) were 
washed in PBS+1% Triton X-100 (PBS-T), blocked in PBS-T+10% FBS, and incubated 
overnight at 4°C with primary antibodies against a series of antigens: rabbit anti-CASZ1 
(Santa Cruz #SC-135453) 1:500, mouse anti-cardiac tropomyosin (TMY) (DSHB, clone 
CH1) 1:50, mouse anti-Islet1 (DSHB, clone 39.4D5) 1:50, rabbit anti-FilaminA 
(Epitomics #2242-1) 1:100, mouse anti-GFP (Clontech #632381) 1:1000, rabbit anti-
phospho histone H3 (Millipore #06-570) 1:200, mouse anti-cardiac troponin T (DSHB, 
clone RV-C2) 1:50, mouse anti-sarcomeric myosin (DSHB, clone MF20) 1:50, rabbit 
anti-caspase 3 (Cell Signaling #9661) 1:100, Alexa Fluor 488 – Phalloidin (Molecular 
Probes #A12379) 1:100, rabbit anti-phosphoRb (Cell Signaling #9308) 1:100, mouse 
anti-PML (Santa Cruz, #SC-966) 1:500, rabbit anti-cleaved caspase 3 (Asp175) (Cell 
Signaling #9661) 1:50. CASZ1 antibody staining required antigen retrieval. Briefly, 
sections were steamed in 10 mM Sodium Citrate pH 6.0/0.05% Tween-20 for 20 
minutes, washed in 1X PBS and subjected to processing as detailed above. The 
following day, sections were washed in PBS-T then incubated for 1 hour at room 
temperature with secondary antibodies: Alexa 488 goat anti-mouse IgG, H+L (Molecular 
Probes #A11001) 1:1000, Alexa 488 donkey anti-rabbit IgG (Molecular Probes 
#A21206) 1:1000, Alexa 546 goat anti-rabbit IgG (Molecular Probes #A11010) 1:1000, 
Alexa 546 goat anti-mouse IgG (Molecular Probes #A11030) 1:1000. Sections were 
washed in PBS-T, incubated with 200ng/mL DAPI (Sigma) and mounted with 
Fluoromount. Stained sections were imaged on Zeiss 700 confocal microscope and 
ImageJ was used for analysis. 
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Cell culture 
HUVECS (Lonza) were maintained and immunostained as previously described 
(Charpentier et al., 2013b). 
 
Reporter crosses 
Tie2-Cre (Kisanuki et al., 2001) mice were crossed to R26ReGFP reporter mice. 
Wt1/IRES/GFP-Cre mice were previously reported (Wessels et al., 2012). Time-mated 
females were harvested at E14.5 and processed for immunostaining with anti-GFP as 
detailed above. Nkx2.5-Cre mice (Moses et al., 2001) were crossed to R26RtdT reporter 
mice (Madisen et al., 2010). Time-mated females were harvested at E7.5, E9.5, E12.5 
and E14.5. Sox2-Cre mice (Hayashi et al., 2002) were crossed to R26RLacZ reporter 
mice (Soriano, 1999) and time-mated females were harvested at E10.5. All embryos 
were imaged with a Leica MZ 16F dissection microscope.  
 
β-Galactosidase Staining 
Embryos were fixed in X-gal fixative (0.2% glutaraldehyde, 2mM MgCl2, 5mM 
EGTA, 0.1M phosphate buffer) for 40 minutes on ice, washed in detergent (0.1M 
phosphate buffer, 2mM MgCl2, 0.01% sodium deoxycholate, 0.02% NP-40), and 
incubated in X-gal staining solution (1mg/ml X-gal in DMF, 5mM potassium ferricyanide, 
5mM potassium ferrocyanide, 0.1M phosphate buffer, 2mM MgCl2, 0.01% sodium 
deoxycholate, 0.02% NP-40, 20mM Tris) at 37°C overnight. 
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Tamoxifen Injections 
Tamoxifen (Sigma#T5648) was dissolved in 1/10 volume 200 proof ethanol and 
9/10 volume sunflower oil to make a 0.03mg/µl solution. Time-mated females were 
injected IP with 3 mg of tamoxifen at E8.5 and embryos were harvested at E12.5. No 
reporter activity was observed in the absence of tamoxifen. Embryos were fixed in 4% 
paraformaldehyde, incubated in Scale U2 solution (Hama et al., 2011) at 4°C for 3 
weeks, imaged with a Leica MZ 16F dissection microscope, washed in 1X PBS, sunk in 
30% sucrose and frozen in OCT. Cryosections were processed and immunostained as 
detailed above.  
 
Imaging and statistical analysis 
A Leica MZ 16F dissection microscope with a Retiga 4000RV camera was used 
for whole-mount imaging and an Olympus BX61 with a Retiga 4000R camera for color 
imaging. Higher magnification images were captured using a Zeiss 700 laser scanning 
confocal microscope. All images and figures were edited and created in either Image J 
or Photoshop CS4. All statistical calculations were performed using Prism 5 (Graph 
Pad). P values for statistical significance were obtained using a Student’s t-test for 
single variable between control and test samples. 
 
Cardiomyocyte counting assay 
Embryos from time-mated females were recovered at E10.5 and E12.5, fixed in 
4% PFA and embedded for cryosection. Sections were stained with tropomyosin (TMY) 
and DAPI. For statistical analysis, 9 transverse sections were analyzed, 3 sections 
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(representing the anterior, mid, and posterior heart) from 3 difference embryos per 
genotype. The number of TMY-positive and DAPI-positive cardiomyocytes were 
counted from six 40X fields per section. Cell counts of total cells positive for TMY and 
DAPI were averaged from 54 sections. Data shown as mean ±SEM. ImageJ was used 
for analysis and cell counts. Data were compared for statistical significance using a 
student t-test. 
 
Proliferation assays 
For EdU analysis, time-mated females were injected IP with 250 µg EdU (5-
ethynyl-2′deoxyuridine, Click-iT EdU Imaging Kit, Invitrogen C10338) three hours prior 
to sacrifice. Embryos were recovered at E12.5, fixed with PFA and embedded for 
cryosections (n=3/3). EdU staining was performed according to the manufacturer's 
instructions. For statistical analysis, 9 transverse sections were analyzed, 3 sections 
(representing the anterior, mid, and posterior heart) from 3 different wild-type embryos 
and two Casz1f/f;Nkx2.5Cre/+ embryos. The number of EdU-positive cardiomyocytes 
relative to the total number of cardiomyocytes (TMY-positive cells) was counted from 
four 40X fields per section (2 fields per ventricle). For mitotic index analysis, cell counts 
of total cells positive for TMY and total cells positive for phospho-histone H3 (pHH3) 
expression were performed on transverse sections using the same statistical analysis of 
wild-type and Casz1 mutant hearts at E12.5 (n=3/3) from four 63X fields per sections (2 
fields per ventricle). Mitotic index was calculated by dividing total cells positive for TMY 
and pHH3 expression by total cells positive for TMY. All sections were processed for 
immunostaining as detailed above. Data shown as mean ±SEM. ImageJ was used for 
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analysis and cell counts. Data were compared for statistical significance using a student 
t-test. 
 
Scanning Electron Microscopy 
A standardized procedure for scanning electron microscopy (Hullinger et al.) of 
the heart was utilized (Pexieder, 1986). Briefly, the pericardial cavity membrane was 
excised in embryos before being fixed in 2.5% glutaraldehyde (EM grade, Electron 
Microscopy Science, PA) as previously reported (Tandon et al., 2013) in 1X PBS at 4°C 
overnight. Embryos were washed in 1X PBS, dehydrated into 100% ethanol dehydration 
and subject to critical point drying. Dried specimens were mounted ventral side up and 
ion sputtered with Gold Palladium to approximately 40 nm thickness before being 
scanned with a Zeiss Supra 25 FESEM microscope. SEM photomicrographs were taken 
in standard orientations and magnifications.  
 
RNA-Seq 
E10.5 hearts were collected from three Casz1f/f;Nkx2.5Cre/+and three 
Casz1f/+;Nkx2.5+/+ embryos. RNA was isolated using standard Trizol extraction. RNA-
seq libraries were generated with TruSeq adaptor barcodes from these six samples 
using standard library preparation protocols (Illumina) by the Vanderbilt Genomic Core. 
Samples were run over three lanes of a HiSeq2500 (Illumina) to generate on average 
103.7 million 50 base pair single-end reads per sample by the Vanderbilt Genomic 
Core. Samples were assessed for quality using Fastqc 0.10.1 and then mapped to the 
mouse genome (build mm10) using TopHat, version 2.0.8 with default parameters 
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(Trapnell et al., 2009; Trapnell et al., 2012). Aligned reads were then tallied per 
annotated gene (RefSeq genes downloaded from www.genome.ucsc.edu July 24, 
2013) were then normalized using RPKM values and analyzed for differential 
expression via Cufflinks, version 2.1.1 (Trapnell et al., 2012). For Gene Ontology 
Analysis, genes tested for differential expression that had a p value of less than 0.05 
were considered differentially expressed. These genes were split into two classes, 
upregulated and downregulated in Casz1 mutant hearts. These genes were assessed 
for Gene Ontology (GO) biological process enrichment using Gorilla (Eden et al., 2009), 
with the annotated gene list provided as a background. GO terms enriched in either 
class with an FDR q-value of less than 0.05 were consolidated based on similar 
processes to generate a more manageable set of GO terms for visualization using 
REVIGO (Supek et al., 2011). 
 
Embryonic Cardiac Nuclei Isolation and Flow Cytometry 
Embryos from time-mated females were recovered at E12.5. Hearts were 
dissected in PBS and atria were removed. Ventricles were placed in liquid nitrogen and 
stored at -80°C. Similar genotypes were pooled (n=4 wild-type/4 cardiac nulls) and 
homogenized in liquid nitrogen following a modified cardiac nuclei extraction protocol 
(Franklin et al., 2011). Briefly, ventricle powder was resuspended in homogenization 
buffer (10mM Tris pH 7.4, 250mM sucrose, 1mM EDTA, 0.1% NP-40, 10mM sodium 
butyrate, 0.1mM PMSF, 1X protease inhibitors) and subjected to 10 strokes with a 
dounce homogenizer on ice. Nuclei were passed through a cell strainer, centrifuged at 
1000g for 10 minutes at 4°C and pellets were resuspended in PBS, and fixed with 70% 
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ETOH for 30 minutes on ice. Nuclei were washed and resuspended in FACS Buffer 
(PBS, 7.5% BSA, 2mM EDTA). Nuclei were and treated with 100 µg/ml RNaseA and 
stained with 50 µg/ml propidium iodide (Sigma #P4170) and analyzed on a flow 
cytometer. All samples were analyzed on an Accuri Flowcytometer using CFlowPlus 
Analysis Software. DNA content was determined using at least 100,000 cardiac nuclei. 
 
RESULTS 
Casz1 is expressed in the developing myocardium  
To address the role of Casz1 in mammalian heart development, we cloned full-
length Casz1 from adult mouse heart tissue and conducted a detailed expression 
analysis. We found that Casz1 is first expressed in the cardiac crescent (E7.5, Figure 
2.1A) and continues to be expressed in the heart during cardiac looping (E8, Figure 
2.1B,F; E8.5 – E9.5, Figure 2.1C,D,G,H), when we observed Casz1 expression in the 
future left and right ventricles, in both the compact layer and the trabeculae, and in the 
primitive atria (E9.5, Figure 2.1D,H). Sectioning of heart tissue at these stages further 
revealed Casz1 to be expressed in both the myocardium and endocardium (E8.5; 
Figure 2.1G). By E11.5 we found expression of Casz1 in the heart but also in other 
tissue types including the limb bud, nasal placode, somites, telencephalon, hindbrain, 
and consistent with recent reports the eye (Konstantinides et al., 2015; Mattar et al., 
2015) (Figure 2.1E).  
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We observed that CASZ1 protein is expressed in a pattern similar to that of 
Casz1 mRNA. Our data demonstrates that CASZ1 is expressed in defined subdomains 
of the nucleus (Figure 2.1I-L). Given that it is not technically possible to investigate 
nuclear domains in cardiac tissue in vivo, we examined the compartmentalization of 
CASZ1 in human primary endothelial cells (HUVECS), a cell type previously shown to 
express CASZ1 (Charpentier et al., 2013b). From these studies we demonstrate that 
CASZ1 co-localizes with promyelocytic leukemia (PML), a defining protein of PML 
bodies (Figure S2.1). PML bodies are well-defined nuclear subdomains found to 
associate with a distinct set of genomic loci however, these loci are undefined and 
moreover, there is no known function for PML in cardiovascular development in disease 
(Matera et al., 2009).  
 
Expression analysis demonstrated that CASZ1 protein is expressed in the 
tropomyosin (TMY)-positive cardiomyocytes (Fig. 1I-L), while its expression is mutually 
exclusive to that of Tie2-positive derived endothelial cells (Figure 2.1M) and Wt1-
positive derived epicardial cells (Figure 2.1N). We further find that CASZ1 is co-
expressed in second heart field cells with the second heart field marker ISL1 (Cai et al., 
2003; Sun et al., 2007) (Figure 2.1O-P). Collectively, this data demonstrates that 
CASZ1 is expressed in the nucleus of cardiomyocytes, and by inference in PML bodies, 
of the first and second heart fields during the early stages of cardiogenesis.  
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Casz1-expressing cells give rise to first and second heart field derivatives  
To determine if cardiomyocytes that express Casz1 contribute to derivatives of 
the first and second heart field, we performed genetic lineage tracing of Casz1-
expressing cells. To permanently label this population of cells and its descendants, we 
generated a tamoxifen-inducible “CreERT2” allele (Casz1CreERT2) by homologous 
recombination in embryonic stem cells (ESCs) and subsequently passed the 
Casz1CreERT2 through the germline (Figure S2.2). Treatment with tamoxifen results in 
Cre recombination and in the presence of a tomato reporter (R26RtdT), identification of 
Casz1-expressing cells and their progeny. Co-staining with the cardiomyocyte marker, 
tropomyosin (TMY), enabled lineage identification of tagged cell populations. From this 
lineage analysis we identified cardiomyocytes derived from Casz1-expressing cells 
(Figure S2.2C-D, Figure 2.2A-J) at E12.5 in the left (Figure 2.2I,J) and right ventricular 
walls (Figure 2.2A,B,G,H), the interventricular septum (Figure 2.2C,D), the compact 
layer (Figure 2.2G,H) and the trabeculae (Figure 2.2E,F). We found no evidence that 
Casz1-expressing cells can give rise to cardiac fibroblasts or cardiac endothelium 
however, we note that the recombination frequency of the Casz1CreERT2 allele with the 
present tamoxifen regime is low and therefore we cannot formally rule out this 
possibility. Collectively, our studies show that E8.5 Casz1-expressing cells give rise to 
cardiomyocytes derived from both the first and second heart fields. 
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Casz1 is essential for cardiac development 
To determine the requirement for Casz1 in cardiac development, we mapped the 
cardiac transcriptional start site(s) of Casz1 (Figure S2.3B). Our analysis identified two 
transcriptional start sites in embryonic hearts: one 275 bp upstream and the other 139 
bp upstream from the predicted translational start site.  Using this data we went on to 
generate a conditional “floxed” null allele (Casz1flox-neo) by homologous recombination in 
ESCs. Successful targeting of the selection cassette generated a Casz1flox-neo allele, 
which flanks exon 6 with loxP sites (Figure S2.3A). Exon 6 was chosen because it is a 
critical coding exon located downstream of both Casz1 transcriptional start sites. 
Furthermore, alternate splicing to the next three exons all result in proteins that are out 
of frame.  
 
The presence of the Casz1flox-neo allele in ESCs was confirmed by Southern blot, 
PCR and genomic sequence analysis (Figure S2.3C,D, data not shown). ESCs 
harboring Casz1flox-neo were used to generate chimeric mice which passed the Casz1flox-
neo through the germline. The PGKneo cassette (Liu et al., 2003) was removed by 
mating F1 heterozygous mice to mice expressing FlpE recombinase (Rodriguez et al., 
2000) and Casz1f/+ progeny were mated to an Nkx2.5-Cre line to generate 
Casz1f/+;Nkx2.5Cre/+ (Moses et al., 2001). The resulting Casz1f/+;Nkx2.5Cre/+ mice were 
mated to Casz1f/f mice to generate a cardiac specific conditional Casz1 mutation: 
Casz1f/f;Nkx2.5Cre/+. Expression of Cre from the Nkx2.5-Cre allele was confirmed by 
mating to R26RtdT reporter mice (Madisen et al., 2010) (Figure S2.4) and loss of Casz1 
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in Casz1f/f;Nkx2.5Cre/+ in cardiac but not neural tissue (dorsal root ganglia) confirmed by 
immuno-histochemistry (Figure S2.3E-H). 
 
We observed that heterozygotes containing the Casz1f/+;Nkx2.5Cre/+ alleles are 
viable, fertile, and display no obvious phenotypic abnormalities. In contrast, no 
homozygous mice for the floxed allele, Casz1f/f;Nkx2.5Cre/+, were recovered postnatally, 
indicating that loss of Casz1 in the developing heart is embryonic lethal.  
 
Analysis of timed intercrosses of Casz1f/+;Nkx2.5Cre/+ mice failed to identify viable 
homozygous Casz1f/f;Nkx2.5Cre/+embryos subsequent to E14.5 (Figure 2.3). Gross 
examination of Casz1f/f;Nkx2.5Cre/+embryos demonstrated that E12.5 mutants are 
indistinguishable from their wild-type littermates (Figure 2.3A,B). However, at E13.5 
Casz1f/f;Nkx2.5Cre/+embryos exhibit inflated pericardial sacs, severe edema and blood 
hemorrhaging, consistently indicative of circulatory distress (Figure 2.3C,D) (Conway et 
al., 2003). 
 
Ultrastructural analysis using Scanning Electron Microscopy (Hullinger et al.) of 
Casz1f/f;Nkx2.5Cre/+ hearts at E12.5, showed detectable cardiac malformations including 
an enlarged right atrium and an malformed left ventricle (Figure 2.3E,F). These defects 
are more pronounced by E13.5 (Figure 2.3G,H) with ballooning of the right atria 
indicative of blood pooling in the right ventricle (Deng et al., 1996). Collectively, these 
results demonstrate an essential requirement for Casz1 in mammalian heart 
development between E10.5 and E12.5. 
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Casz1 is required for growth of the cardiac chambers 
Histological examination showed that Casz1f/f;Nkx2.5Cre/+ and wild-type hearts 
were indistinguishable at E10.5 (mean ventricular wall thickness of 15.4±0.44 µm 
versus 16.1±0.70 µm respectively, n=3, p0.42) (Figure 2.3I-J’,O). However by E12.5, 
severe thinning of the myocardium and associated decreased wall thickness was 
observed in Casz1f/f;Nkx2.5Cre/+ embryos as compared to wild-type littermate controls 
(mean of 22.6±1.2 µm; n=2 versus 14.3±0.91 µm; n=4, p<0.005), indicating that Casz1 
is required in the ventricular myocardium. In addition, we observed an underdeveloped 
interventricular septum and decreased trabeculation (Figure 2.3K-L’,P). By E13.5, 
Casz1f/f;Nkx2.5Cre/+ hearts were hypoplastic, with narrower ventricular lumens and 
membranous ventricular septal defects (Figure S2.5). Together these results 
demonstrate that Casz1 is essential for development of the cardiac chambers and 
further imply that Casz1 is essential for cardiomyocyte growth. 
 
Casz1 embryonic nulls phenocopy Casz1f/f;Nkx2.5Cre/+ embryos 
To test if Casz1 is required for embryogenesis prior to E12.5 we generated a 
complete embryonic null allele of Casz1 by mating Casz1f/f mice to a Sox2-Cre driver: 
Casz1f/f;Sox2Cre/+ (Hayashi et al., 2002). Extensive studies have established that Sox2-
Cre is expressed and functions in all cells of the epiblast (Figure 2.4A,B) (Hayashi et al., 
2002; Barrow et al., 2007; Arnold et al., 2009; Delgado-Esteban et al., 2013). We found 
that Casz1f/f;Sox2Cre/+ mice, as with Casz1f/f;Nkx2.5Cre/+, do not survive beyond E14.5. 
Histological examination at E12.5 confirmed that Casz1f/f;Sox2Cre/+ homozygotes have a 
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cardiac phenotype indistinguishable from that of Casz1f/f;Nkx2.5Cre/+mice (ventricular 
wall thickness mean of 41.2±2.1 µm versus 25.8±1.6 µm respectively, n=2, p<0.0005) 
(Figure 2.3I-P,4E-I). These results demonstrate that an initial and essential requirement 
for Casz1 in the mouse embryo is in the developing heart and confirm that loss of 
Casz1 in cardiac tissue leads to hypoplastic growth and embryonic lethality.  
 
Casz1 is essential in the second heart field  
 Cells from the second heart field give rise to the right ventricle, the 
interventricular septum, the outflow tract, both atria, and the atrial septum (Kelly, 2012). 
Our data demonstrated that CASZ1 is co-expressed with the second heart field marker 
ISL1 at E10.5 (Figure 2.1O,P), and our fate mapping studies identified descendants of 
Casz1 expressing cells within second heart field derivatives (Figure 2.2A,B,G,H). We 
further observed that loss of Casz1 in Nkx2.5-positive cells leads to a hypoplastic right 
ventricle. Based on these observations we hypothesize that Casz1 is required for 
second heart field development. To test this hypothesis we generated mice that lack 
Casz1 in the second heart field by crossing Casz1f/f mice to an Isl1-Cre driver, 
Casz1f/f;Isl1Cre/+ (Srinivas et al., 2001). Gross examination of Casz1f/f;Isl1Cre/+ embryos 
showed that they are viable and indistinguishable from heterozygous and wild-type 
littermates at least until E14.5 (Figure 2.5G,H). Examination showed that at E14.5 
Casz1f/f;Isl1Cre/+ hearts have a normal left ventricle (mean=82.6±3.7 µm versus 79.7±5.4 
µm, n=2, p-value=0.66) (Figure 2.5J) while displaying reduced thickness in the right 
(mean=64.5±1.7 µm versus 37.9±4.3 µm, n=2, p-value<0.005) (Figure 2.5I). Though 
there were significant differences in thickness of the ventricular free wall, we did not 
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detect any observable ventricular septal defects (Figure 2.5A-F). Consistently with right 
ventricular hypoplasia, no Casz1f/f;Isl1Cre/+ mice were recovered postnatally, indicating 
that Casz1 is required for the growth of the second heart field. 
 
Regulation of cell growth by Casz1  
The observations that the loss of Casz1 in cardiac tissue leads to a hypoplastic 
heart and a concomitant decrease in chamber wall thickness led us to hypothesize that 
Casz1 functions to regulate cardiomyocyte proliferation. To test this hypothesis, we 
determined the number of cardiomyocytes in wild-type and Casz1f/f;Nkx2.5Cre/+ mice. 
From this analysis, we find cardiomyocytes, as marked by expression of tropomyosin 
(TMY), were significantly reduced in Casz1 cardiac null versus wild-type ventricles at 
E12.5 (Figures 2.6A-F, S2.6), and further found a striking reduction in cardiomyocyte 
number within the ventricular walls of the heart at E12.5 (mean of 868±69 versus 
638±60 cardiomyocytes, n≥3, p<0.05). We note that the cardiac hypoplasia observed in 
Casz1cardiac null hearts is specific to the cardiomyocytes and does not affect the 
epicardium or the endothelial cells at E12.5 (Figure 2.6P,Q). Furthermore, the reduction 
in cell number is not associated with programmed cell death (Figure S2.8). Consistently, 
cardiomyocytes in Casz1 cardiac null hearts continue to express the cardiomyocyte 
markers TMY and cardiac troponin T (cTNT) and we can detect higher order structures 
including sarcomeres with Z-disks (Figure 2.6R-U). Together, these studies support a 
role for Casz1 in cardiomyocyte growth.  
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To validate our findings, we performed a comparative expression analysis of the 
developing heart using RNA isolated from E10.5 hearts (n = 3, cardiac null; n = 3, 
controls), a period before we can detect any cardiac abnormalities in Casz1f/f;Nkx2.5Cre/+ 
embryos. RNA-seq data was processed for differential expression (DE) analysis using 
Cufflinks (Trapnell et al., 2012) (Raw data and full analysis is available at the NCBI 
Gene Expression Omnibus (accession #GSE55394)). We used unbiased gene ontology 
and from this analysis determined the three largest categories of genes downregulated 
as a result of the loss of Casz1 were “Regulation of growth”, Regulation of systems 
processes” and “Cardiac muscle development” (Figure S2.7). Thus, these analyses 
suggest that Casz1 functions to regulate the growth of the cardiac chambers.  
  
Casz1 is required for cardiomyocyte G1-to-S phase transition  
Our phenotypic analysis, cell quantification, and transcriptional profiling are all 
consistent with a role for Casz1 in cardiomyocyte cell division.  To gain insight into the 
mechanisms of Casz1-mediated cardiomyocyte growth, we conducted a detailed 
analysis of cell proliferation. Our results show a significant reduction in EdU 
incorporation in myocardial cells in the developing myocardium in Casz1 cardiac null 
ventricles versus controls (mean of 19.5±0.9%; n=3 versus 13.6±0.8%; n=3, p<0.0001) 
(Figure 2.6G-J,M). The cardiomyocyte mitotic index in E12.5 Casz1f/f;Nkx2.5Cre/+ 
ventricles (mean of 19.6±1.1% versus 13.7±0.98%, n=3, p<0.005) and Casz1f/f;Isl1Cre/+ 
right ventricles (mean of 19.3±1.1% versus 13.5±2.1%, n=2, p<0.05) was also reduced 
as assessed by phospho-histone H3 (pHH3) (Figure 2.6K-L,N,O). Thus, Casz1 acts to 
control cardiomyocyte proliferation in both the first and second heart fields.  
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To further define the mechanism by which Casz1 functions in cardiomyocyte cell 
division, we conducted cell cycle profiling of cardiac nuclei from control and Casz1 
cardiac null heart tissue (Figure 2.7A). Our results indicate that cardiac nuclei null for 
Casz1 display a significant increase in cells in G1-phase (52.3% versus 60.1%) and a 
concomitant decrease of cells in S-phase (26.1% versus 19.4%) while displaying no 
alteration of the percent of cells in G2-phase (21.5% versus 20.5%).  Consistently, we 
observe a significant increase in Casz1 cardiac null cardiomyocytes expressing the 
phosphorylated form of the tumour suppressor protein RB, a highly effective inhibitor of 
the G1-to-S transition (mean of 3.5±0.3% versus 5.3±0.7%, p<0.05) (Figure 2.7B-D) 
(Mulligan and Jacks, 1998). Taken together, our results show that a loss of Casz1 leads 
to a prolonged or arrested S-phase, a decrease in DNA synthesis, an increase in 
phospho-RB, and a decrease in the cardiac mitotic index. Thus, these results support a 
role for Casz1 in the cardiomyocyte G1-to-S cell cycle transition.  
 
DISCUSSION 
Here we report that Casz1 is expressed in mammalian cardiomyocytes and by 
genetic fate mapping studies demonstrate that Casz1-positive cells give rise to 
cardiomyocytes in the first and second heart field.  We show through our phenotypic 
analysis of cardiac conditional null Casz1 embryos, that Casz1 is essential for 
proliferation of cardiomyocytes in both heart fields and define a role of Casz1 in 
cardiomyocyte proliferation. 
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We note that these findings differ from those reported for a Casz1 gene trap line 
of mice that were generated from an ESC line carrying a βgeo cassette integrated into 
the 9th intron of Casz1 (Liu et al., 2014). Mice homozygous for the insertion led to 
embryonic arrest at E16.5, a time point in development much later than those reported 
here in mice in which Casz1 was depleted in both the primary and secondary heart 
fields (Casz1f/f;Nkx2.5Cre/+), in those mice depleted of Casz1 in the second heart field 
(Casz1f/f;Isl1Cre/+) or in a complete embryonic null (Casz1f/f;Sox2Cre/+).  Since the trapped 
allele and our panel of Casz1 mutants are in the same genetic background, it is unclear 
why the trapped allele is less penetrant though it remains formally possible that the 
allele disrupted by the βgeo insertion occurs in an alternatively spliced form of Casz1 
and/or is hypomorphic.  
 
CASZ1 and the G1-to-S phase transition 
During early G1, cells respond to mitotic signals to pause or initiate DNA 
replication (Bertoli et al., 2013).  Our analysis of the cardiomyocyte mitotic index 
coupled with our cell cycle profiling demonstrates a decrease in Casz1 cardiac null cells 
progressing through S-phase. The failure to progress through S-phase, and the 
decrease in cardiomyocyte number in Casz1-null hearts, is not associated with 
programmed cell death, and we show that at the period when we observe decreased 
cardiomyocyte numbers, Casz1-null cardiomyocytes maintain their structural integrity 
and higher ordered structure (Figure 2.6). Given that we observe a decrease in DNA 
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replication in Casz1 null hearts, as shown by EdU, and a concomitant increase in 
phospho-RB, our data strongly imply that Casz1 acts at the G1-to-S phase transition. 
 
We note in our cell cycle profiling that an appreciable number of cells pass 
through the G1-to-S phase. Since it is not possible to isolate pure cardiomyocyte 
population from our Casz1 null embryos these cells most likely represent other cardiac 
cell populations including cardiac fibroblasts and endothelial cells. However, it is 
formally possible that some of these cells may represent cardiomyocytes that have not 
reached the G1-to-S transition; i.e. a period after which they require Casz1.  
 
One the major checkpoint controls of cell cycle is the ‘commitment point’ or 
‘restriction point’ associated with the G1-to-S phase transition. This point in the cycle, 
also known as ‘start’ in yeast, is the point beyond which a cell will pass through the 
cycle without external input (Bertoli et al., 2013). Based on our findings, we presently 
favor a model by which Casz1 is necessary but not sufficient for cardiomyocytes to pass 
the restriction point and commit to the next round of division. We note this role of Casz1 
must be stage specific as we fail to see any phenotypic consequences of removing 
Casz1 during the initial stages of cardiac specification and determination (E6-E8). This 
observation would imply that this checkpoint control is under a separate, as of yet 
unidentified mechanism in the early stages of heart development. In the future, it will be 
of importance to identify the Casz1-dependent pathway during these early stages of 
cardiac development and determine what role, if any, CASZ1 plays in adult 
homoeostasis and injury repair. 
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Figure 2.1. Casz1 is expressed in the developing heart 
Whole mount in situ hybridization at E7.5 (A), E8.0 (B) and (F), E8.5 (C) and (G), E9.5 
(D) and (H), and E11.5 (E). Casz1 is first expressed in myocardial precursors cells 
beginning at embryonic day e7.5 (A). At E8.0, Casz1 transcripts are found in the linear 
heart tube (B) and as the heart undergoes looping (C, D). (E) Casz1 is also expressed 
in the eye, the nasal placode, somites, telencephalon, hindbrain, and the developing 
limb bud. (F-H) Vibratome sections of whole mount embryos reveal that Casz1 is 
expressed specifically in the first heart field at early stages of heart development (F). 
Casz1 is expressed in the myocardium and the endocardium (G) and in the trabeculae 
(H). (I- L) CASZ1 colocalizes with the cardiomyocyte marker tropomyosin (TMY) in the 
myocardium of an E14.5 left ventricle. CASZ1 is not expressed at E14.5 in Tie2-positive 
endothelial cells (M) nor Wt1-positive epicardial cells (N). (M,N) Sections of Tie2-
Cre;R26R-EGFP reporters were used to mark endothelial cells (M) and a Wt1-
Cre;R26R-EGFP reporters to mark epicardial cells. (L) Enlarged image (white box in 
Fig. 1K) of the left ventricular myocardium highlights the expression of CASZ1 within the 
nuclear bodies of the nucleus. (O-P) Immunofluorescent staining for CASZ1 and 
ISL1shows coexpression in OFT myocardium at E10.5. (P) Enlarged images of OFT 
myocardium depicted in (O). MP, myocardial progenitor cells; HT, developing heart 
tube; LH, looped heart; N, neural tube; E, eye; HB, hindbrain; NP, nasal placode; T, 
telencephalon; LB, limb bud; S, somites; PME, pharyngeal mesoderm; MY, 
myocardium; EN, endocardium; TR, trabeculae; CAC, common atrial chamber; CVC, 
common ventricular chamber; CL, compact layer; EPI, epicardium; LV, left ventricle; 
OFT, outflow tract; FG, foregut. Scale bars indicate 20 µm (I – K, M, N), 5 µm (L), 10 µm 
(P), 20 µm (O). 
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Figure 2.2. Lineage tracing with Casz1CreERT2-neo labels cardiomyocytes in first and 
second heart field derivatives 
 (A-J) Immunofluorescent staining for cardiac tropomyosin and DAPI (blue) of 
Casz1CreERT2/+;R26RtdT/+ embryo depicted in (Fig.S2) shows Casz1-expressing cells give 
rise to cardiomyocytes located in the walls of the left (I,J) and right ventricles (A,B,G,H) 
the interventricular septum (C,D), and the trabeculae (E,F). Scale bars indicate 20 µm. 
RV, right ventricle; LV, left ventricle; IVS, interventricular septum; TR, trabeculae; CL, 
compact layer.  
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Figure 2.3. Casz1 is required for cardiac development 
 (A – D) Gross morphology of Casz1f/+;Nkx2.5+/+ wild-type (WT) and Casz1f/f;Nkx2.5Cre/+ 
embryos. By E13.5 Casz1f/f;Nkx2.5Cre/+ embryos are beginning to exhibit edema and 
have decreased blood flow throughout the vasculature. (E – H) SEM analysis of wild-
type and Casz1f/f;Nkx2.5Cre/+ hearts at E12.5 and E13.5 highlights cardiac defects. At 
E12.5, Casz1f/f;Nkx2.5Cre/+ embryos have cardiac malformations including an enlarged 
right atria and an aberrant left ventricle. These defects are more pronounced at E13.5. (I 
– P) Histological analysis of WT and Casz1f/f;Nkx2.5Cre/+ hearts. Casz1f/f;Nkx2.5Cre/+ 
embryos exhibit severe cardiac hypoplasia and ventral septal defects. Hematoxylin & 
Eosin staining of transverse sections shows thinning of the ventricular walls beginning 
at E12.5 leading to severe cardiac hypoplasia. Boxed areas represent enlarged images 
shown to the right of the corresponding section. (L) Arrow highlights the ventricular 
septal defect. (O – P) Quantification of ventricular wall thickness in WT and 
Casz1f/f;Nkx2.5Cre/+ embryos at E10.5 (O), E12.5 (P). Data shown as mean ±SEM and * 
denotes a statistically significant difference (at P<0.05) between WT and 
Casz1f/f;Nkx2.5Cre/+ embryos and NS denotes not significant. Scale bars indicate 60µm 
(I, J, K, L) and 15µm (I’, J’, K’, L’). RV, right ventricle; LV, left ventricle; RA, right atria; 
LA, left atria; OFT, outflow tract; IVS, interventricular septum; CL, compact layer; TR, 
trabeculae.  
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Figure 2.4. Casz1 null embryos phenocopy Casz1 cardiac null embryos   
(A-B) Whole mount LacZ staining of Sox2+/+;R26RLacZ/+ and Sox2Cre/+;R26RLacZ/+ E10.5 
embryos demonstrates that Sox2-Cre is ubiquitously expressed. (C-D) Gross 
morphology of E12.5 Casz1f/+.Sox2+ wild-type (WT) and Casz1f/f;Sox2Cre/+embryos. (E-I) 
Histological analysis of WT and Casz1f/f;Sox2Cre/+ hearts. Casz1f/f;Sox2Cre/+ embryos 
exhibit severe cardiac hypoplasia and ventral septal defects. H & E staining of 
transverse sections shows cardiac hypoplasia at E12.5 Boxed areas represent enlarged 
images shown to the right of the corresponding section. (G) Arrow highlights the 
ventricular septal defect. (I) Quantification of ventricular wall thickness in WT and 
Casz1f/f;Sox2Cre/+ embryos at E12.5. Data shown as mean ±SEM and and *** denotes a 
statistically significant difference (at P<0.0005) between WT and Casz1f/f;Sox2Cre/+ 
embryos and NS denotes not significant. RV, right ventricle; LV, left ventricle; RA, right 
atria; LA, left atria; OFT, outflow tract. Scale bars indicate 60µm (E,G) and 15µm (F,H).  
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Figure 2.5. Casz1 is required in the second heart field 
Histological analysis of WT and Casz1f/f;Isl1Cre/+ hearts at E14.5 demonstrates that 
Casz1f/f;Isl1Cre/+ hearts are misshapen and have a thin right ventricle. Boxed areas 
represent enlarged images shown to the right of the corresponding section. (G-H) Gross 
morphology of E14.5 Casz1f/+;Isl1+ wild-type (WT) and Casz1f/f;Isl1Cre/+ embryos. (I,J) 
Quantification of right (I) and left (J) ventricular wall thickness in WT and Casz1f/f;Isl1Cre/+ 
embryos at E14.5. Data shown as mean ±SEM and *** denotes a statistically significant 
difference (at P<0.0005) between WT and Casz1f/f;Isl1Cre/+ embryos. Scale bars indicate 
60µm (A,D) and 15µm (B,C,E,F).  
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Figure 2.6. Casz1 regulates cardiomyocyte proliferation 
 (A-D’) Immunofluorescent staining for TMY and DAPI (blue) highlights a decrease in 
the number of differentiated cardiomyocytes at E12.5. (E,F) Quantification of results 
from cardiomyocyte cell numbers counted per field at E10.5 (E) and E12.5 (F). In all 
cases, data shown as mean ±SEM of three embryos, and * denotes a statistically 
significant difference (at P<0.05) between WT and Casz1f/f;Nkx2.5Cre/+ embryos and NS 
denotes not significant. (G-J) Immunofluorescent staining for EdU and TMY shows a 
reduction in proliferation in Casz1f/f;Nkx2.5Cre/+ ventricles at E12.5. Zoomed images of 
boxed area in WT (I) and Casz1f/f;Nkx2.5Cre/+ left ventricles (J). (K,L) Immunofluorescent 
staining for phospho-histone H3 along with TMY demonstrates a decreased 
cardiomyocyte mitotic index in Casz1f/f;Nkx2.5Cre/+ embryos as compared to WT in 
sections of E12.5 hearts. (M) Quantitative evaluation of reduced proliferation of 
cardiomocytes in Casz1f/f;Nkx2.5Cre/+ ventricles at E12.5 by EdU incorporation and (N) 
reduced cardiomyocyte mitotic index in Casz1f/f;Nkx2.5Cre/+ ventricles and (O) 
Casz1f/f;Isl1Cre/+right ventricles at E12.5. In all cases, data shown as mean ±SEM of 
three embryos, and *** denotes a statistically significant difference (at P<0.0005) 
between WT and Casz1f/f;Nkx2.5Cre/+ embryos at a given stage. (P,Q) 
Immunofluorescent staining for cTNT to mark cardiomyocytes and FILA to mark the 
epicardium and endothelial cells demonstrates a reduction in cardiomyocytes while 
FILA expression within the epicardium and endothelial cells is comparable to WT at 
E12.5. (R-U) Immunofluorescent staining for phallodin demonstrates that actin filaments 
are intact in Casz1f/f;Nkx2.5Cre/+ E12.5 hearts. (T,U) Boxed areas represent enlarged 
images shown below the corresponding section. Scale bars indicate 10µm (A’-
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D’,K,L,T,U), 20 µm (P-R), 50µm (I,J), 100µm (A,B), and 200µm (C,D,G,H). RV, right 
ventricle; LV, left ventricle; RA, right atria; LA, left atria; OFT, outflow tract, EPI, 
epicardium, MY, myocardium; EN, endothelial cells; S, sarcomere; Z-d, Z-disks. 
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Figure 2.7 – Casz1 is essential for cardiac G1 to S cell cycle transition 
(A) Cell cycle profiles of E12.5 PI-stained cardiac nuclei for Casz1f/+;Nkx2.5+/+ and 
Casz1f/f;Nkx2.5Cre/+ and quantitation of cells with G1, S, or G2/M DNA content, showed 
an increase in G1-phase cells and decrease in S-phase cells in Casz1 null heart tissue. 
(B-C) Immunofluorescent staining for phospho-RB (pRB) and TMY demonstrates an 
increase in the number of pRB-positive cardiomyocytes in Casz1 cardiac null hearts 
versus controls at E12.5. (D) Quantification of results and * denotes a statistically 
significant difference (at P<0.05) between WT and Casz1f/f;Nkx2.5Cre/+ embryos.  
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Supplemental Figure 2.1. CASZ1 is expressed in PML bodies 
Immunofluorescent staining reveals that CASZ1 is co-expressed with PML in the 
nucleus of HUVECS.  
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Supplemental Figure 2.2. Generation of a Casz1CreERT2-neo lineage tracing allele 
(A) Gene targeting strategy for Casz1CreERT2 allele. (B) Germline transmission was 
validated by Southern blot using a 5’ external probe. Heterozygous mice containing the 
Casz1CreERT2 allele are viable, fertile, and display no obvious phenotypic abnormalities. 
(C) Fate mapping experimental design – pregnant females were injected with a single 
dose of tamoxifen at E8.5 and embryos were harvested at E12.5. (D) Image of an E12.5 
Casz1CreERT2/+;R26RtdT/+ embryo. (E) Enlarged image of the heart in (D) shows Casz1-
expressing cells in the embryonic heart. E – EcoRI cut sites; FRT sites – white triangles; 
loxP sites – black triangles. 
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Supplemental Figure 2.3. Generation of a conditional Casz1 allele  
(A) Conditional gene targeting strategy for Casz1flox allele. loxP sites were introduced 
into the Casz1 locus flanking exon 6. (B) 5’ RLM-RACE identified 2 transcription start 
sites in the murine heart. +RT indicates cDNA sample treated with reverse transcriptase 
(RT); -RT indicates control cDNA sample not treated with RT. (C) Germline 
transmission was validated by Southern blot using a 5’ external probe. (D) Mice were 
genotyped by PCR for the presence of the flox allele. Immunofluorescent staining for 
CASZ1, TMY and DAPI confirms depletion of CASZ1 in the myocardium in 
Casz1f/f;Nkx2.5Cre/+ E13.5 hearts (E,F), but is maintained in the dorsal root ganglia 
(DRG) (G,H). H – HindIII cut site; FRT sites – white triangles; loxP sites – black 
triangles; blue bar represents location of a nuclear localization signal; green bars 
indicate location of C2H2 zinc-fingers; red stop sign indicates the location of a premature 
stop codon subsequent to the frameshift following exon6 removal. Scale bars indicate 
20 µm (Bergmann et al.).   
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Supplemental Figure 2.4. Nkx2.5Cre Lineage analysis 
Gross morphology of Nkx2.5Cre/+;R26RtdT/+ embryos at E7.5 (A,E) and E9.5 (B,F), and 
hearts at E12.5 (C,G) and E14.5 (D,H). Cre recombination is observed in the cardiac 
crescent at E7.5 (E), the looped heart at E9.5 (F), the ventricles, the OFT and the atria 
of the four-chambered heart at E12.5 (G) and similarly in the fetal heart at E14.5 (H). 
EXE, extraembryonic tissue; CC, cardiac crescent; LH, looped heart; PME, pharyngeal 
mesoderm; LV, left ventricle; LA, left atria; RV, right ventricle; RA, right atria; OFT, 
outflow tract. 
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Supplemental Figure 2.5. Casz1 cardiac null embryos exhibit severe cardiac 
defects 
Histological analysis of WT (A) and Casz1f/f;Nkx2.5Cre/+ (B) hearts at E13.5 highlights the 
enlarged right atria observed in the SEM data. At E13.5, the cardiac hypoplasia and 
ventricular septal defect is more pronounced and further shows that the 
Casz1f/f;Nkx2.5Cre/+ heart is misshapen and does not form an apex for either the left or 
the right ventricle as seen in the wild-type (highlighted by the arrows in each panel). 
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Supplemental Figure 2.6. Casz1 is required for myocardial development  
(A-L) Immunofluorescent staining for TMY of anterior, mid and posterior sections 
highlights a decrease in differentiated cardiomyocytes in Casz1f/f;Nkx2.5Cre/+ hearts at 
E10.5 (A,B,E,F,I,J) and E12.5 (C,D,G,H,K,L). A, anterior; P, posterior. 
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Supplemental Figure 2.7. RNA-Seq Analysis 
(A) Gene Ontology (GO) Analysis – significant cellular processes downregulated in 
Casz1f/f;Nkx2.5Cre/+ E10.5 hearts. (B) Cell growth genes downregulated in 
Casz1f/f;Nkx2.5Cre/+ hearts.  
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Supplemental Figure 2.8. Loss of Casz1 does not lead to programmed cell death.    
Immunofluorescent staining for cleaved caspase-3, TMY and DAPI (blue) to identify 
apoptotic cells shows that Casz1f/f;Nkx2.5Cre/+ hearts do not have an increase in 
programmed cell death compared to controls. As a positive control, sections of the 
neural tube (NT) were also analyzed. Data represents 2 independent experiements. LV, 
left ventricle; RV, right ventricle; IVS, interventricular septum.  
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Supplemental Table 2.1. Primer sequences 
 
Gene  Primer Sequence  Size 
Casz1 Genotyping  Forward: 5’ – CACAGGAACTGTCTCCACTGTC – 3’ 
Reverse: 5’ – GTTTCTGTTGCTGGGTTAGGTT – 3’ 
Flox: 571 bp 
WT: 471 bp 
Cre Genotyping  Forward: 5’ – TGGGCCAGCTAAACATGCTT – 3’ 
Reverse: 5’ – GGTGTTATAAGCAATCCCCAGA – 3’ 
236 bp 
R26RtdT Genotyping  Forward: 5’ – GGCATTAAAGCAGCGTATCC – 3’ 
Reverse: 5’ – CTGTTCCTGTACGGCATGG – 3’  
126 bp 
Casz1 5’ RACE Outer 
Primer 
Reverse: 5’ – GGATGTATTCCTCGTATTTGGAGA – 3’ 
 
N/A 
Casz1 5’ RACE Inner 
Primer 
Reverse: 5’ – AGCTGATCTTCTTGGCCAGCTCAT – 3’ 
 
N/A 
Casz1 5’ Southern 
Probe 
Forward: 5’ – CTGAAAGCACCCGGTGCACCGACC – 3’ 
Reverse: 5’ – CTGAAGCCTGCCTGGTGCTGGGGC – 3’ 
486 bp 
Casz1 In Situ Probe  Forward: 5’ – GAGAAACCTCCTCTCTGAGGGACT – 3’ 
Reverse: 5’ – CTGGCAATATATTTCTGGTAAATG – 3’ 
904 bp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
123 
 
REFERENCES 
Ahuja, P., Sdek, P. and MacLellan, W. R. (2007). Cardiac myocyte cell cycle control in 
development, disease, and regeneration. Physiological reviews 87, 521-544. 
Amin, N. M., Gibbs, D. and Conlon, F. L. (2014). Differential regulation of CASZ1 
protein expression during cardiac and skeletal muscle development. Developmental 
dynamics : an official publication of the American Association of Anatomists 243, 948-
956. 
Arnold, S. J., Sugnaseelan, J., Groszer, M., Srinivas, S. and Robertson, E. J. 
(2009). Generation and analysis of a mouse line harboring GFP in the Eomes/Tbr2 
locus. Genesis 47, 775-781. 
Barrow, J. R., Howell, W. D., Rule, M., Hayashi, S., Thomas, K. R., Capecchi, M. R. 
and McMahon, A. P. (2007). Wnt3 signaling in the epiblast is required for proper 
orientation of the anteroposterior axis. Developmental biology 312, 312-320. 
Bergmann, O., Bhardwaj, R. D., Bernard, S., Zdunek, S., Barnabe-Heider, F., 
Walsh, S., Zupicich, J., Alkass, K., Buchholz, B. A., Druid, H. et al. (2009). Evidence 
for cardiomyocyte renewal in humans. Science 324, 98-102. 
Bersell, K., Arab, S., Haring, B. and Kuhn, B. (2009). Neuregulin1/ErbB4 signaling 
induces cardiomyocyte proliferation and repair of heart injury. Cell 138, 257-270. 
Bertoli, C., Skotheim, J. M. and de Bruin, R. A. (2013). Control of cell cycle 
transcription during G1 and S phases. Nature reviews. Molecular cell biology 14, 518-
528. 
Cai, C. L., Liang, X., Shi, Y., Chu, P. H., Pfaff, S. L., Chen, J. and Evans, S. (2003). 
Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and 
contributes a majority of cells to the heart. Developmental cell 5, 877-889. 
Charpentier, M. S., Dorr, K. M. and Conlon, F. L. (2013a). Transcriptional regulation 
of blood vessel formation: The role of the CASZ1/Egfl7/RhoA pathway. Cell cycle 12. 
Charpentier, M. S., Christine, K. S., Amin, N. M., Dorr, K. M., Kushner, E. J., 
Bautch, V. L., Taylor, J. M. and Conlon, F. L. (2013b). CASZ1 promotes vascular 
assembly and morphogenesis through the direct regulation of an EGFL7/RhoA-
mediated pathway. Developmental cell 25, 132-143. 
Christine, K. S. and Conlon, F. L. (2008). Vertebrate CASTOR is required for 
differentiation of cardiac precursor cells at the ventral midline. Developmental cell 14, 
616-623. 
Christoffels, V. M., Habets, P. E., Franco, D., Campione, M., de Jong, F., Lamers, 
W. H., Bao, Z. Z., Palmer, S., Biben, C., Harvey, R. P. et al. (2000). Chamber 
124 
 
formation and morphogenesis in the developing mammalian heart. Developmental 
biology 223, 266-278. 
Conway, S. J., Kruzynska-Frejtag, A., Kneer, P. L., Machnicki, M. and Koushik, S. 
V. (2003). What cardiovascular defect does my prenatal mouse mutant have, and why? 
Genesis 35, 1-21. 
Creazzo, T. L., Godt, R. E., Leatherbury, L., Conway, S. J. and Kirby, M. L. (1998). 
Role of cardiac neural crest cells in cardiovascular development. Annual review of 
physiology 60, 267-286. 
Delgado-Esteban, M., Garcia-Higuera, I., Maestre, C., Moreno, S. and Almeida, A. 
(2013). APC/C-Cdh1 coordinates neurogenesis and cortical size during development. 
Nature communications 4, 2879. 
Deng, M. C., Dasch, B., Erren, M., Mollhoff, T. and Scheld, H. H. (1996). Impact of 
left ventricular dysfunction on cytokines, hemodynamics, and outcome in bypass 
grafting. The Annals of thoracic surgery 62, 184-190. 
Eden, E., Navon, R., Steinfeld, I., Lipson, D. and Yakhini, Z. (2009). GOrilla: a tool 
for discovery and visualization of enriched GO terms in ranked gene lists. BMC 
bioinformatics 10, 48. 
Eulalio, A., Mano, M., Dal Ferro, M., Zentilin, L., Sinagra, G., Zacchigna, S. and 
Giacca, M. (2012). Functional screening identifies miRNAs inducing cardiac 
regeneration. Nature 492, 376-381. 
Franklin, S., Zhang, M. J., Chen, H., Paulsson, A. K., Mitchell-Jordan, S. A., Li, Y., 
Ping, P. and Vondriska, T. M. (2011). Specialized compartments of cardiac nuclei 
exhibit distinct proteomic anatomy. Molecular & cellular proteomics : MCP 10, M110 
000703. 
Hama, H., Kurokawa, H., Kawano, H., Ando, R., Shimogori, T., Noda, H., Fukami, 
K., Sakaue-Sawano, A. and Miyawaki, A. (2011). Scale: a chemical approach for 
fluorescence imaging and reconstruction of transparent mouse brain. Nature 
neuroscience 14, 1481-1488. 
Hayashi, S., Lewis, P., Pevny, L. and McMahon, A. P. (2002). Efficient gene 
modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Mechanisms of 
development 119 Suppl 1, S97-S101. 
Heallen, T., Zhang, M., Wang, J., Bonilla-Claudio, M., Klysik, E., Johnson, R. L. and 
Martin, J. F. (2011). Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte 
proliferation and heart size. Science 332, 458-461. 
Hullinger, T. G., Montgomery, R. L., Seto, A. G., Dickinson, B. A., Semus, H. M., 
Lynch, J. M., Dalby, C. M., Robinson, K., Stack, C., Latimer, P. A. et al. (2012). 
125 
 
Inhibition of miR-15 protects against cardiac ischemic injury. Circulation research 110, 
71-81. 
Ikenishi, A., Okayama, H., Iwamoto, N., Yoshitome, S., Tane, S., Nakamura, K., 
Obayashi, T., Hayashi, T. and Takeuchi, T. (2012). Cell cycle regulation in mouse 
heart during embryonic and postnatal stages. Development, growth & differentiation 54, 
731-738. 
Kelly, R. G. (2012). The second heart field. Current topics in developmental biology 
100, 33-65. 
Kisanuki, Y. Y., Hammer, R. E., Miyazaki, J., Williams, S. C., Richardson, J. A. and 
Yanagisawa, M. (2001). Tie2-Cre transgenic mice: a new model for endothelial cell-
lineage analysis in vivo. Developmental biology 230, 230-242. 
Konstantinides, N., Rossi, A. M. and Desplan, C. (2015). Common temporal identity 
factors regulate neuronal diversity in fly ventral nerve cord and mouse retina. Neuron 
85, 447-449. 
Lavine, K. J., Yu, K., White, A. C., Zhang, X., Smith, C., Partanen, J. and Ornitz, D. 
M. (2005). Endocardial and epicardial derived FGF signals regulate myocardial 
proliferation and differentiation in vivo. Developmental cell 8, 85-95. 
Levy, D., Ehret, G. B., Rice, K., Verwoert, G. C., Launer, L. J., Dehghan, A., Glazer, 
N. L., Morrison, A. C., Johnson, A. D., Aspelund, T. et al. (2009). Genome-wide 
association study of blood pressure and hypertension. Nature genetics 41, 677-687. 
Li, F., Wang, X., Capasso, J. M. and Gerdes, A. M. (1996). Rapid transition of cardiac 
myocytes from hyperplasia to hypertrophy during postnatal development. Journal of 
molecular and cellular cardiology 28, 1737-1746. 
Liu, P., Jenkins, N. A. and Copeland, N. G. (2003). A highly efficient recombineering-
based method for generating conditional knockout mutations. Genome research 13, 
476-484. 
Liu, Z., Yang, X., Tan, F., Cullion, K. and Thiele, C. J. (2006). Molecular cloning and 
characterization of human Castor, a novel human gene upregulated during cell 
differentiation. Biochemical and biophysical research communications 344, 834-844. 
Liu, Z., Li, W., Ma, X., Ding, N., Spallotta, F., Southon, E., Tessarollo, L., Gaetano, 
C., Mukoyama, Y. S. and Thiele, C. J. (2014). Essential Role of the Zinc Finger 
Transcription Factor Casz1 for Mammalian Cardiac Morphogenesis and Development. 
The Journal of biological chemistry. 
Lu, X., Wang, L., Lin, X., Huang, J., Charles Gu, C., He, M., Shen, H., He, J., Zhu, J., 
Li, H. et al. (2014). Genome-wide association study in Chinese identifies novel loci for 
blood pressure and hypertension. Human molecular genetics. 
126 
 
Madisen, L., Zwingman, T. A., Sunkin, S. M., Oh, S. W., Zariwala, H. A., Gu, H., Ng, 
L. L., Palmiter, R. D., Hawrylycz, M. J., Jones, A. R. et al. (2010). A robust and high-
throughput Cre reporting and characterization system for the whole mouse brain. Nature 
neuroscience 13, 133-140. 
Maillet, M., van Berlo, J. H. and Molkentin, J. D. (2013). Molecular basis of 
physiological heart growth: fundamental concepts and new players. Nature reviews. 
Molecular cell biology 14, 38-48. 
Manner, J., Perez-Pomares, J. M., Macias, D. and Munoz-Chapuli, R. (2001). The 
origin, formation and developmental significance of the epicardium: a review. Cells, 
tissues, organs 169, 89-103. 
Matera, A. G., Izaguire-Sierra, M., Praveen, K. and Rajendra, T. K. (2009). Nuclear 
bodies: random aggregates of sticky proteins or crucibles of macromolecular assembly? 
Developmental cell 17, 639-647. 
Mattar, P., Ericson, J., Blackshaw, S. and Cayouette, M. (2015). A conserved 
regulatory logic controls temporal identity in mouse neural progenitors. Neuron 85, 497-
504. 
Moses, K. A., DeMayo, F., Braun, R. M., Reecy, J. L. and Schwartz, R. J. (2001). 
Embryonic expression of an Nkx2-5/Cre gene using ROSA26 reporter mice. Genesis 
31, 176-180. 
Mulligan, G. and Jacks, T. (1998). The retinoblastoma gene family: cousins with 
overlapping interests. Trends in genetics : TIG 14, 223-229. 
Pasumarthi, K. B. and Field, L. J. (2002). Cardiomyocyte cell cycle regulation. 
Circulation research 90, 1044-1054. 
Porrello, E. R., Johnson, B. A., Aurora, A. B., Simpson, E., Nam, Y. J., Matkovich, 
S. J., Dorn, G. W., 2nd, van Rooij, E. and Olson, E. N. (2011). MiR-15 family 
regulates postnatal mitotic arrest of cardiomyocytes. Circulation research 109, 670-679. 
Rodriguez, C. I., Buchholz, F., Galloway, J., Sequerra, R., Kasper, J., Ayala, R., 
Stewart, A. F. and Dymecki, S. M. (2000). High-efficiency deleter mice show that FLPe 
is an alternative to Cre-loxP. Nature genetics 25, 139-140. 
Sedmera, D., Reckova, M., DeAlmeida, A., Coppen, S. R., Kubalak, S. W., Gourdie, 
R. G. and Thompson, R. P. (2003). Spatiotemporal pattern of commitment to slowed 
proliferation in the embryonic mouse heart indicates progressive differentiation of the 
cardiac conduction system. The anatomical record. Part A, Discoveries in molecular, 
cellular, and evolutionary biology 274, 773-777. 
Sojka, S., Amin, N. M., Gibbs, D., Christine, K. S., Charpentier, M. S. and Conlon, 
F. L. (2014). Congenital heart disease protein 5 associates with CASZ1 to maintain 
myocardial tissue integrity. Development 141, 3040-3049. 
127 
 
Soonpaa, M. H., Kim, K. K., Pajak, L., Franklin, M. and Field, L. J. (1996). 
Cardiomyocyte DNA synthesis and binucleation during murine development. The 
American journal of physiology 271, H2183-2189. 
Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. 
Nature genetics 21, 70-71. 
Srinivas, S., Watanabe, T., Lin, C. S., William, C. M., Tanabe, Y., Jessell, T. M. and 
Costantini, F. (2001). Cre reporter strains produced by targeted insertion of EYFP and 
ECFP into the ROSA26 locus. BMC developmental biology 1, 4. 
Sun, Y., Liang, X., Najafi, N., Cass, M., Lin, L., Cai, C. L., Chen, J. and Evans, S. M. 
(2007). Islet 1 is expressed in distinct cardiovascular lineages, including pacemaker and 
coronary vascular cells. Developmental biology 304, 286-296. 
Supek, F., Bosnjak, M., Skunca, N. and Smuc, T. (2011). REVIGO summarizes and 
visualizes long lists of gene ontology terms. PloS one 6, e21800. 
Takeuchi, F., Isono, M., Katsuya, T., Yamamoto, K., Yokota, M., Sugiyama, T., 
Nabika, T., Fujioka, A., Ohnaka, K., Asano, H. et al. (2010). Blood pressure and 
hypertension are associated with 7 loci in the Japanese population. Circulation 121, 
2302-2309. 
Testa, G., Zhang, Y., Vintersten, K., Benes, V., Pijnappel, W. W., Chambers, I., 
Smith, A. J., Smith, A. G. and Stewart, A. F. (2003). Engineering the mouse genome 
with bacterial artificial chromosomes to create multipurpose alleles. Nature 
biotechnology 21, 443-447. 
Trapnell, C., Pachter, L. and Salzberg, S. L. (2009). TopHat: discovering splice 
junctions with RNA-Seq. Bioinformatics 25, 1105-1111. 
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., 
Salzberg, S. L., Rinn, J. L. and Pachter, L. (2012). Differential gene and transcript 
expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature 
protocols 7, 562-578. 
Vacalla, C. M. and Theil, T. (2002). Cst, a novel mouse gene related to Drosophila 
Castor, exhibits dynamic expression patterns during neurogenesis and heart 
development. Mech Dev 118, 265-268. 
von Gise, A., Lin, Z., Schlegelmilch, K., Honor, L. B., Pan, G. M., Buck, J. N., Ma, 
Q., Ishiwata, T., Zhou, B., Camargo, F. D. et al. (2012). YAP1, the nuclear target of 
Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not 
hypertrophy. Proceedings of the National Academy of Sciences of the United States of 
America 109, 2394-2399. 
128 
 
Wadugu, B. and Kuhn, B. (2012). The role of neuregulin/ErbB2/ErbB4 signaling in the 
heart with special focus on effects on cardiomyocyte proliferation. American journal of 
physiology. Heart and circulatory physiology 302, H2139-2147. 
Wessels, A., van den Hoff, M. J., Adamo, R. F., Phelps, A. L., Lockhart, M. M., 
Sauls, K., Briggs, L. E., Norris, R. A., van Wijk, B., Perez-Pomares, J. M. et al. 
(2012). Epicardially derived fibroblasts preferentially contribute to the parietal leaflets of 
the atrioventricular valves in the murine heart. Developmental biology 366, 111-124. 
Xin, M., Olson, E. N. and Bassel-Duby, R. (2013). Mending broken hearts: cardiac 
development as a basis for adult heart regeneration and repair. Nature reviews. 
Molecular cell biology 14, 529-541. 
Xin, M., Kim, Y., Sutherland, L. B., Qi, X., McAnally, J., Schwartz, R. J., 
Richardson, J. A., Bassel-Duby, R. and Olson, E. N. (2011). Regulation of insulin-like 
growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart 
size. Science signaling 4, ra70. 
 
  
129 
 
Chapter 3: Discussion and Future Directions 
 
The four-chambered vertebrate heart arises from a series of complex processes 
during embryonic development that includes the specification and differentiation of the 
different cardiac cell types within the heart, proliferation, and morphological movements 
of the early heart fields (Parameswaran and Tam, 1995; Tam et al., 1997; Christoffels et 
al., 2000; Harvey, 2002; Buckingham et al., 2005; Tzouanacou et al., 2009; van den 
Berg et al., 2009; Evans et al., 2010; Meilhac et al., 2014). These processes are closely 
associated with the onset in expression of a number of critical cardiogenic 
transcriptional factors, which function combinatorally to activate the appropriate 
cardiogenic gene program and promote proper heart growth. Studies on the progression 
of cardiogenesis all support the idea that there is no master regulator of cardiac 
development that is necessary and sufficient to activate the cardiac program. Instead 
the transcriptional control of heart development occurs by the combinatorial activity of a 
number of critical cardiogenic transcription factors (Sepulveda et al., 1998; Morin et al., 
2000; Hiroi et al., 2001; Buckingham et al., 2005; Stennard et al., 2005; Stennard and 
Harvey, 2005; Abu-Issa and Kirby, 2007; Abu-Issa and Kirby, 2008; Vincentz et al., 
2008; Junion et al., 2012; Meilhac et al., 2014). One of these factors, Casz1, is critical 
for heart development; however, there are huge deficiencies in our understanding of the 
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mechanism by which Casz1 regulates aspects of cardiac development. This dissertation 
comprises a set of studies that investigates the role of Casz1 during cardiac 
development. In an effort to identify the requirement for Casz1 during cardiac 
development, we generated a Casz1 conditional “floxed” allele and a Casz1 tamoxifen-
inducible allele and subsequently produced mice harboring these constructs. In 
addition, we developed an embryonic cardiac nuclei extraction protocol and determined 
cell cycle profiles of wild-type hearts and hearts depleted of Casz1. From these studies, 
we determined that Casz1 is required for cardiac development. Furthermore, we show 
that Casz1 is a critical regulator of cardiomyocyte proliferation and is necessary for 
proper G1-to-S-phase cell cycle progression, thus identifying Casz1 as a key 
cardiogenic transcription factor required for proper heart growth.        
 
Casz1 is an essential cardiac transcription factor required for development 
 In Chapter 2, we demonstrated that Casz1 is required for cardiac development, 
and is specifically required for the growth and proper development of the cardiac 
chambers. Casz1-null mice exhibit severe ventricular hypoplasia and ventricular septal 
defects (VSDs) (Dorr et al., in review). In normal mammalian development, the wall 
between the left and right ventricle, termed the interventricular septum (IVS), closes 
before birth. This separation of the chambers is critical to separate oxygen-rich blood 
from oxygen-low blood. A VSD is congenital heart defect (CHD) defined as a hole in the 
interventricular septum, which leads to a higher work load for the heart, higher pressure 
in the heart and/or reduced oxygen to the body. Normally, the left ventricular chamber 
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only pumps blood to the body, and the right ventricular chamber only pumps blood to 
the lungs. However, in a patient with VSD, blood can travel across the hole from the left 
to the right ventricle and be pumped into the lung arteries, leading to lung congestion 
and labored breathing. VSDs are the most common type of human congenital heart 
defects. Currently, VSDs are treated primarily through surgical repair and the patient 
can enjoy a high quality of life. However, if untreated, VSDs can lead to heart failure, 
pulmonary hypertension and subsequent death. As such, early detection of these 
malformations in the newborn is critical to avoid mortality, morbidity, and handicap 
(Hoffman, 1995; Richmond and Wren, 2001; Hoffman and Kaplan, 2002; van der Linde 
et al., 2011; Fahed et al., 2013; Pediatric Cardiac Genomics et al., 2013). Despite this, 
heart disease goes unrecognized in newborn babies in more than half of those with 
congenital cardiac malformations due to the fact that many infants with heart defects are 
asymptomatic at birth (Richmond and Wren, 2001).  
Studies that identify essential cardiac transcription factors and their gene targets 
and protein interaction partners will lead to an even more comprehensive list of potential 
risk factors for CHD. Contemporary genomic methodologies provide opportunities for 
comprehensive genomic analyses of all CHD patients. The NIH Heart, Lung, and Blood 
Institute are leading the effort to study genetic pathogenesis in thousands of CHD 
patients (Pediatric Cardiac Genomics et al., 2013). Deciphering the contributions of 
genetic and nongenetic causes of CHD has benefited from extensive model organism 
studies that have provided a wealth of insights into cardiac development. Molecular 
pathways have been identified that orchestrate formation of the cardiogenic fields, and 
which drive atrial, ventricular, inflow, and outflow tract morphogenesis. Within these 
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pathways, details have emerged about molecules that promote lineage specification, 
differentiation, cell growth and proliferation, migration, and that orchestrate temporal 
and spatial patterns of gene expression  (Fishman and Olson, 1997; Srivastava and 
Olson, 2000; Buckingham et al., 2005; Srivastava, 2006; Evans et al., 2010; Vincent 
and Buckingham, 2010; Singh et al., 2011; Boettger and Braun, 2012; Kim et al., 2012; 
Munshi, 2012; von Gise and Pu, 2012; Fahed et al., 2013; Meilhac et al., 2014). 
Positioning previously discovered and novel CHD genes onto this blueprint presents 
extraordinary opportunities to enhance our knowledge of cardiac development and to 
fully understand the causes and mechanisms of CHD. The studies outlined in this 
thesis, focused on the role of Casz1 during murine cardiac development. Interestingly, 
the human ortholog of CASZ1 localizes to chromosome 1p36. Deletion of this region of 
the genome is quite common and leads to a myriad of genetic abnormalities including 
cardiac structural defects and cardiomyopathy (Heilstedt et al., 2003a; Heilstedt et al., 
2003b; Battaglia et al., 2008). Of the structural defects observed, VSDs and ASDs 
(atrial septal defects) are the most common (Battaglia et al., 2008). Here, we have 
identified a novel CHD gene, Casz1, in mice, and demonstrated that cardiac-specific as 
well as complete loss of Casz1 gives rise to a VSD phenotype, providing further 
knowledge about the causes and mechanisms giving rise to CHD.       
 
Casz1 regulates G1-to-S-phase cardiomyocyte cell cycle progression 
Our studies demonstrated an essential requirement for Casz1 in regulating 
cardiomyocyte proliferation in both the first and second heart fields. Specifically, we 
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showed that loss of Casz1 in the embryonic heart leads to a prolonged or arrested S-
phase, a decrease in DNA synthesis, an increase in phosphorylated-Rb and an 
associated decrease in the cardiomyocyte mitotic index, suggesting that Casz1 is 
required for G1-to-S-phase cell cycle progression. This leads to a severely hypoplastic 
heart, characterized by a dramatic decrease in the number of cardiomyocytes and 
eventual embryonic lethality.  
The identification of the molecules and signals that regulate cardiomyocyte cell 
cycle progression is critical to understanding cardiac growth and regeneration potential. 
As described in Chapter 1, the embryonic heart is characterized by a burst of 
cardiomyocyte proliferation that decreases as development proceeds. Conversely, the 
adult heart shows limited ability to proliferate (Erokhnia, 1968a; Erokhnia, 1968b; Dowell 
and McManus, 1978; Clubb and Bishop, 1984; Oparil et al., 1984; Goldspink et al., 
1986; Li et al., 1996; Soonpaa et al., 1996; Soonpaa and Field, 1997; Bergmann et al., 
2009; Walsh et al., 2010; Laflamme and Murry, 2011; Maillet et al., 2013; Mollova et al., 
2013). Although much is known about the cardiac transcription factors and pathways 
that are required for proper heart development, very little is known about the cardiac 
transcription factors that regulate the cardiomyocyte cell cycle. In addition, the stage 
specific transcriptional requirements for cardiomyocyte cell cycle regulators are 
unknown. Furthermore, the length of the cell cycle remains elusive; however, studies 
suggest that it is extremely long, with estimates of greater than 24 hours (Bersell et al., 
2009; Mollova et al., 2013). With all of this in mind, the demonstration that Casz1 plays 
a role in regulating the G1-to-S-phase transition of the cardiomyocyte cell cycle is a 
significant finding and worth further exploration.       
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In Chapter 2, we demonstrated, using a novel cardiac nuclei isolation technique 
followed by cell cycle analysis, that Casz1-cardiac-null hearts show a significant 
increase in number of cells in G1-phase combined with a significant decrease in the 
number of cells in S-phase. This indicated that a proportion of the cells were either 
arrested in G1-phase, or had undergone cell death. To validate these findings, we 
further showed an increase in the number of cardiomyocytes expressing the G1-phase 
marker, phophosphorylated-Rb protein. Rb is a well-established negative regulator of 
the cell cycle and is responsible for a major G1-phase checkpoint, which blocks S-phase 
entry (Figure 1.1) (Pardee, 1989; Weinberg, 1995; Foster et al., 2010; Bertoli et al., 
2013). Subsequent programmed cell death analysis did not show an alteration 
indicating that cell cycle arrest occurred instead of death. The mammalian cell cycle 
consists of 2 main parts: mitosis and interphase. During interphase or S-phase (for 
synthesis), the genome is duplicated. During mitosis (M-phase) cell division occurs. G1- 
and G2-phases are gaps between mitosis and S phase and between S phase and 
mitosis, respectively. G1-phase is usually where decisions are made as to whether to 
enter a resting quiescent stage known as G0 or to continue cycling and commit to 
replicating the genome and mitosis. The point in G1-phase where this growth factor–
dependent decision is made is known as the restriction point (R) (Morgan, 1997; Foster 
et al., 2010; Lim and Kaldis, 2013; Alberts, 2015). Based on our findings, we presently 
favor a model by which Casz1 is necessary but not sufficient for cardiomyocytes to pass 
the restriction point and commit to the next round of division. We note this role of Casz1 
must be stage specific as we fail to see any phenotypic consequences of removing 
Casz1 during the initial stages of cardiac specification and determination (E6-E8). This 
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observation would imply that this checkpoint control is under a separate, as of yet 
unidentified mechanism in the early stages of heart development. In the future, it will be 
of importance to identify the Casz1-dependent pathway during these early stages of 
cardiac development and determine what role, if any, Casz1 plays in adult 
homoeostasis and injury repair. 
 
Future Directions 
To date, our Casz1 studies have focused on the role of Casz1 during embryonic 
development. Going forward, our efforts will be aimed towards an in-depth phenotypic 
analysis to determine what role, if any, Casz1 plays in adult homeostasis and injury 
repair. I have previously shown by RT-PCR analysis that Casz1 is expressed in the 
adult heart. Furthermore, Casz1CreERT2 adult mice treated with a diet of tamoxifen chow 
for 3 weeks identified Casz1-expressing cells in the cardiomyocytes of the adult 
myocardium (Dorr et al, unpublished). Together this data suggests that Casz1 plays a 
role in the adult heart. To elucidate the genetic requirement for Casz1 in the postnatal 
heart, the Casz1flox/flox mice will be crossed first to the tamoxifen inducible α–MHC-
MerCreMer driver (Sohal et al., 2001). The α-MHC promoter drives expression 
exclusively in cardiomyocytes and has been used extensively in studies of cardiac gene 
function. The promoter drives expression in embryonic and adult atrial cardiomyocytes. 
Expression in ventricular cardiomyocytes is observed mainly after birth (Ng et al., 1991; 
Palermo et al., 1996; Buerger et al., 2006). The main advantage to the tamoxifen-
inducible system is the temporal control of Cre activation (Nagy, 2000). Six-week old 
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adult mice will be given a single dose of tamoxifen via intraperitoneal injection for 5 
sequential days (Sohal et al., 2001). First, it will be essential to determine if any overt 
phenotype is displayed and if so, to determine if it leads to lethality. Observable 
phenotypes include: lethargy, labored breathing, weight loss, and sudden death. Next, a 
detailed phenotypic analysis will be necessary and include: histology to identify 
structural defects, echocardiograms to measure cardiac function, and Picrosirius red 
staining to measure fibrosis. 
Having established in Chapter 2 that Casz1 is a critical regulator of embryonic 
cardiomyocyte proliferation with links to the cardiomyocyte cell cycle, identifying the role 
of Casz1 in the adult myocardium is of utmost importance. Many questions arise that 
need to be addressed: 1) Is Casz1 upregulated during myocardial injury? 2) Do hearts 
depleted of Casz1 show any defects in injury repair? 3) If so, are these defects related 
to the cardiomyocyte cell cycle – do we observe dramatic changes in proliferation levels 
when compared to controls? 4) What genes does Casz1 regulate and what genes does 
Casz1 interact with in the adult heart? Preliminary evidence in neonatal cardiomyocytes 
indicates that Casz1 does play a role in regulating the cardiomyocyte cell cycle. We 
generated a human CASZ1 shRNA knockdown lentivirus and a mouse Casz1 
overexpression adenovirus for in vitro analyses (Charpentier et al., 2013)(Dorr et al., 
unpublished).  Next, we treated P1 wild-type neonatal cardiomyocytes with each virus 
and subsequently performed cell cycle analsysis to reveal a significant increase of 
cardiomyocytes in G1-phase and a concomitant decrease of cardiomyocytes in S-
phase. This data recapitulates what we observed in embryonic cardiomyocytes and 
indicates that Casz1 plays a role in postnatal cardiomyocyte cell cycle regulation (Dorr 
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et al., unpublished). To address these issues in vivo and to complement the adult 
Casz1-cardiac-null mice detailed above, we must first examine Casz1 gene expression 
levels in myocardial injured wild-type adult hearts. Next, it will be critical to determine if 
our Casz1flox/flox;α-MHC-MerCreMer mice show defects in cardiomyocyte proliferation as 
assessed by EdU and pHH3 analyses. If we see alterations in cardiomyocyte 
proliferation, then we will perform myocardial injury experiments on Casz1 cardiac null 
adult hearts.  Studies in mice have demonstrated that adult cardiomyocytes proliferate 
at a low rate by division of pre-existing cardiomyocytes during normal aging and this 
process increases by four-fold in areas adjacent to myocardial injury (Li et al., 1996; 
Soonpaa et al., 1996; Soonpaa and Field, 1997; Soonpaa and Field, 1998; Walsh et al., 
2010; Maillet et al., 2013; Porrello et al., 2013; Senyo et al., 2013). If Casz1 is required 
for adult cardiomyocyte proliferation, then we would expect to see a decrease in the 
proliferation rate of cardiomyocytes in response to injury. 
  To date, all genetic manipulations of Casz1 have been done via loss-of-functions 
studies. Casz1 gain-of-function studies have been limited to cell culture experiments 
and RNA injection techniques in Xenopus embryos. We generated a Casz1-
overexpression adenovirus and seen successful incorporation and enhanced 
expression of Casz1 in neonatal cardiomyocytes (See above). We have gone on to 
show that overexpression of Casz1 in these cells leads to cell cycle defects further 
demonstrating that Casz1 is necessary to regulate the cardiomyocyte cell cycle and 
suggesting that it could be sufficient as well. In Xenopus, overexpression of Casz1 also 
results in abnormal cardiac morphogenesis (Sojka et al., 2014). To determine if Casz1 
is necessary and sufficient for cardiomyocyte cell cycle progression and to further define 
138 
 
the role of Casz1 during cardiac development, we aim to generate a transgenic mouse 
that overexpresses Casz1. To overexpress Casz1 in the embryonic heart, we will clone 
the full-length mouse Casz1 cDNA (utilized for the neonatal studies detailed above) into 
the Nkx2.5 promoter, which is expressed in early cardiac progenitor cells beginning at 
E7.5 (Moses et al., 2001). To overexpress Casz1 in the adult heart, we will clone this 
construct into the α-MHC promoter which is expressed in the adult myocardium (Ng et 
al., 1991; Palermo et al., 1996; Buerger et al., 2006). Our phenotypic analysis will 
include a detailed characterization of any proliferation and cell cycle defects in addition 
to a thorough histological analysis.      
The regulatory architecture of the Casz1 locus in vertebrates remains largely 
unknown. Therefore, the identification of a cardiac-specific enhancer of Casz1 would 
reveal further insights into the Casz1 gene as a whole. This is long term project goal. To 
complete it, we will utilize in vivo bacterial artificial chromosome (BAC) recombination to 
generate a Casz1-EGFP BAC that recapitulates the endogenous pattern of Casz1 
expression in transgenic embryos (Liu et al., 2003). We will need to include several of 
the first exons of the mouse gene as well as a large piece upstream and downstream of 
the translational start site. Next, we will look for areas of high sequence conservation in 
noncoding regions between human and mouse. To be able to visualize expression, we 
will clone an EGFP gene into the Casz1 locus such that the start codon is deleted, but 
exon boundaries are preserved. This strategy allows translational initiation from EGFP 
instead of from Casz1 but allows transcriptional initiation to occur from the endogenous 
Casz1 start sites present in the BAC.  
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 We have established that Casz1 is an essential cardiac transcription factor that 
regulates cardiomyocyte proliferation. Nevertheless, only one direct target of Casz1 has 
been identified: the extracellular matrix protein Egfl7, which is required for endothelial 
cell development and angiogenesis (Charpentier et al., 2013). It is critical to identify the 
mechanism(s) by which Casz1 regulates cardiomyocyte proliferation in the adult heart. 
To do this, an in-depth whole genome analysis of Casz1 is vital. First, we need to 
perform RNA-Seq on Casz1-depleted adult hearts to identify genes and pathways 
misregulated by the loss of Casz1. Bioinformatics analysis of cell-cycle related genes 
and genes involved in cardiomyocyte cell growth will be prioritized. Going forward, it is 
absolutely essential to identify the genes that Casz1 directly regulates in the heart. To 
address this, we need to perform chromatin immunoprecipitation followed by high-
throughput DNA sequencing (ChIP-Seq) for Casz1 in embryonic and adult hearts. ChIP-
Seq is a genome-wide method to map the binding sites of a target protein (CASZ1) 
(Landt et al., 2012). The analysis of Casz1 binding sites at these two time points is 
critical not only for elucidating the mechanism by which Casz1 regulates cardiomyocyte 
proliferation, but also can provide insight into the cardiomyocyte cell cycle regulation in 
general. 
Many mammalian tissues respond to injury by activating committed progenitor 
cells or through proliferation of differentiated cells such as skin, endothelial, and liver 
cells (Brockes and Kumar, 2005; Horky et al., 2006; Lai et al., 2012; McDonough and 
Martinez-Cerdeno, 2012). In addition, lower level vertebrates like fish and amphibians 
are capable of regenerating myocardium after injury via the activation of proliferation 
pathways in differentiated cells (Nag et al., 1979; Oberpriller et al., 1995; Matz et al., 
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1998; Bettencourt-Dias et al., 2003). In contrast, the adult mammalian heart has limited 
potential for regeneration and repair (Soonpaa et al., 1996; Soonpaa and Field, 1997; 
Soonpaa and Field, 1998; Bergmann et al., 2009; Walsh et al., 2010; Laflamme and 
Murry, 2011; Mollova et al., 2013; Porrello et al., 2013; Senyo et al., 2013; Senyo et al., 
2014). Moreover, the biological explanations underlying cell cycle exit leading to the 
dramatic proliferative decreases in the adult heart remain poorly understood. Why is it 
that terminally differentiated cardiomyocytes have such limited potential to reactivate the 
cardiomyocyte cell cycle following injury? This is the question that has plagued 
cardiovascular biologists for many years and it is an area of intense investigation as the 
loss of cardiomyocytes during injury and disease proves to be so fatal, making 
cardiovascular disease the leading cause of death worldwide (Seidman and Seidman, 
2001; Lopez et al., 2006). Furthermore, congenital heart defects represent the most 
common type of human birth defect worldwide (Hoffman, 1995; Hoffman and Kaplan, 
2002; Dolk et al., 2010a; Dolk et al., 2010b; van der Linde et al., 2011). Insults to the 
heart, including ischaemic coronary artery disease, hypertension, and genetic mutations 
can cause heart disease, which is associated with loss or dysfunction of cardiac muscle 
cells, diminished pump function, arrhythmias and oftentimes subsequent death 
(Seidman, 2000; Seidman and Seidman, 2001; Lopez et al., 2006; Hill and Olson, 2008; 
Morita et al., 2008). Congenital malformations and certain types of cardiac injury can be 
surgically repaired to modest success depending on the condition. Also, there are 
numerous drugs and mechanical devices that provide temporary improvements to 
cardiac function, but most results are transient because they do not replace damaged or 
lost cardiac muscle. Efforts are now focused on identifying and exploiting the molecular 
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and cellular processes and regulatory mechanisms involved in heart growth to repair the 
adult injured heart by reviving pathways that are active during embryogenesis. 
Extensive efforts towards cardiac repair have gone into the development of 3 
major strategies to enhance cardiac regeneration: 1) stem-cell based therapies, 2) 
reprogramming of non-muscle cells into a cardiac fate, and 3) the induction of 
cardiomyocyte cell cycle activity. Studies in both rodents and humans have shown that 
the injection of stem cells directly into the injured heart or into the circulation system can 
result in modest benefits to cardiac function. However, these results appear to be 
transient as little evidence exists that the transplanted cells are actually retained in the 
heart (Passier et al., 2008; Segers and Lee, 2008; Wollert and Drexler, 2010; Laflamme 
and Murry, 2011; Ptaszek et al., 2012; Anversa et al., 2013). Fibroblasts can be 
reprogrammed into induced pluri-potent stem cells (iPSCs) through the expression of 
four pluirpotency genes: OCT4, SOX2, KLF4, and MYC (Takahashi and Yamanaka, 
2006; Yamanaka and Takahashi, 2006; Takahashi et al., 2007a; Takahashi et al., 
2007b). iPS cells generated from human fibroblasts have been successfully 
differentiated into beating cardiomyocytes (Yoshida and Yamanaka, 2011; Qian et al., 
2012; Fu et al., 2013; Nakamura et al., 2013; Priori et al., 2013; Qian et al., 2013; Qian 
and Srivastava, 2013). Caridac fibroblasts account for the majority of all heart cells 
(Jugdutt, 2003). Recent studies have demonstrated that a combination of three 
transcription factors, namely GATA4, myocyte-specific enhancer factor 2C (MEF2C) 
and TBX5 (collectively referred to as GMT factors), can reprogram both mice cardiac 
and dermal fibroblasts into induced cardiac-like myocytes. Further work demonstrated 
that the inclusion of the cardiac transcription factor, HAND2, (GHMT factors) enhanced 
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the reprogramming efficiency (Ieda et al., 2010; Chen et al., 2012; Qian et al., 2012; 
Song et al., 2012; Addis et al., 2013; Fu et al., 2013; Qian et al., 2013; Qian and 
Srivastava, 2013; Wang et al., 2015).  Current work is focused on improving the 
efficiency of this process to convert more fibroblasts into cardiac-like myocytes. An 
alternative approach for cardiac repair is to reactivate the proliferative potential of 
existing cardiomyocytes as observed in lower vertebrates. Studies have focused on 
overexpressing cell cycle regulatory factors, such as c-Myc, Cyclins D1-D3, Cyclin A2, 
and SV40 large T antigen, to promote cell cycle progression in injured adult hearts. The 
results of these studies were variable. However, increases in cardiomyocyte DNA 
synthesis did occur in many cases, but none were able to induce cytokinesis and so it is 
unclear as to whether true heart regeneration took place (Field, 1988; Sen et al., 1988; 
Jackson et al., 1990; Chaudhry et al., 2004; Pasumarthi et al., 2005).   
In conclusion, an understanding of the regulation of the cardiac cell cycle is 
essential for the advancement of the cardiac regeneration field. The studies outlined in 
this thesis, have identified Casz1 as a critical regulator of the embryonic cardiomyocyte 
cell cycle. The role of Casz1 in regulating the adult cardiomyocyte cell cycle is unknown, 
but provides an exciting research avenue to pursue in the context of heart regeneration. 
Regardless of whether it is to therapeutically reactivate the cell cycle in existing 
cardiomyocytes, to establish methodologies to expand current cardiac stem cells from 
losing their differentiation potential in vivo, or to more efficiently reprogram fibroblasts 
into cardiomyocytes, the ultimate goal is to improve human health and survival. To do 
so, it is essential to identify the molecules and signals that regulate cardiac growth and 
homeostasis. These efforts not only hold the potential to benefit cardiovascular patients, 
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but encompass much broader implications to advance the scientific field in general 
thereby improving the lives of patients suffering from other cell cycle related diseases, 
such as cancer. CASZ1, in particular, has many broad clinical implications beyond just 
congenital heart defects and cardiovascular disease. It has also been identified as a 
tumor-suppressor gene implicated in Neuroblastoma (NB), a neural crest derived 
malignant brain tumor (Liu et al., 2011; Henrich et al., 2012). Loss of CASZ1 is 
associated with poor prognosis in human NB patients. Interestingly, restoration of 
CASZ1 in a NB cell line induced cell differentiation, enhanced cell adhesion, inhibited 
migration and suppressed tumorigenicity, but showed no effect on proliferation (Liu et 
al., 2011). A follow-up in vitro study using NB cells found that CASZ1 inhibits cell cycle 
progression by restoring pRB activity, leading to decreased proliferation (Liu et al., 
2013). Furthermore, a recent study demonstrated that Casz1 controls the production of 
mid-/late-born neurons in the murine retina, thus suggesting that Casz1 is a temporal 
identity factor for retina progenitor cells. Moreover, Casz1 does not regulate the 
proliferation of these progenitor cells, implying that it does not determine a specific cell 
identity (Mattar et al., 2015). In Chapter 2, I described the broad expression of Casz1 in 
multiple tissues, including the neural tube and the eye. Together, this data suggests that 
Casz1 is a critical modulator of neural development. Of particular interest is the contrast 
between the proliferation requirement in heart tissue that I demonstrated in Chapter 2 
and is described above versus the lack of proliferative defects illustrated in these two 
neuronal cell populations. This difference highlights the dynamic function of Casz1 
during development and further emphasizes the need to explore the requirement for 
Casz1 in a cell-type and tissue-specific manner.  
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The studies I have conducted in this thesis have generated many of the 
necessary biological tools to investigate this very issue. The two novel mouse lines that 
I generated and described in this thesis can be used to explore the role of Casz1 in 
neural development or cancer. The Casz1flox/flox mouse affords the ability to delete 
Casz1 in a tissue-specific manner with alternate Cre drivers. Additionally, the 
Casz1CreERT2 tamoxifen-inducible mouse can be used to identify neuronal cell types and 
structures that Casz1-expressing cells give rise to during development and in the adult. 
Most importantly, Casz1 has been identified as a critical cardiac transcription factor. 
This, combined with the future studies I have proposed here will yield additional 
information about the genes associated with human congenital heart defects and lead to 
a great understanding of how Casz1 contributes to cardiovascular development and 
disease.   
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Appendix 1: CASZ1 Promotes Vascular Assembly and Morphogenesis Through 
the Direct Regulation of an EGFL7/RhoA-mediated Pathway2  
 
INTRODUCTION 
Endothelial cells (ECs) are building blocks for the formation of a functional 
vascular system during embryonic development. Early stages of blood vessel 
development occur via vasculogenesis whereby mesodermal cells differentiate into EC 
progenitors that subsequently proliferate, migrate, and assemble into vascular cords. 
Cords then undergo tubulogenesis, or lumen formation, continuing to mature by 
angiogenesis where vessels sprout, branch, and remodel. Vessels then become 
surrounded and stabilized by pericytes and smooth muscle cells that provide structural 
support (Patan, 2000; De Val, 2011). The critical nature of these events is emphasized 
by observations that disruption of these processes is associated with human disease 
states including cancer, stroke, and atherosclerosis, therefore necessitating a better 
understanding of transcriptional networks that regulate these key developmental steps 
(Carmeliet, 2003; Carmeliet and Jain, 2011; Potente et al., 2011). 
While numerous transcription factors have been discovered to regulate 
endothelial gene expression, relatively few factors are necessary for development. 
Deletions or mutations of a number of single genes, especially members of Ets and  
______________________ 
2This chapter previously appeared as an article in the journal Developmental Cell. The original 
citation is as follows: Charpentier, M.S.#, Christine, K.S.#, Amin, N.M., Dorr, K.M., Kushner, E.J., 
Bautch, V.L., Taylor, J.M., and Conlon, F.L. CASZ1 promotes vascular assembly and 
morphogenesis through the direct regulation of an EGFL7/RhoA-mediated pathway. Dev Cell 
25, no.2 (April 2013): 132. #These authors contributed equally to this work. 
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forkhead families, result in moderate to no vascular phenotypes likely due to functional 
redundancy (Barton et al., 1998; Lelievre et al., 2001; De Val and Black, 2009; De Val, 
2011). Previous studies have implicated the zinc finger transcription factor CASZ1 in 
cardiovascular development with depletion of CASZ1 in Xenopus embryos resulting in 
failure of a subset of progenitor cells to differentiate into cardiomyocytes (Christine and 
Conlon, 2008). Recent genome-wide association studies have shown a genetic link 
between human Casz1 and high blood pressure and hypertension, suggesting a possible 
role for CASZ1 in EC biology (Levy et al., 2009; Takeuchi et al., 2010). However, no 
studies have addressed expression, function, or transcriptional targets of CASZ1 in 
vascular tissue. 
Despite an essential role for the vasculature in development and disease, our 
knowledge of molecular mechanisms controlling these events remains incomplete (De 
Val and Black, 2009). One protein recently shown to play a role in EC morphogenesis is 
Epidermal Growth Factor-Like Domain 7 (Egfl7), an extracellular matrix (ECM) protein 
expressed exclusively in EC progenitors and vessels during embryonic and neonatal 
development. EGFL7 is also expressed in highly vascularized adult organs and is 
upregulated upon injury (Fitch et al., 2004; Parker et al., 2004; Campagnolo et al., 
2005). Depletion studies in zebrafish have defined a role for EGFL7 in tubulogenesis 
likely through modulation of cell-matrix interactions (Parker et al., 2004; Nikolic et al., 
2010). In addition, overexpression of Egfl7 in mouse results in abnormal patterning of 
embryonic and postnatal vasculature (Nichol et al., 2010). However, the specific 
function of EGFL7 has been complicated by recent discovery of microRNA miR-126, the 
only EC-specific microRNA, within intron 7 of the Egfl7 locus. While Egfl7 and miR-126 
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are co-expressed, the function of miR-126 has indicated a distinct role from its host 
gene in maintaining vessel integrity and modulating angiogenesis through repression of 
targets Spred1 and PIK3R2 (Fish et al., 2008; Kuhnert et al., 2008; Wang et al., 2008). 
In this study, we demonstrate CASZ1 is required for angiogenic sprouting and 
lumen morphogenesis. CASZ1 regulates EC contractility, adhesion, and sprouting 
promoting assembly and tubulogenesis of blood vessels. Furthermore, we demonstrate 
CASZ1 activates Egfl7/miR-126 in mammals and Xenopus by directly binding to an 
intronic element but does not regulate miR-126 in Xenopus. Moreover, defects 
associated with CASZ1-depletion can be phenocopied by EGFL7-depletion, and 
importantly, rescued by restoration of Egfl7 levels. We further show CASZ1 
transcriptional control of EGFL7 modulates EC behavior through RhoA. Collectively, our 
studies point to a network whereby CASZ1 regulates an EGFL7/RhoA-mediated 
pathway to promote vessel assembly and morphogenesis. 
 
MATERIALS AND METHODS 
Xenopus Embryo Collection and Morpholino Design  
Preparation and collection of Xenopus embryos was performed as described 
(Showell et al., 2006). Embryos were staged according to Nieuwkoop and Faber 
(Nieuwkoop and Faber, 1967). MOs were obtained from Gene Tools, LLC. Casz1-
specific MOs used as reported (Christine and Conlon, 2008). Egfl7-specific MO 
designed against acceptor region of X. laevis exon 6 and miR-126-specific MO 
designed against guide dicer region of X. laevis (Supplemental information).  
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In Situ Hybridization 
  Whole mount in situ analysis was carried out as described (Harland, 1991) using 
probes of Casz1 (Christine and Conlon, 2008), Msr (Devic, 1996), Ami (Inui and 
Asashima, 2006), Erg (cloned from st. 39 X. laevis cDNA), Egfl7 (cloned from st. 33-38 
X. tropicalis cDNA), and EphrinB2 (cloned from st. 39 X. laevis cDNA). miR-126 locked 
nucleic acid probe from Exiqon (38523-05) and hybridization was performed according 
to manufacturer’s instructions at 51°C.  
 
Chromatin Immunoprecipitation (ChIP)  
Four hundred cardiovascular-enriched regions were dissected from st. 29 X. 
tropicalis embryos and processed for ChIP as reported (Weinmann and Farnham, 2002) 
(Taranova et al., 2006) with following exceptions: (1)Sonication was carried out with 
Branson Digital Sonifier at 20% amplitude (2.5 cycles, 30s [1s on/0.5s off]) to yield 4kb 
DNA fragments. (Porrello et al.)Affinity-purified rabbit anti-CASZ1 polyclonal antibody 
was added and incubated overnight at 4°C. (Dowell and McManus)DNA was digested 
with NlaIII (NEB) and ligated into SphI-digested (NEB) pUC19 using DNA ligation kit 
(Stratagene). Ligated DNA was transformed into NEB10β electrocompetent cells. 
Transformants were selected by blue/white screening, cultured, and isolated plasmids 
were sequenced. CASZ1 target DNA sequences were assessed by BLAT analysis 
using UCSC X. tropicalis Genome Browser (http://genome.ucsc.edu, August 2005 
assembly). DNA scaffold location coordinates were imported into the annotated Joint 
Genome Institute. v4.1 database (http://genome.jgi-psf.org/Xentr4/Xentr4.home.html). 
Validation of targets by ChIP PCR was performed as above with following exceptions: 
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(1)Thirty st. 32 X. tropicalis embryos were collected and processed as described. 
(Porrello et al.)Nuclear samples were sonicated at 20% amplitude (5 cycles, 30s [1s 
on/0.5s off]) to generate ~300bp DNA fragments. 
 
In vivo Transcriptional Assays  
Egfl7 intronic regions (introns 2,3,4,5) were subcloned into pGL3-Promoter firefly 
luciferase vector (Promega). X. laevis embryos were injected at 1-cell stage with 300 pg 
reporter plasmid and 10 pg Renilla reporter plasmid in presence or absence of CASZ1 
mRNA. Injected embryos were cultured until st. 11.5. Ten injected embryos were lysed 
in 50 l Passive Lysis Buffer (Promega) in triplicate. 20 l of cleared lysates were 
assayed using Dual-Luciferase Reporter Assay System (Promega).  
 
Cell Culture 
Pooled population of HUVEC (Lonza) were maintained in Complete EBM-2 
(Lonza) containing 10% fetal bovine serum, 100 U/mL penicillin and streptomycin and 
used between passages 1-6. hCASZ1 was IP’ed from HUVECs using polyclonal rabbit 
anti-human CASZ1 (LifeSpan Biosciences) and probed by western blot with same 
antibody.  
 
shRNA  
shRNA viral constructs specific to human Casz1 and Egfl7 were obtained from 
Open Biosystems TRC1 shRNA library. Casz1, Egfl7, and control scrambled sequence 
(Addgene) shRNA lentiviral particles were prepared by UNC Lentiviral Core Facility. 40-
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50% confluent HUVECs were infected with 1x106 IU lentivirus combined with 10 g/mL 
polybrene (Sigma) for 7.5 hr. Infected cells were placed under 1.5 g/mL puromycin 
selection for 3 days and processed for further analysis. 
 
Live Time-Lapse Imaging 
Cells seeded on uncoated or Fibronectin-coated (10 g/mL) 12-well dishes, or 
embedded in fibrin gel were imaged over 24 hr using Olympus IX70 inverted 
microscope encased in Plexiglas housing to control internal environment (37°C, 5% 
CO2 and relative humidity of 60%). Images were collected by Volocity 5.4.1 software.  
 
Immunofluorescence  
Cells seeded in chamber slides (BD Falcon) were fixed with cold 
methanol/acetone, blocked, and incubated with phospho-histone H3 (Millipore) or 
cleaved caspase-3 (Cell Signaling) overnight. Cells were incubated with rabbit anti-Cy3 
(Sigma), stained with DAPI, and mounted (DakoCytomation). For cytoskeletal staining, 
cells were serum-starved (EBM-2+0.75% FBS) overnight, half of the cells were treated 
with 10M Y-27632 (Sigma). Cells were fixed in 4% PFA, permeabilized with 0.1% 
Triton X-100, and incubated overnight with anti-vinculin (Sigma), and anti-phospho-
paxillin (pY118, Invitrogen). Cells were incubated with fluorescent secondary antibodies, 
stained with FITC-conjugated phalloidin (Invitrogen) and DAPI, mounted and imaged 
(Zeiss 710 or 700 microscope). 
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Sprouting Angiogenesis Assay 
Sprouting assays were performed as described (Nakatsu et al., 2003; Sweet et 
al., 2012). Cells were stained with phalloidin (FITC) to visualize actin and with DRAQ5 
to mark EC nuclei, and imaged (Olympus FLV500 inverted confocal microscope, 20x 
objective). Assay quantified measuring total length of protruding sprouts and number of 
branch points. 
 
Western Blotting 
Western blots were performed with 50 g protein using RhoA (Santa Cruz), 
phospho-myosin light chain 2 (Cell Signaling [Ser 19]), RhoC (Santa Cruz [K-12]). 
 
Statistical Analysis  
Data are expressed as means ± SEM as indicated. Statistical analysis was done 
by Student’s t-test and p<0.05 was considered significant. 
 
RESULTS 
EC Expression of CASZ1 is Evolutionarily Conserved  
Analysis of Casz1 expression in Xenopus embryos showed transcripts in the 
vitelline vein network (vvn) at a stage when the network is primarily made up of vascular 
ECs and devoid of smooth muscle cells (Figure A1.1A) (Warkman et al., 2005; Cox et 
al., 2006; Christine and Conlon, 2008) suggesting Casz1 is expressed in vascular ECs. 
Furthermore, RT-PCR on vascular explants from late tailbud stage embryos (stage 32) 
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demonstrated that Casz1 is co-expressed in the vitelline vein region with vascular 
markers, Msr and Erg (Figure SA1.1A). Consistently, we found CASZ1 co-localizes with 
the EC-specific marker PECAM in blood vessels of mouse embryos (Figure A1.1B). We 
have also cloned human Casz1 and showed, as in Xenopus and mouse, Casz1 is 
expressed in primary human umbilical vein ECs (HUVEC)(Figures A1.1C and A1.1D). 
These results taken together with sequence homology and synteny of CASZ1 across 
vertebrates (Christine and Conlon, 2008)  demonstrate CASZ1 is an evolutionarily 
conserved transcription factor expressed in ECs. 
 
CASZ1 is Required for Vascular Patterning and Lumen Morphogenesis  
To ascertain the function of CASZ1 in vascular development, we depleted 
CASZ1 in Xenopus embryos using a morpholino-based approach (Christine and 
Conlon, 2008). Whole-mount in situ hybridization using a panel of EC markers such as 
Msr and Erg (Devic, 1996; Baltzinger et al., 1999) demonstrated that at stages when 
ECs begin to migrate dorsally from ventral blood islands within the trunk region, there 
were no noticeable differences between control and CASZ1-depleted embryos (stage 
29, Figures SA1.1B, SA1.1C, SA1.1J, SA1.1K). However, when ECs begin to assemble 
into cords (stage 32), defects became apparent whereby CASZ1-depleted embryos 
displayed a dramatically reduced vascular plexus (Figures A1.2A-2D, SA1.1D—
SA1.1E). Extension of intersomitic vessels from posterior cardinal veins, which is known 
to occur in Xenopus via sprouting angiogenesis in an anterior-to-posterior direction 
(Cleaver et al., 1997; Levine et al., 2003), was also absent or significantly delayed in 
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CASZ1-depleted embryos (Figures A1.2A, 2C, 2E, 2G). By mid- to late tadpole stages 
(stages 36 and 39), vascular networks of CASZ1-depleted embryos were comprised of 
cords which ran predominately in a dorsal-to-ventral pattern and underwent little to no 
branching or remodeling (Figures A1.2E-2H, SA1.1F-SA1.1I, SA1.1L-SA1.1M). Overall, 
at stage 36, total length of the vitelline vein vasculature and number of branch points 
and intersomitic vessels were all significantly decreased in CASZ1-depleted embryos 
implying a role for CASZ1 in sprouting and remodeling of the vasculature (Figure A1.2I). 
While our studies focused on vein-derived sprouts, CASZ1-depletion unlikely disrupts 
arterial/venous differentiation due to proper specification and localization of the aortic 
arches (arterial) and posterior cardinal veins as well as due to the lack of arterial marker 
expression in veins (data not shown).  
Noting the posterior cardinal veins of CASZ1-depleted embryos appeared 
thickened (stage 36), we sought to determine the time course of lumen formation in 
Xenopus. At stage 29, control and CASZ1-depleted ECs, as marked by Msr, were 
localized to positions of the future veins but had not yet undergone lumen formation 
(Figures A1.2J, 2N). By stage 32, ECs separated in control embryos but remained as 
aggregates in CASZ1-depleted embryos (Figures A1.2K, 2O). By stages 36 and 39, the 
veins of control embryos exhibited well-formed lumens surrounded by Msr-positive ECs 
while CASZ1-depleted veins remained closed and failed to open even at late stages 
(Figures A1.2L, 2M, 2P, 2Q). Collectively, these studies demonstrate CASZ1 is required 
for angiogenic remodeling and lumen morphogenesis during vertebrate vascular 
development. 
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Since we have previously established CASZ1 is required for heart development 
(Christine and Conlon, 2008), we determined if the vascular requirements for CASZ1 
were secondary to its role in cardiac tissue. Taking advantage of the amenability of 
Xenopus embryos to organotypic culture (Mandel et al., 2010), we removed anterior 
regions of embryos, including all cardiac tissue at a stage prior to heart formation. 
Culture of explants showed in the absence of cardiac tissue, control explants formed 
vascular networks, as marked by the EC-specific gene Ami (Inui and Asashima, 2006), 
that were indistinguishable from un-manipulated embryos, demonstrating blood flow is 
not essential for correct patterning of the early vasculature (Figures SA1.1N, SA1.1P). 
Critically, we observed severe defects in vascular networks of CASZ1-depleted 
explants, strongly suggesting the role of CASZ1 in vascular development is independent 
of its role in cardiogenesis (Figures SA1.1O, SA1.1Q). 
 
CASZ1 Regulates EC Behavior 
To examine vascular development in more detail and determine if the function of 
CASZ1 is evolutionarily conserved, we depleted CASZ1 in HUVECs by lentiviral-
mediated short hairpin RNA (shRNA, 16-fold decrease in Casz1 mRNA; Figure A1.3A). 
CASZ1-depleted cells displayed a thin and elongated morphology in stark contrast to 
characteristic cobblestone appearance of uninfected HUVECs or HUVECs infected with 
control shRNA (Figure A1.3B).  
To determine the precise requirement for CASZ1 and to characterize the 
dynamics of CASZ1-depleted HUVECs in real time, we coupled time-lapse imaging with 
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quantitative analysis. Time-lapse movies showed that CASZ1-depleted cells initially 
adhered to plastic or fibronectin-coated substrates but a proportion of cells rounded up 
and detached (33%, Figure A1.3C, Movie SA1.1, data not shown). Of CASZ1-depleted 
HUVECs that adhered, live imaging demonstrated the elongated morphology resulted 
from defects in contractility whereby the leading edge of CASZ1-depleted cells moved 
forward without retraction of the trailing edge (Figure A1.3C, Movie SA1.1). CASZ1-
depleted cells also stopped dividing (0% shCasz1 vs. 20% control) and consistently, we 
failed to detect any phospho-histone H3 (pH3)-positive CASZ1-depleted cells (vs. 3% 
control cells; Figure SA1.2A). Using fluorescence-activated cell sorting (FACS), we 
determined CASZ1-depleted ECs were blocked at the G1/S transition as seen by the 
significantly reduced number of cells in S-phase (Figure SA1.2B). Blockage in G1/S 
progression was not associated with programmed cell death as determined by cleaved 
caspase-3 staining (Figure SA1.2C). Furthermore, inability of CASZ1-depleted cells to 
maintain adhesion to the substrate was not a secondary consequence of cell cycle 
arrest as wildtype HUVECs chemically treated with mitomycin C did not divide yet 
remained attached (data not shown). Taken together, these results indicate CASZ1 has 
a conserved role in vascular development and is required for EC adhesion, contractility, 
and G1/S cell cycle progression. 
To assess how adhesive and morphological defects of CASZ1-depleted cells 
manifested themselves in vessel assembly, we assessed sprouting using a sprouting 
angiogenesis assay in which HUVEC-coated beads were placed in fibrin. While control 
cells displayed elongated sprouts with multiple branch points, similar to our findings in 
Xenopus, CASZ1-depleted HUVECs had strikingly few sprouts and branches (Figure 
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A1.3D). Live time-lapse imaging further showed that CASZ1-depleted cells extended 
out from beads to initiate sprout formation but then abruptly detached, indicating that 
CASZ1 is required for proper EC adhesion to promote angiogenic sprouting (Movie 
SA1.4).   
 
Isolation of Egfl7/miR-126 Locus by CASZ1 Chromatin Immunoprecipitation 
To identify direct cardiac and endothelial transcriptional targets of CASZ1, we 
generated a CASZ1-specific antibody and performed cloning chromatin 
immunoprecipitation (ChIP) from dissected cardiovascular Xenopus tissue (stages 27-
29, i.e. same time and tissue requiring CASZ1)(Figure A1.4A). We identified 110 
putative transcriptional targets including Egfl7, an ECM protein specifically secreted by 
ECs shown to be associated with similar cellular processes as we observe for CASZ1; 
EC adhesion and vessel tubulogenesis (Figure A1.4B, Table S1)(Parker et al., 2004; 
Nichol et al., 2010; Nikolic et al., 2010). 
Recently, studies in mouse and zebrafish identified the evolutionarily conserved 
miR-126 contained within intron 7 of Egfl7 (Fish et al., 2008; Kuhnert et al., 2008; Wang 
et al., 2008). We cloned Egfl7 and miR-126 from Xenopus and showed EGFL7 is 47% 
identical to human and 45% identical to mouse EGFL7, while Xenopus miR-126 is 
completely (100%) conserved between mouse and human (Fitch et al., 2004)(Figure 
SA1.3A). Genome analysis and characterization of Xenopus BACs corresponding to the 
Egfl7/miR-126 locus confirmed that like other model systems, miR-126 is located within 
intron 7 of the Xenopus Egfl7 locus (Figure A1.4B).  
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Expression analysis revealed Egfl7 is expressed in all major vessels at all stages 
of vasculogenesis in Xenopus, as reported for zebrafish, mouse, and human (Figures 
4C, 4E, 4G, 4I)(Fitch et al., 2004; Parker et al., 2004). Though Egfl7 and miR-126 have 
been reported to be co-transcribed and co-expressed in the vasculature, we found 
Xenopus miR-126 has an expression pattern distinct from Egfl7 as well as that reported 
in other species (Fish et al., 2008; Wang et al., 2008). Most notably, miR-126 
expression is initiated in ECs at stage 32, slightly later than Egfl7 (stage 29), and we 
observed strong expression of miR-126, but not Egfl7, in the developing somites (Figure 
SA1.3B-SA1.3I). Taken together these data show that the sequence, genomic 
arrangement, and vascular expression of Egfl7 and miR-126 are evolutionarily 
conserved, however in Xenopus, miR-126 has developed additional levels of regulation 
distinct from Egfl7.   
Consistent with Egfl7 being a direct target of CASZ1, analysis in CASZ1-depleted 
embryos showed Egfl7 was initiated but not maintained in vascular tissues at all stages 
analyzed (Figures A1.4D, 4F, 4H, 4J). Consistently, Egfl7 levels were significantly 
reduced in CASZ1-depleted HUVEC (3-fold; Figure A1.4K). We further observed a 
dramatic reduction in miR-126 (9-fold) in CASZ1-depleted HUVECs (Figure A1.4K). 
These effects were specific as the EC marker Flk1 was unaltered (Figure A1.4K). 
However, we did not observe reduction in miR-126 in CASZ1-depleted Xenopus 
embryos at mid- and late-tadpole stages (stages 32-39, Figures S3E, S3G, S3I). 
Collectively, these studies demonstrate regulation of Egfl7 and miR-126 expression in 
human ECs is dependent on CASZ1 while Xenopus miR-126 appears to have evolved a 
CASZ1-independent mechanism of regulation. 
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Egfl7 is a Direct Transcriptional Target of CASZ1 
To determine whether CASZ1 directly regulates Egfl7, we performed in vivo 
transcriptional assays where single copies of intronic regions of Egfl7 corresponding to 
the putative CASZ1-bound region (introns 2-5) were placed upstream of a basal 
promoter driving luciferase activity. Of these intronic regions, only the 5’ half of intron 3 
(E1) resulted in a dose-dependent, reproducible increase in transcriptional activity in 
response to CASZ1 (Figures A1.4L-4M). To determine if CASZ1 endogenously binds to 
this element in vivo and to further refine the region within E1, we performed ChIP of 
endogenous CASZ1 from early embryos (stage 32), a time point when CASZ1 is 
required for Egfl7 expression. Results showed CASZ1 binds to nucleotides 59-173 of 
intron 3 (E1.2) but not the most 5’ end of E1 (E1.1)(Figure A1.4N, data not shown). 
Thus, CASZ1 directly binds to the Egfl7 locus in vivo and can activate Egfl7 
transcription through a regulatory element within intron 3 of the Egfl7 locus. 
 
EGFL7 Functions Downstream of CASZ1 to Control Vascular Morphogenesis 
To determine if CASZ1 acts through EGFL7 to regulate EC development, we 
depleted Egfl7 in embryos using a morpholino that left miR-126 expression intact 
(Figures SA1.4A-SA1.4E). Strikingly, EGFL7-depletion resulted in vascular phenotypes 
that phenocopied CASZ1-depletion (Figures A1.5A-5H, SA1.4F-SA1.4S). As with 
CASZ1-depleted embryos, we found a reduction in density of ECs within the vitelline 
vein network (stage 32)(Figures A1.5A-5D, SA1.4F-SA1.4G, SA1.4J-SA1.4M). 
Furthermore, while blood vessels did form in EGFL7-depleted embryos, there was 
171 
 
significantly reduced branching and intersomitic vessel sprouting at later stages 
(Figures A1.5E-5H, SA1.4H-SA1.41, SA1.4N-SA1.4Q). Quantification of vitelline vein 
networks at stage 36 revealed results similar to CASZ1-depletion whereby the total 
length of the vasculature and number of branch points and intersomitic vessels of 
EGFL7-depleted embryos was significantly decreased compared to controls (Figure 
A1.5I). Furthermore, like CASZ1-depleted embryos, and in accordance with reports of 
EGFL7-depletion in zebrafish (Parker et al., 2004), lumens of posterior cardinal veins of 
EGFL7-depleted embryos failed to form (Figures A1.5J-5M). Morpholinos targeting the 
Dicer cleavage site of Xenopus pri-miR-126 had no effect on Egfl7 expression (Figures 
SA1.5A-SA1.5E) and did not result in gross defects in vessel morphology or patterning, 
in accordance with reports in zebrafish (Figures SA1.5F-SA1.5U)(Fish et al., 2008). 
Consistently, lumens of posterior cardinal veins of miR-126-depleted embryos were 
indistinguishable from controls (Figures SA1.5V-SA1.5Y). Taken together these results 
imply EGFL7 functions downstream of CASZ1 to regulate angiogenesis and vascular 
remodeling. 
Similar to our studies in Xenopus, time-lapse imaging of HUVECs revealed 
depletion of EGFL7 by shRNA (shEgfl7, 11-fold decrease in mRNA; Figure A1.5N) 
phenocopied CASZ1-depletion. Most notably, EGFL7-depleted cells demonstrated 
similar adhesion and proliferation defects as those of CASZ1-depleted cells (Figure 
A1.5O, Movie SA1.2) and also displayed an elongated morphology similar to but not as 
extensive as observed in CASZ1-depleted cells. The sprouting angiogenesis assay 
further demonstrated similar defects to CASZ1-depleted cells whereby the total length 
of sprouts and number of branch points were significantly decreased in EGFL7-depleted 
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cells compared to controls (Figure A1.5P). Live imaging showed failure to sprout was 
due to the inability of EGFL7-depleted cells to maintain adhesion (Movie SA1.5). 
Results were specific since we observed minimal effect on expression of Casz1 or Flk1 
(Figure A1.5N). Collectively, these studies show Egfl7 functions downstream of CASZ1 
to control vascular morphogenesis in Xenopus and humans. In addition, miR-126 does 
not function downstream of CASZ1 in Xenopus vascular development. 
 
Egfl7 and miR-126 Function Downstream of CASZ1 to Regulate Cell Adhesion and 
Shape 
To test if CASZ1 functions through Egfl7 or miR-126 to regulate vascular 
development and morphogenesis in human ECs, we assessed if restoration of Egfl7 or 
miR-126 levels rescues defects associated with CASZ1-depletion. While 29% of cells 
infected with shCasz1 rounded up and detached compared to 3% of control cells, 
infection of CASZ1-depleted cells with adenoviral constructs expressing either human 
Egfl7 (Ad-Egfl7) or miR-126 (Ad-miR-126) recovered proper adhesion as only 7.6% and 
1% of cells detached, respectively (Figures A1.6A, SA1.6A-SA1.6B, Movie SA1.3). 
However, restoration of Egfl7, but not miR-126, partially rescued EC morphology 
associated with CASZ1-depletion as measured by length-to-width ratio (L:W)(Figures 
A1.6B, SA1.6C). Restoration of either Egfl7 or miR-126 failed to rescue proliferation 
defects (data not shown). Taken together, these studies demonstrate that CASZ1 acts 
to control EC adhesion through direct transcriptional regulation of Egfl7 and miR-126. 
These data further indicate EGFL7 and miR-126 have distinct functions in regards to 
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cell morphology since EGFL7 but not miR-126 can rescue cell shape changes, and 
further imply CASZ1 control of G1/S progression occurs by Egfl7- and miR-126-
independent pathways. 
 
CASZ1 and EGFL7 Regulate RhoA  
Past studies have provided evidence that two of the physiological outputs of the 
CASZ1/EGFL7 pathway, cell adhesion and morphology, are directly controlled by 
activation of Rho GTPases. Specifically, RhoA is required for actomyosin-dependent 
cell contractility and formation of focal adhesions (FA)(Burridge and Wennerberg, 2004; 
Parsons et al., 2010; Katoh et al., 2011). To identify mechanisms that mediate the 
physiological function of the CASZ1/EGFL7 pathway, we aimed to determine the 
relationship between CASZ1/EGFL7 and RhoA. We found RhoA activity and levels 
were dramatically diminished in CASZ1 and EGFL7-depleted cells, however, levels of 
other Rho proteins such as RhoC were unaltered (Figure A1.6C, SA1.6D-SA1.6E). The 
decrease in RhoA protein occurred at the transcriptional level as RhoA but not RhoC 
mRNA levels were markedly diminished in both CASZ1 and EGFL7-depleted ECs 
(Figure A1.6D). However, RhoB levels were slightly increased possibly indicating a 
compensatory mechanism for loss of RhoA (Figure A1.6D). 
We reasoned reduction of RhoA expression in CASZ1- and EGFL7-depleted 
cells would result in concomitant impaired downstream activity. Consistently, 
phosphorylation of regulatory subunit of myosin light chain (p-MLC) was decreased in 
CASZ1-depleted cells (Figure SA1.6F). To further assess whether decreased RhoA 
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activity directly plays a role in the adhesion and cell shape defects we observe in 
CASZ1-depleted cells, we analyzed a panel of cytoskeletal and FA markers. Control 
cells displayed discrete bundles of F-actin stress fibers, as assayed by phalloidin 
staining, that contained short or punctate bands of FA markers vinculin and 
phosphorylated paxillin (Figure 6E, left panels). However, CASZ1-depletion mimicked 
treatment with the Rho kinase (ROCK) inhibitor Y-27632 resulting in diffuse actin 
networks devoid of stress fibers and failure of vinculin and phosphorylated paxillin to 
properly localize to adhesion sites on the periphery of the cell (Figure A1.6E, middle 
panels)(Narumiya et al., 2000). This phenotype was partially rescued by restoration of 
Egfl7 levels in CASZ1-depleted cells (Figure A1.6E, right panels). Taken together these 
studies show CASZ1 acts through the direct transcriptional regulation of EGFL7 to 
control EC adhesion and shape via the RhoA pathway.  
 
DISCUSSION 
In this work we demonstrate an essential and conserved role for the 
CASZ1/EGFL7/RhoA pathway in vascular patterning. Collectively, these data support a 
mechanism whereby CASZ1 directly binds to and maintains expression of Egfl7 in ECs. 
EGFL7 is then localized extracellularly where it modulates signals between ECs and the 
underlying ECM. This in turn is responsible for transcriptional upregulation and activity 
of the RhoA GTPase which ultimately mediates EC contractility and adhesive properties 
to promote assembly, lumen formation, and functionality of the vasculature (Figure 
A1.7).    
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CASZ1 Regulates EC Behavior Via EGFL7/RhoA to Promote Assembly of a Well-
Branched Vascular Network 
During embryogenesis, ECs assemble into cord-like structures that undergo 
further remodeling to form the primary vascular plexus. We have shown CASZ1 acts 
through the direct transcriptional regulation of EGFL7 to promote two critical processes 
during this period of embryogenesis: sprouting angiogenesis and lumen 
morphogenesis. The presence of thickened cords lacking lumens in CASZ1-depleted 
embryos, together with the observation that CASZ1-depleted ECs fail to sprout properly 
or adhere to extracellular substrates, strongly implies that CASZ1 functions through the 
EGFL7/RhoA pathway to maintain proper EC adhesion during vessel assembly.  
 
Casz1 and RhoA 
RhoA has been shown to be a central component of pathways which facilitate 
vascular remodeling. In this regard, RhoA has been demonstrated to be required for 
stress fiber formation, acting through the actomyosin contractile machinery, and for FA 
formation (Nobes and Hall, 1995; Chrzanowska-Wodnicka and Burridge, 1996; Burridge 
and Wennerberg, 2004; Katoh et al., 2011). In accordance with CASZ1 acting through 
RhoA to promote proper EC adhesion, we find that depleting CASZ1 phenocopies 
inhibition of RhoA and leads to a lack of discrete stress fibers, decreased myosin II 
activity, and strikingly, the absence of FA markers at sites of substrate contact. 
Moreover, these alterations in EC adherence can all be rescued in a CASZ1-depleted 
background by restoration of Egfl7. 
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The role of RhoA in tubulogenesis has been controversial. While reports have 
demonstrated RhoA activity is central for lumen formation, for example in the formation 
of the mouse dorsal aorta (Strilic et al., 2009), other reports have shown that in culture 
RhoA is not required for lumen formation but rather, for maintenance of patent vessels 
(Bayless and Davis, 2002). However, the in vivo relevance of the latter observation is 
yet to be determined since the mechanism by which lumens arise in 3D collagen culture 
differs significantly from that of cord hollowing in vivo (Davis et al., 2007; Strilic et al., 
2009). Paradoxically, it has been recently demonstrated RhoA and myosin II activity 
must be suppressed to promote lumen formation of mouse vessels via negative 
regulation by Ras interacting protein 1 (RASIP1) (Xu et al., 2011). Collectively these 
studies along with our present findings imply that a precise level of RhoA activity is 
required for lumen formation with either too low or too high activity leading to failure of 
vascular cords to hollow and form lumens. 
The finding that RhoA protein and mRNA expression are significantly diminished 
in CASZ1 and EGFL7-depleted HUVECs indicates transcriptional control of RhoA is 
impaired. Very few studies to date have focused on how RhoA transcription is 
controlled. While EGFL7 has been shown to interact with lysyl oxidases responsible for 
vascular elastogenesis as well as some Notch receptors on both ECs and neural stem 
cells, it is still unclear how these interactions may be influencing RhoA transcription or 
activity (Lelievre et al., 2008; Schmidt et al., 2009; Nichol et al., 2010). However, our 
results would support a mechanism by which CASZ1 modulates RhoA signaling through 
EGFL7 as restoration of Egfl7 levels in CASZ1-depleted cells rescues adhesion, proper 
FA marker localization, and stress fiber formation. It was recently shown that RhoA is 
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directly activated by the Myc-Skp2-Miz1-p300 transcriptional complex (Chan et al., 
2010). Given a role for c-Myc in embryonic vascular development and later angiogenic 
remodeling (Baudino et al., 2002; Rodrigues et al., 2008; Kokai et al., 2009), it will be 
interesting to investigate whether CASZ1 transcriptional regulation of Egfl7 directly 
plays into Myc-mediated transcriptional control of RhoA.   
   
Transcriptional Regulation of Egfl7 and miR-126 
Studies on Egfl7 and miR-126 have identified a 5.4Kb upstream sequence that is 
sufficient to drive EC-specific expression of a reporter gene in mouse, and mutation of 
two evolutionarily conserved Ets binding sites within this element eliminated expression 
in culture (Wang et al., 2008). We have demonstrated CASZ1 is required for expression 
of Egfl7 where CASZ1 is endogenously bound to intron 3 of the Egfl7 locus in 
developing embryos and depletion of EGFL7 phenocopies CASZ1-depletion in embryos 
and HUVEC. Consistently, we note CASZ1 is not required for onset of Egfl7 expression 
in embryos but rather its maintenance. Based on our studies, we favor a model by 
which Ets factors activate Egfl7 via an upstream element and CASZ1 binds to intron 3 
and functions to maintain Egfl7 levels. This model is complementary to findings for the 
role of Ets factors in regulating the spatial pattern of Egfl7 in mouse (Wang et al., 2008).  
Our finding that EGFL7 and miR-126 are both regulated in a CASZ1-dependent 
manner in humans is congruent with reports in mouse. However, despite complete 
conservation of miR-126 across species, we also demonstrate miR-126 has undergone 
an evolutionarily divergent and unique means of regulation exemplified by our findings 
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that Xenopus miR-126 is expressed in domains mutually exclusive to Egfl7 (i.e. 
somites) and expression of Xenopus miR-126 in the vasculature is CASZ1-independent. 
These observations are broadly consistent with recent reports that miR-126 
transcription can occur independently of host gene transcription through differential 
intronic promoters (Monteys et al., 2010).  
  
Conclusions 
The vascular system arises via concerted efforts of individual ECs to harness 
their unique behaviors to assemble into tubular structures. The molecular and cellular 
mechanisms by which the vasculature arises are still unclear but we have identified 
previously unknown roles for CASZ1 in regulating sprouting and morphogenesis. While 
endothelium becomes stabilized and quiescent after embryonic development, vessels 
retain sensitivity to changes in environment due to injury, inflammation, or improper 
cardiac output thus making them susceptible to vascular dysfunction. In this regard, it is 
interesting that human CASZ1 has been linked to adult vascular diseases such as 
hypertension (Takeuchi et al., 2010). Events resulting in vascular dysfunction during this 
disease are associated with aberrant ECM remodeling, proliferation, and adhesion, all 
of which we have demonstrated to also be dysregulated upon depletion of CASZ1 
(Lemarie et al., 2010). Therefore it will be intriguing to examine mechanisms by which 
CASZ1 itself is regulated and identify additional transcriptional targets that could trigger 
development of innovative therapeutic strategies in cardiovascular disease. 
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Figure A1.1. CASZ1 Expression in Vascular ECs is Evolutionarily Conserved 
(A) In situ analysis of Casz1 Xenopus embryos (stage 41). Lateral view with anterior to 
left. Casz1 is expressed in vascular structures including vitelline vein network (vvn, 
enlarged panel on right). (B) CASZ1 co-localizes with PECAM (red) in neural blood 
vessels of E14.5 mouse embryos. (C) RT-PCR analysis of human Casz1 in HUVEC 
cDNA. Gapdh was used as loading control. (D) Immunoprecipitation (IP) of CASZ1 from 
HUVECs. Control lane (left) represents IP with no antibody (Ab). Arrowhead represents 
125kD human CASZ1. 
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Figure A1.2. CASZ1 is Required for Vascular Development and Lumen Formation 
In situ analysis with EC marker Msr control and CASZ1-depleted embryos (stages 32-
36;  lateral view with anterior to left). Vessel patterning and branching within vitelline 
vein network (vvn) are severely compromised at stage 32 in CASZ1-depleted embryos 
(A,C high magnification of vvn in B,D) and stage 36 (E,G high magnification of vvn in 
F,H). Note poor sprouting of intersomitic vessels (isv) in CASZ1-depleted embryos at 
both stages (enlarged box in A,C,E,G). (n=10 embryos/condition/stage, 3 independent 
experiments). (I) Quantification of vascular defects in control and CASZ1-depleted 
embryos (stage 36) representing combined total length of vessels, number of branch 
points within vvn, and number of isvs/embryo, respectively. Data represent mean ± 
SEM. (n=7 control and 10 Casz1 MO embryos). *: p<0.05; **:p<0.01; ***:p<0.001. 
(J-Q) Histological analysis illustrates time course of lumen formation in Xenopus from 
stages 29-39 (J-M). Note posterior cardinal vein (pcv) lumens begin to open between 
stages 32 and 36 in control embryos (K,L) but fail to form in CASZ1-depleted embryos 
(N-Q). Dorsal is top, ventral is bottom. Arrowheads correspond to positions of pcv which 
are enlarged in lower panels (n=2-5 embryos/ condition/stage). See also Figure S1. 
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Figure A1.3. CASZ1 Regulates EC Behavior 
(A) mRNA levels of Casz1 after infection of HUVECs with shCasz1. Casz1 is decreased 
by 16-fold. mRNA levels relative to Rps29 ± SEM. ***: p<0.001. (B) Phase contrast 
images of control and shCasz1 HUVECs. Controls display cobblestone-like morphology 
while CASZ1-depleted cells are thin and elongated (red arrowheads for examples of 
each). (C) Time-lapse images of control and shCasz1 cells. Red arrowheads represent 
dividing control cell and rounded up CASZ1-depleted cell. Minutes elapsed presented at 
bottom right, taken every 5 min for 24 hr. Red arrow refers to elongated shCasz1 cell 
with trailing edge defects. Graph represents quantification of cells that round up and 
detach during imaging. Data represent mean ± SEM of 3 experiments conducted on 
independent batches of shRNA-infected cells (n=200 cells). **:p<0.01. (D) Sprouting 
angiogenesis assay was performed with control and CASZ1-depleted HUVEC. On day 
6, cultures were fixed and stained for phalloidin and DRAQ5 (blue). Graphs represent 
mean ± SEM of total sprout length and number of branch points/bead (n=11 
beads/condition). Experiments were repeated twice on independent batches of shRNA-
infected cells. **:p<0.01; ***p<0.001. See also Figure S2, Movies SA1.1 and SA1.4. 
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Figure A1.4. CASZ1 Directly Activates Egfl7 Transcription 
(A) Illustration of cardiovascular-enriched region dissected from X. tropicalis for 
chromatin immunoprecipitation (ChIP). (B) Genomic structure of Xenopus Egfl7 locus 
denoting CASZ1 ChIP fragment. White boxes: exons; shaded boxes, miR-126 in intron 
7 and intronic region potentially containing CASZ1 element (+/- 4kb). (C-J) In situ 
analysis of Egfl7 of stages 29-39 control and CASZ1-depleted embryos (lateral view 
with anterior to left). Note downregulation of Egfl7 in vitelline vein network (vvn) and 
intersomitic vessels (isv) in CASZ1-depleted embryos. Pcv-posterior cardinal vein. (K) 
Relative mRNA expression of Egfl7, miR-126, and Flk1 after infection of HUVECs with 
shCasz1. mRNA levels relative to Rps29 ± SEM. ***:p<0.001; NS: not significant. (L) 
Schematic demarcating Egfl7 genomic DNA regions (in bp) tested for transcriptional 
activation. E1 (-55–1614) within intron 3 but not E2 (1773–3840) resulted in increased 
luciferase (Ying et al.) activity. (M) Egfl7 genomic region E1 in presence or absence of 
Casz1. Bars represent fold increase in activity relative to control ± SEM. Experiments 
were repeated twice on independent batches of embryos, **:p<0.01. (N) Identification of 
90bp region endogenously bound by CASZ1located within non-overlapping region of 
E1.2 (113-227) PCR amplicon. See also Figure S3. 
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Figure A1.5. EGFL7-Depletion in Embryos and HUVECs Phenocopies CASZ1-
Depletion 
In situ analysis with EC marker Msr control and EGFL7-depleted embryos (stages 32-
36, lateral view with anterior to left). Note lack of branching in vitelline vein network 
(vvn) at stage 32 (A,C high magnification of vvn in B,D) and stage 36 (E,G high 
magnification of vvn in F,H). Intersomitic vessel (isv) sprouting is also impaired 
(A,C,E,G). (n=10 embryos/condition/stage, 3 independent experiments). (I) 
Quantification of vascular defects control and EGFL7-depleted embryos (stage 36) 
representing total vessel length, number of branch points within vvn, and number of 
isvs/embryo. Data represent mean ± SEM. (n=7 control and 10 Egfl7 MO embryos). *: 
p<0.05; **:p<0.01; ****:p<0.0005. (J-M) Histological analysis reveals lumenless posterior 
cardinal veins (pcv) in stage 36 (K) and stage 39 (M) Control and EGFL7-depleted 
embryos (J,L), dorsal top, ventral bottom, arrowheads correspond to pcv positions 
enlarged in lower panels (n=3 embryos/condition/stage). (N) mRNA expression of Egfl7, 
miR-126, Casz1, and Flk1 after infection of HUVECs with shEgfl7. Egfl7 is decreased 
11-fold. mRNA levels relative to Rps29 ± SEM. ***:p<0.001; NS: not significant. (O) 
Quantification of cells that round up and detach during imaging. Data represent mean ± 
SEM of 2 experiments conducted on independent batches of shRNA-infected cells. 
(n=100 cells). **:p<0.01. (P) Sprouting angiogenesis assay was performed with control 
and EGFL7-depleted HUVEC. On day 6, cultures were fixed and stained for phalloidin 
and DRAQ5 (blue). Graphs represent mean ± SEM of total sprout length and number of 
branch points/bead (n=11 beads/condition). Experiments were repeated twice on 
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independent batches of shRNA-infected cells. **:p<0.01; ***p<0.001. See also Figures 
S4-S5 and Movies SA1.2 and SA1.5. 
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Figure A1.6. EGFL7 and miR-126 Play Distinct Roles Downstream of CASZ1 
(A) Quantification of cells co-infected with shCasz1 and Ad-Egfl7 or Ad-miR-126 that 
round up and detach versus shCasz1 or control shRNA alone. Data represent mean  ± 
SEM of 2 average experiments conducted on independent batches of shRNA-infected 
cells. (n=100 cells). **:p<0.01; ****:p<0.0005. (B) Quantification of cell morphology 
determined by measuring length-to-width (L:W) ratio. Morphology was improved in cells 
co-infected with shCasz1 and Ad-Egfl7 but not in cells co-infected with Ad-miR-126. 
Data represent mean ± SEM of 3 experiments conducted on independent batches of 
shRNA-infected cells. (n=300-600 cells). **:p<0.01; ****:p<0.0005. (C) RhoA protein 
expression in shRNA-infected HUVECs. RhoA levels were markedly decreased by 
depletion of CASZ1 and EGFL7. Graph of densitometry of RhoA levels relative to 
GAPDH. (D) Relative RhoA, RhoB, and RhoC mRNA expression after shRNA infection. 
mRNA levels relative to Rps29 ± SEM. *:p<0.05; ***:p<0.001; NS: not significant. (E) 
Stress fibers and FAs disrupted in CASZ1-depleted HUVECs resemble cells treated 
with ROCK inhibitor Y-27632 (10M). Restoration of Egfl7 in CASZ1-depleted cells 
rescues proper FA localization. Phalloidin marks F-actin filaments, vinculin (red) and 
phosphorylated paxillin (yellow) mark FAs. See also Figure S6 and Movie SA1.3. 
 
  
191 
 
 
192 
 
Figure A1.7. A model describing CASZ1 function in endothelial cells 
CASZ1 functions by binding to an intronic element within the Egfl7 locus to activate 
proper levels of Egfl7 in endothelial cells. EGFL7 is then secreted to the extracellular 
matrix (ECM) where it likely binds cell-surface receptors which signal downstream to 
activate RhoA expression. Consequently, RhoA signaling modulates endothelial cell 
behaviors such as adhesion and contractility to promote  vessel assembly and 
morphogenesis. 
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Supplemental Figure A1.1. CASZ1 is Required for Vascular Development 
(A) Vascular explants excluding the head, heart, and somitic region were dissected from 
stage 32 embryos for RNA isolation and cDNA synthesis. RT-PCR showed that Casz1 
is co-expressed in this region with other vascular markers, Msr and Erg. Eomesodermin 
(Eomes), a marker of the forebrain and primitive mesendoderm, was a negative control 
while Ef1 was a loading control. (B-I) Whole-mount in situ analysis with EC marker Erg 
of stages 29-39 control and CASZ1-depleted embryos (lateral view with anterior to left). 
Erg was a secondary marker used to confirm vascular defects were not specific to Msr. 
Vessel branching and patterning were severely compromised in CASZ1-depleted 
embryos. Note lack of branching within vitelline vein network (vvn) as well as reduced 
sprouting of intersomitic vessels (isv). Posterior cardinal vein (pcv). (n=10 
embryos/condition/stage, 3 independent experiments). (J-M) Whole-mount in situ 
analysis with EC marker Msr of stage 29 and 39 control and CASZ1-depleted embryos. 
(n=10 embryos/condition/stage, 3 independent experiments). (N-Q) The anterior-most 
region including the cardiac portion was dissected from early tailbud stage 29 control 
and CASZ1-depleted embryos prior to heart tube formation and therefore circulation. 
Explants were cultured until early tadpole stage 36 when the embryo has an established 
circulation and assayed by in situ hybridization with the endothelial marker Ami. (N,P) In 
the absence of functional circulation, control explants form a dense grossly normal 
vascular network similar to un-manipulated embryos (lateral view with anterior to the 
left). (O,Q) In the absence of CASZ1-depleted cardiac tissue and circulation, we 
observe an identical vascular phenotype in the trunk explants as we do in the un-
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manipulated embryo indicating the vascular defects in the CASZ1-depleted embryos are 
independent of the cardiac defects.  
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Supplemental Figure A1.2. CASZ1 is Required for EC Proliferation 
(A) Control and shCasz1 cells were stained with anti-phospho-histone H3 (pH3-red) and 
DAPI (blue) to identify mitotic cells. Images were taken at 25x magnification while far 
right panels were taken at 63x. White arrowheads indicate pH3-positive cells. Graph 
represents quantification of pH3-positive cells. Data represent mean ± SEM of 3 
independent experiments. (n=1000-2500 cells). (B) FACS analysis showing CASZ1-
depleted cells arrest at G1/S with reduced proportion of cells in S phase compared to 
controls. (C) Control and CASZ1-depleted HUVECs were stained with anti-cleaved 
caspase-3 (red) and DAPI (blue) to identify apoptotic cells (top two panels). As a 
positive control, wildtype HUVECs were serum starved for 24 hr to induce apoptosis 
(lower panels). Images were taken at 25x magnification while far left panels were taken 
at 63x magnification. White arrowheads indicate cleaved caspase-3-positive cells. 
Graph represents quantification of cleaved caspase-3-positive cells. Data represent 
mean ± SEM of 2 independent experiments. (n=200-1000 cells). 
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Supplemental Figure A1.3. Sequence Alignment of miR-126 and Expression of 
miR-126 in CASZ1-Depleted Embryos 
(A) Xenopus miR-126 was cloned from genomic DNA and confirmed to be located in 
Egfl7 intron 7. Evolutionary conservation of mature miR-126 is shown. (B-I) Whole 
mount in situ analysis of miR-126 of stage 29-39 control and CASZ1-depleted embryos 
(lateral view with anterior to the left). miR-126 expression commences in the 
vasculature including the vitelline vein network (vvn) at stage 32 (D,E) and remains 
intact at all stages thereafter even in the absence of CASZ1 suggesting that it may be 
differentially regulated than its host gene. Note the robust expression of miR-126 in 
somites (s). (n=10 embryos/condition/stage, 3 independent experiments).    
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Supplemental Figure A1.4.  EGFL7-Depletion Phenocopies CASZ1-Depletion 
During Vascular Development 
(A) RT-PCR analysis of early tailbud stage 29 embryos injected at the one-cell stage 
with 40 ng Egfl7 MO demonstrating inhibition of proper splicing of Egfl7 pre-mRNA. 
Control MO-injected embryos are negative controls and genomic DNA is a positive 
control for PCR amplification. (B-C) Whole mount in situ analysis of miR-126 expression 
in control and EGFL7-depleted early tadpole stage 36 embryos. There are no 
detectable alterations in miR-126 expression in EGFL7-depleted embryos. (D-E) Whole 
mount in situ analysis of Casz1 expression in control and miR-126-depleted early 
tadpole stage 36 embryos. There are no detectable changes in Casz1 expression in 
miR-126-depleted embryos. (F-I) Whole-mount in situ analysis with EC marker Msr of 
stage 29 and 39 control and EGFL7-depleted embryos. (n=10 embryos/condition/stage, 
3 independent experiments). (J-Q) Whole-mount in situ analysis with EC marker Erg of 
stages 29-39 control and EGFL7-depleted embryos (lateral view with anterior to left). 
Vascular branching and patterning were severely disrupted in EGFL7-depleted 
embryos. Vitelline vein network-vvn, posterior cardinal vein- pcv, intersomitic vessels- 
isv. (n=10 embryos/condition/stage, 3 independent experiments). 
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Supplemental Figure A1.5. miR-126 Depletion Does Not Phenocopy CASZ1-
Depletion During Vascular Development  
 (A) Relative expression of miR-126 in embryos injected with miR-126 MO compared to 
control. Bars represent expression relative to miR-16 ± SEM. *:p<0.05. (B-C). Whole 
mount in situ analysis of Egfl7 expression in control and miR-126-depleted early tadpole 
stage 36 embryos. There are no detectable alterations in Egfl7 expression in miR-126-
depleted embryos. (D-E) Whole mount in situ analysis of Casz1 expression in control 
and miR-126-depleted early tadpole stage 36 embryos. There are no detectable 
changes in Casz1 expression in miR-126-depleted embryos. (F-U) Whole mount in situ 
analysis of Msr (F,G,J,K,N,O,R,S) and Erg (H,I,L,M,P,Q,T,U) of stages 29-39 control 
and miR-126-depleted embryos (lateral view with anterior to the left). The vasculature 
forms normally in miR-126-depleted embryos with no apparent disruptions in vascular 
patterning or assembly. Vitelline vein network- vvn, posterior cardinal vein- pcv, 
intersomitic vessels- isv. (n=10 embryos/condition/stage, 3 independent experiments). 
(V-Y) Histological analysis shows normal lumens of pcv in stage 36 (W) and stage 39 
(Y) miR-126-depleted embryos compared to controls (V,X). Dorsal is top, ventral is 
bottom. Arrowheads correspond to positions of pcv which are enlarged in lower panels. 
(n=2 embryos/condition/stage). 
  
202 
 
 
 
 
203 
 
Supplemental Figure A1.6. Efficacy of Ad-Egfl7 and Ad-miR-126 
(A) Western blot of EGFL7 protein in HUVECs infected with control shRNA alone or co-
infected with 25 MOI (multiplicity of infection) Ad-Egfl7. (B) Relative expression of miR-
126 in HUVECs co-infected with shCasz1 and 25 MOI Ad-miR-126 compared to 
shCasz1 alone. mRNA levels are relative to miR-16 ± SEM. *:p<0.05. (C) Phase 
contrast images demonstrate elongated shCasz1-infected cells become more uniform in 
length and width after co-infection with Ad-Egfl7 but remain thin and elongated after co-
infection with Ad-miR-126. (D) RhoA activity in un-stimulated (-) and Thrombin-
stimulated (Thr) shRNA-infected HUVECs. RhoA activity was markedly decreased by 
depletion of CASZ1 and EGFL7. (E) Western blot representing unaltered RhoC protein 
levels in HUVECs infected with shCasz1, shEgfl7, or control shRNA. (F) Western blot 
showing decreased phosphorylation of myosin light chain (p-MLC) in CASZ1-depleted 
HUVECs versus control. Graph represents densitometry of p-MLC relative to GAPDH.  
  
204 
 
 
  
205 
 
Movie SA1.1. Time-lapse imaging of control and shCasz1 HUVECs 
HUVECs infected with lentivirus encoding scrambled sequence shRNA (control) readily 
establish adhesion to the substrate and display very dynamic motility. In addition, cell 
divisions are frequently observed over a 24 hr time period. However, shCasz1-infected 
HUVECs initially adhere to the substrate but round up and detach (33%). Furthermore 
cells display defects in contractility as the trailing edge fails to properly retract resulting 
in thin, elongated cells. In over three independent experiments, a dividing CASZ1-
depleted cell has never been observed. Imaging was performed at 20x magnification 
with images taken every 5 min.  
 
Movie SA1.2. EGFL7-depletion phenocopies CASZ1-depletion in HUVECs  
Depletion of EGFL7 phenocopies adhesion and proliferation defects of CASZ1-depleted 
cells. 43% of shEgfl7-infected cells fail to remain attached to the substrate and instead 
round up and detach (Compare to Movie SA1.1). In over 3 independent experiments, a 
dividing EGFL7-depleted cell has never been observed. 
 
Movie SA1.3. Restoration of Egfl7 or miR-126 levels rescues the adhesion defects 
of CASZ1-depletion 
Co-infection of shCasz1 and an Egfl7-expressing adenovirus (Ad-Egfl7) results in cells 
that maintain adhesion to the substrate and no longer round up (compare to shCasz1 in 
Movie SA1.1). Cells also appear more rounded and spread compared to thin, elongated 
shCasz1-infected alone cells.  Co-infection of shCasz1 and a miR-126-expressing 
adenovirus (Ad-miR-126) also results in cells that maintain adhesion to the substrate 
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and no longer round up (compare to shCasz1 in Movie SA1.1). Note that while adhesion 
is rescued, cells still display trailing edge contractility defects thus maintaining a thin, 
elongated appearance.   
 
Movie SA1.4. Time-lapse imaging of sprouting control and shCasz1 HUVECs 
 HUVECs infected with control shRNA and embedded in fibrin gels extend from the 
beads to form sprouts and branches with neighboring vessels. However, shCasz1-
infected HUVECs initially extend out from the bead but are unable to remain attached to 
the substrate subsequently detaching and preventing sprout formation. Imaging was 
performed over the course of 24 hr between Days 2 and 3 of the assay. 
 
Movie SA1.5. EGFL7-depletion phenocopies CASZ1-depletion in the sprouting 
angiogenesis assay 
shEgfl7-infected HUVECs also fail to properly sprout from the bead due to the inability 
to maintain adhesion to the fibrin gel (Compare to Movie SA1.1).  
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Supplemental Table A1.1. Putative direct targets of CASZ1  
Table represents additional putative CASZ1 direct transcriptional targets that were 
identified through the cloning ChIP screen. 
Putative CASZ1 Targets 
Target DNA 
Location General Function 
N-myc Downregulated Gene 1 (Ndrg1) 3743 bp 3' Cell Growth Pathway 
Jumonji Domain Containing 1A Internal Cell Growth Pathway 
Cyld 8075 bp 5' Cell Growth Pathway 
MDM2 4868 bp 3' Cell Growth Pathway 
MDM4 Internal Cell Growth Pathway 
Cyclin L2 16 bp 3' Cell Growth Pathway 
Inhibitor of Growth 1 (Ing1) 309 bp 5' Cell Growth Pathway 
Gli2 3680 bp 3' Cell Growth Pathway 
Plexin A2 Internal Migration/Adhesion 
Neurexin 3 Internal Migration/Adhesion 
FAT-J Internal Migration/Adhesion 
Wnt1 Induced Secreted Pathway 1 (Wisp1) 
Internal and 
2867 bp 3' Wnt Signaling Pathway 
Novel Band 4.1-like Protein 4 (NBL4) 6788 bp 5' Wnt Signaling Pathway 
Shisa2 Internal Wnt Signaling Pathway 
Prickle1 Internal Wnt Signaling Pathway 
Msx1 8775 bp 5'  Patterning 
Alk2/ACVR1 9351 bp 5'  Patterning 
Troponin T Type 3 (Tnnt3) 4654 bp 5' Structural 
Myosin 5C internal Structural 
Cytochrome b5 internal Metabolism 
Cytochrome b5 reductase isoform 2 10,000 bp 3' Metabolism 
Cytochrome C Oxidase Subunit VIII-Heart 
specific isoform 3859 bp 3' Metabolism 
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Supplemental Table A1.2. Oligonucleotides Used for Quantitative Real-Time PCR 
Gene 
Name Species Forward Reverse 
Egfl7 Human GGGATGACTGATTCTCCTCC CACCAGAAGCCACATCAGCAG 
Casz1 Human CCTTCTCCAAAACAGACTCC GTTTACATCTTCAGTGACGGC 
miR-126 Human/Xenopus TCGTACCGTGAGTAATAATGCG GCGAGCACAGAATTAATACGAC 
Flk1 Human GAAACTGACTTGGCCTCGG GACCCGAGACATGGAATCAC 
RhoA Human CAGTTCCCAGAGGTGTATGTG GCGATCATAATCTTCCTGCC 
RhoB Human GACACCGACGTCATTCTCATG GATGATGGGCACATTGGGAC 
RhoC Human CTACGTCCCTACTGTCTTTG GCAGTCGATCATAGTCTTCC 
RPS29 Human CGGTCTGATCCGGAAATATG CCCGGATAATCCTCTGAAGG 
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Appendix 2: Transcriptional regulation of blood vessel formation: The role of the 
CASZ1/Egfl7/RhoA pathway3 
 
INTRODUCTION 
Formation of a functional vascular system is critical for the delivery of nutrients, 
the removal of waste, and gas exchange. During vasculogenesis, the de novo formation 
of blood vessels, mesodermal cells differentiate into endothelial cell precursors that 
proliferate and migrate to specified locations in the embryo before assembling into cord-
like structures to form the primary vascular plexus (Herbert and D.Y., 2011). 
Redistribution of junctional molecules, establishment of apicobasal polarity, and cell 
morphology changes all facilitate the opening of vessel lumens. These primitive blood 
vessels are further pruned and remodeled by angiogenesis when new vascular 
branches form by sprouting from pre-existing vessels. Additionally, endothelial cells 
become specified to contribute to either the venous or arterial vasculature (Herbert and 
D.Y., 2011). Understanding the molecular and cellular mechanisms underlying 
endothelial cell behavior will enable us to develop more efficacious therapies for 
diseases, such as atherosclerosis, rheumatoid arthritis, and tumorigenesis.  
 The specification of the cardiovascular lineage and the subsequent 
morphogenesis of the heart and vessels depend on the combined activities of a number  
______________________ 
3This chapter previously appeared as an article in the journal Developmental Cell. The original 
citation is as follows: Charpentier, M.S., Dorr, and Conlon, F.L. Transcriptional regulation of 
blood vessel formation: The role of the CASZ1/Egfl7/RhoA-mediated pathway. Cell Cycle 12, 
no.14 (July 2013): 2165.  
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 of transcription factors. Work within our lab revealed a novel role for the transcription 
factor CASZ1 in Xenopus cardiogenesis by regulating cardiomyocyte differentiation 
(Christine and Conlon, 2008). In a recent study, we also showed that CASZ1 is required 
for blood vessel branching and lumen formation in Xenopus embryos, independent of its 
role in cardiac development (Charpentier et al., 2013). At the cellular level, depletion of 
CASZ1 in primary human endothelial cells results in impaired adhesion to the 
underlying substrate, aberrant contractility, and G1/S cell cycle arrest, indicating that 
CASZ1 is necessary for promoting endothelial cell behaviors associated with proper 
vascular assembly (Charpentier et al., 2013). Utilizing a chromatin immunoprecipitation-
cloning screen, we found that CASZ1 modulates these endothelial cell behaviors by 
activating the expression of its direct transcriptional target, epidermal growth factor-like 
domain 7 (EGFL7). Depletion of EGFL7, an endothelial-secreted extracellular matrix 
(ECM) protein, resulted in poorly arborized vascular networks that were devoid of vessel 
lumens, indicating a requirement for EGFL7 in angiogenesis and lumen morphogenesis 
in accordance with previous reports (Nichol and Stuhlmann, 2012; Nikolic et al., 2013). 
Moreover, the EGFL7-deficient vascular networks were similar to those in CASZ1-
depleted embryos. We linked this CASZ1/EGFL7 transcriptional hierarchy to the RhoA 
GTPase signaling pathway, which directly controls the cellular outputs we observed to 
be defective under CASZ1 and EGFL7-depleted conditions. RhoA transcript levels and 
activity were significantly diminished in the absence of either CASZ1 or EGFL7. 
Consequently, formation of actin-based stress fibers and localization of focal adhesion 
markers at sites of substrate contact were aberrant in CASZ1-depleted cells, but these 
defects were rescued by reintroduction of EGFL7.  
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From these results, we propose a model whereby CASZ1 binds to and activates 
EGFL7 gene expression in endothelial cells in order to release EGFL7 into the ECM. 
Through yet unknown mechanisms, we hypothesize that EGFL7 binds to cell-surface 
receptors, such as integrins, to activate a signaling cascade necessary for RhoA 
transcription and its subsequent activity. RhoA then directly modulates endothelial cell 
behaviors, such as adhesion and contractility, to promote the proper assembly of 
vascular networks (Figure A2.1). While we have shown that activation of this pathway is 
necessary for the formation of a functional vascular system from a developmental 
standpoint, it is not surprising that improper activation of such a pathway could lead to 
pathological vascular remodeling in adult tissues, such as during tumorigenesis. While 
highly expressed in developing vessels, EGFL7 is downregulated in the quiescent 
vasculature of the adult, but is upregulated again in response to injury or cellular stress 
(Nichol and Stuhlmann, 2012). Indeed, high EGFL7 levels are correlated with several 
tumors and cancer cell lines, and EGFL7 monoclonal antibodies are currently being 
tested in clinical trials for use in vascular tumor therapies 
(http://www.gene.com/medical-professionals/pipeline) (Nichol and Stuhlmann, 2012). 
RhoA has been shown to be required for lumen formation, but increased RhoA activity 
also induces vascular permeability, which potentially associates RhoA with the unstable, 
leaky vasculature characteristic of tumors (Karlsson et al., 2009). Therefore, uncovering 
the molecular networks underlying embryonic development may provide novel targets 
for the design of therapeutics to treat patients with cancer.  
There have been limited studies on mammalian CASZ1 in both development and 
disease. Recently, the human ortholog of Casz1 was identified and shown to be highly 
218 
 
expressed in adult heart tissue (Liu et al., 2006). The evolutionary role of CASZ1 in 
cardiovascular development is further emphasized by a recent genome-wide association 
study, demonstrating a genetic association between the Casz1 locus and both blood 
pressure and hypertension (Takeuchi et al., 2010). However, despite the essential role of 
CASZ1 in cardiovascular development and human disease, the cellular requirements 
and molecular mechanisms by which CASZ1 regulates cardiac development remain 
unknown. To address these issues, we generated a Casz1 knockout mouse that will 
provide a means to understand mechanistically how this transcription factor functions in 
cardiovascular disease. Future studies include identifying additional transcriptional targets 
of CASZ1 in the heart and vasculature and investigating how CASZ1 regulates 
transcription. To that end, we are undertaking a number of proteomics-based approaches 
to determine how CASZ1 itself is regulated, to identify cardiac and/or vascular-specific co-
factors with which CASZ1 interacts to regulate transcription, and to uncover novel 
downstream pathways dependent on CASZ1 function.  
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 Figure A2.1. Function of CASZ1 in endothelial cells. 
 (A) Proper expression and activity of CASZ1 in endothelial cells results in 
transcriptional activation of Egfl7 and subsequent RhoA activity thereby promoting the 
assembly of a well-branched, lumenized vascular system. (B) Disruption of CASZ1 
function results in cords of endothelial cells lacking a central lumen and angiogenic 
sprouts. Branches that are apparent consist of thin, elongated cells that are unable to 
maintain adhesion to the underlying matrix or existing vasculature. 
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APPENDIX 3: The cardiac TBX5 interactome reveals a chromatin remodeling 
network essential for atrial septation4 
 
INTRODUCTION 
Congenital malformations, or structural birth defects, are the leading cause of 
infant mortality in the US and Europe (Dolk et al., 2010) (Heron et al., 2009). Congenital 
heart disease (CHD) remains the most common congenital malformation, with atrial 
septal defects present in 56 per 100,000 live births. The health problem is compounded 
by the fact that most children are otherwise asymptomatic and that the disease, in most 
instances, has with no identifiable cause. Holt Oram Syndrome (HOS) is an autosomal 
disorder associated with cardiac septal defects and is caused by dominant mutations in 
the T-box transcription factor Tbx5 (Basson et al., 1997; Li et al., 1997). Mice 
heterozygous for a null mutation in Tbx5 display many of the phenotypic abnormalities 
of HOS, while mice homozygous null for a mutation in Tbx5 die by E10.5 due to cardiac 
defects (Bruneau et al., 2001; Moskowitz et al., 2004; Moskowitz et al., 2007). In 
addition to its role in cardiogenesis, Tbx5 is one of the key factors for cellular 
reprogramming of fibroblasts into induced cardiomyocytes (Qian et al., 2012).   
 
 
______________________ 
4This chapter is an article currently in review in the Journal of Clinical Investigation. The original 
citation is as follows: Waldron, L., Kweon, J., Greco, T., Dorr, K.M., Steimle, J.D., Yang, X.H., 
Temple, B., Cristea, I.L., Moskowitz, I.P., and Conlon, F.L. The cardiac TBX5 interactome 
reveals a chromatin remodeling network essential for atrial septation (2015). Journal of Clinical 
Investigation (in review).  
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Whilst Tbx5 is an essential transcription factor for heart development and 
reprogramming, and its disease relevance is well established, there are many critical 
questions unanswered about the mechanism of TBX5 function. It is not understood what 
proteins complex with TBX5 during different stages of cardiac development and 
homeostasis, how these interactions regulate TBX5's choice of distinct transcriptional 
targets, or how these interactions function to activate and/or repress target gene 
transcription. Nor is it known how these events, when disrupted, manifest into CHD. To 
these ends, we initiated a directed proteomic-based approach to identify endogenous 
cardiac proteins that function in association with TBX5. 
 
MATERIALS AND METHODS 
Generation of Tbx5Avi mice 
The targeting construct used to create a conditional knock-in allele of Tbx5Avi was 
created in collaboration with the UNC Animal Models Core and the UNC BAC Core 
(Chapel Hill). Briefly, the biotin acceptor peptide (Avi) targeting cassette was inserted in 
frame to the terminal exon of the Tbx5 gene. Targeted ES cells were selected and 
introduced into B6 mouse blastocysts. High-chimera males were mated with B6 females 
to produce F1 heterozygotes (Tbx5Avi-Neo/+). Incorporation of the Tbx5Avi construct was 
confirmed by PCR and Southern analysis (Supplemental Figure A3.1b), while presence 
of Tbx5Avi mRNA was confirmed by RT-PCR (Supplemental Figure A3.1d). F1 
heterozygotes were crossed with Sox2-Cre mice (Hayashi et al., 2002) to remove the 
neomycin selection cassette in the F2 generation (Supplemental Figure A3.1c). F2 
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compound heterozygous mice were intercrossed to remove the Sox2-Cre allele and 
establish Tbx5Avi/Avi homozygous lines. Tbx5Avi/Avi mice were crossed to Rosa26BirA mice 
(JAX), which have been previously described (Driegen et al., 2005), and intercrossed to 
obtain compound homozygotes. Genotyping was performed by PCR. Genotyping 
primers can be found in Supplemental Table A3.4. Southern probe was designed to 
Tbx5 intron 8. Genomic DNA was digested with EcoRV or BamHI. Animal care and 
animal experiments were conducted in accordance with the Animal Care Committee at 
the University of North Carolina, Chapel Hill. 
Preparation of cardiac nuclei 
Frozen hearts from 4 week old Tbx5Avi/Avi; Rosa26BirA/BirA (n=3, 2 replicates) and 
control mice (n=3) were homogenized using a mortar and pestle in liquid nitrogen. 
Nuclei were prepared as previously described (Franklin et al., 2011) and snap frozen in 
liquid N2.  
Solubilization of protein complexes 
Plasmids were transfected into HEK-293 cells, harvested, and lysed as 
previously described (Kaltenbrun et al., 2013). Cells and nuclear pellets were 
resuspended in lysis buffer (200mM K-HEPES pH 7.4, 1.1M KOAc, 20mM MgCl2, 1% 
Tween-20, 10M ZnCl2, 10mM CaCl2, 0.5% Triton X-100, 500 mM NaCl, 1X protease 
inhibitors (Roche), 1X phosphatase inhibitors (Sigma), optimized for TBX5 complexes. 
Nuclei were then homogenized using a Polytron (Kinematica), and processed for 
immunoprecipitation as previously described (Kaltenbrun et al., 2013).  
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Conjugation of magnetic beads and immunoaffinity purification 
Conjugation of V5 antibody to magnetic beads (Invitrogen), and immunoisolation 
of protein complexes was performed as previously described, (Cristea et al., 2005; 
Kaltenbrun et al., 2013) but modified as follows for streptavidin IPs. Immunoaffinity 
purifications were performed using streptavidin conjugated Dynabeads (Invitrogen) by 
slow rocking at RT for 30 minutes. The isolated protein complex was eluted from the 
beads for 20 min at 95°C in 40L elution buffer (80mM NaOAc pH 9.0, 95% formamide). 
Western blots were probed with mV5 (1:5000, Invitrogen), rCHD4 (1:500, Active Motif), 
mHDAC2 (1:1000, Abcam), rMTA1 (1:5000, Bethyl), rTBX5 (1:1000, Aviva), gTBX5 
(1:500, Santa Cruz) mGFP (1:10000, Clontech). 
Mass spectrometry 
Immunoisolated proteins were analyzed by mass spectrometry as previously 
described (Kaltenbrun et al., 2013). Briefly, tandem mass spectra were extracted by 
Proteome Discoverer (Thermo Fisher Scientific), and all MS/MS samples were analyzed 
with SEQUEST (Thermo Fisher Scientific; version 1.2.0.208), set up to search the 
human and mouse UniProt-SwissProt protein sequence database, assuming digestion 
pattern with trypsin. Scaffold (version Scaffold_3_00_06, Proteome Software Inc., 
Portland, OR) was used to validate MS/MS-based peptide and protein identifications. 
Peptide sequences were deemed a match if they could be established at >95.0% 
probability as specified by the Peptide Prophet algorithm (Keller et al., 2002). In turn, 
protein identifications were deemed a match if they could be established at >99.0% 
probability by the ProteinProphet algorithm and have at least two sequenced peptides. 
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Protein identifications and associated spectral counts were exported to Excel for further 
data processing. 
Interaction bioinformatics analysis 
Protein identifications were filtered to exclude non-specific associations. Proteins 
were retained as specific candidates if they (1) had at least two spectral counts in both 
Tbx5Avi/Avi; Rosa26BirA/BirA replicates with at least 4 spectral counts in one replicate, and 
were uniquely identified or had at least a 2.5-fold spectral count enrichment in the 
Tbx5Avi/Avi; Rosa26BirA/BirA condition versus the control. Candidates were assigned GO 
ontology classification using the UniProt GOA annotations from within the Cytoscape 
(v3.2) platform (Cline et al., 2007). Gene symbols were submitted to the web-based 
STRING database (Franceschini et al., 2013) for interaction network analysis. 
Interactions with a combined STRING score of > 0.4 (medium confidence) were 
retained, exported, and further visualized in Cytoscape. 
Transcriptional assays 
ChIP peak regions from our candidate genes of interest were amplified from 
mouse genomic DNA and subcloned into the PGL3-Promoter Luciferase vector 
(Promega). Primer sequences for each candidate gene are provided in Supplemental 
Table 5. HEK-293 cells were transfected with 600ng total DNA in 12 well plates using 
FuGene6 (Promega) and harvested 48 hours later for transcription assay. 
Transcriptional assays were performed using Dual Reporter Assay System (Promega) 
according to the manufacturer’s protocol.  
226 
 
DNA constructs 
Generation of the Tbx5Avi targeting construct for embryonic stem cells and 
generation of chimeric mice was performed by JrGang Chen (UNC BAC Core-Chapel 
Hill). Tbx5-Avi-V5 was generated by synthesizing an oligo encoding the Avi tag (5’ ggc 
ctg aac gac atc ttc gag gct cag aaa atc gaa tgg cac gaa 3’) and subcloning it into the 
pcDNA3.1/V5-His TOPO vector (Invitrogen). Tbx5 full length and truncations were then 
subcloned into pcDNA3.1-Avi-V5. pEF1-BirA-V5-Neo was generously provided by 
Stuart Orkin (Harvard University) (Kim et al., 2009). GFP tagged full length, C-terminal, 
and N-terminal CHD4 constructs were generously provided by Stephen Jackson 
(Cambridge) (Polo et al., 2010). Site-directed mutagenesis primers are available in 
Supplemental Table A3.6. 
Genetic interaction and histology  
Tbx5fl/fl mice were generously provided by Jon and Christine Seidman (Harvard 
Medical School) (Bruneau et al., 2001). The Tbx5+/- mouse has been previously 
reported (Bruneau et al., 2001). The Mta1+/- mouse line was generated by Harold Olivey 
(Indiana University Northwest) and generously provided by Eric Svensson (Novartis 
Institutes for Biomedial Research). All mice are in a mixed B6/129/SvEv/CD-1 
background and all mouse experiments were performed according to a protocol 
reviewed and approved by the Institutional Animal Care and Use Committee of the 
University of Chicago, in compliance with the USA Public Health Service Policy on 
Humane Care and Use of Laboratory Animals. E13.5 wild type, Tbx5+/-, Mta1+/,- and 
Tbx5+/-;Mta1+/- compound heterozygous embryos were dissected from timed 
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mating between Tbx5+/- and Mta1+/- mice. Embryos were fixed in 4% PFA overnight and 
sent to the Human Tissue Resource Center at the University of Chicago for paraffin 
embedding, sectioning, and H&E staining. Slides were imaged on a Leica DM2500 
microscope and QImaging Retiga 2000R 1394 Color Cooled camera.  
RNA-seq 
Heart tube dissections were performed as described previously (Hoffmann et al., 
2014). Briefly, E9.5 Tbx5+/+ and Tbx5-/- heart tubes were dissected away from the body 
nearest the myocardial reflections and four heart tubes were pooled to isolate sufficient 
RNA. Genotypes were assigned via PCR. Pools of tissue were mechanically 
homogenized in TRIzol Reagent (Invitrogen, Carlsbad CA) and then RNA was isolated 
in accordance to the manufacturer’s instructions. RNA resuspended in water was further 
purified with 500 µl of 1-butanol (4 times) and 500 µl diethyl ether (twice) (Krebs et al., 
2009). Isolated RNA underwent library preparation and 50-bp single-ended RNA 
sequencing at the Genomics Core Facility at The University of Chicago. Briefly, mRNA 
was selected for using an oligo-dT pulldown, and barcoded libraries were prepared 
according to Illumina's instructions accompanying the TruSeq RNA Sample prep kit 
v2 (Lavine et al., RS-122-2001). Library fragments of ~275 bps (insert plus adaptor and 
PCR primer sequences) were quantitated using the Agilent Bio-analyzer 2100 and 
pooled in equimolar amounts. The pooled libraries were sequenced on the HiSeq2500 
in Rapid Run Mode following the manufacturer's protocols (Invitrogen, 2013). 
 To determine statistical significance of transcripts between Tbx5+/+ and Tbx5-/- 
heart tubes, computations were made using a pipeline following quality control, genome 
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alignment, noise filtering, and two-group comparison. Transcripts with an FDR adjusted 
P < 0.05 and absolute fold change>1.57 were accepted as statistically significant. 
Chromatin IP 
HEK-293 cells were transfected with the Kctd16-Luciferase construct used in 
transcriptional assays, as well as wild type TBX5 or TBX5S261C (20 g total DNA) using 
FuGene 6 (Promega). Cells were fixed in 1% PFA for 10 minutes at RT. 10 million cells 
were used per ChIP. Cells were lysed in ChIP Buffer (50mM Tris pH 7.5, 140 mM NaCl, 
1mM EDTA, 1 mM EGTA, 0.1% sodium deoxycholate, 0.1% SDS), sonicated using a 
Branson 450d, 12 cycles, 30s/cycle (1s on, 0.5s off), 30% amplitude), and spun at top 
speed to isolate chromatin. Triton X-100 was added to 1% and added to Chd4-
conjugated Protein G beads (Life Technologies) at 4°C O/N. ChIP was resumed using 
ChIP Protocol (Agilent). ChIP primer sequences are available in Supplemental Table 7. 
TBX5 NID Modelling 
The mouse TBX5 sequence was submitted to the DisProt PONDR-FIT disorder 
predictor in order to identify disordered regions in the protein. Both the entire protein 
and just the NID region were submitted to the fold recognition server HHpred 
(http://toolkit.tuebingen.mpg.de/hhpred) to determine if any suitable templates were 
available for structural modeling.  A small coil-to-helical region involving residues 255-
264 was predicted by HHpred. This region of TBX5 was modeled based on the 
correspondingly small region of the structure of the CRISPR-associated protein [PDB ID 
3VZI]. 
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RESULTS 
Past attempts to isolate endogenous T-box protein complexes have been 
hampered by their relative low abundance and insolubility. Therefore, we knocked-in an 
Avitag epitope into the Tbx5 locus to generate a Tbx5Avi allele (Supplemental Figure 
SA3.1). The Avitag is a small peptide tag that is biotinylated in the presence of the 
bacterial enzyme BirA. Thus, the Avitag/BirA system combines minimal structural 
invasiveness and the specificity and strength of the biotin-streptavidin interaction. This 
is the strongest non-covalent peptide-ligand interaction in nature, and therefore the 
affinity greatly exceeds that of any antibody-antigen interaction (Roesli et al., 2006; 
Wang et al., 2006). Tbx5Avi mice were mated to mice ubiquitously expressing BirA 
(Rosa26BirA) (Driegen et al., 2005). The Tbx5Avi; Rosa26BirA compound homozygous 
mice show no overt phenotype, have no cardiac phenotype, and are fertile. Thus, the 
Avitag appears to have no effect on TBX5 activity and expression of biotinylated 
TBX5Avi is not deleterious. 
 To define the TBX5 cardiac interactome, we performed mass spectrometry 
analysis of immnuoaffinity purified TBX5 complexes from Tbx5Avi/Avi;Rosa26BirA/BirA 
cardiac nuclei (Figure A3.1a). We used an unbiased gene ontology-based 
bioinformatics classification to screen the functions of proteins associated with TBX5. 
This analysis defined a subset of 60 candidate interactions (Supplemental Table 
SA3.1). We analyzed these candidates by functional network analysis; drawing upon 
the STRING database of protein-protein interactions, 40 out of the 60 candidates were 
assigned to a single interconnected network (Figure A3.1b and Supplemental Figure 
SA3.2). This network contained the heterodimeric facilitates chromatin transcription 
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(FACT) complex and several members of the transcription initiation factor TFIID 
complex, both of which play roles in RNA Pol II-dependent gene transcription (Berk, 
1999; Saunders et al., 2003). TBX5 has been long considered to be a cardiac 
transcriptional activator. Surprisingly, in our analysis we identified TBX5 in association 
with multiple components of the NuRD complex (Figure A3.1b, c) which in most 
instances functions as a chromatin modifying complex that represses gene transcription 
(Wade et al., 1998; Xue et al., 1998). We find TBX5 in association with six components 
of the NuRD transcriptional repression complex: CHD4, MTA1, RBBP4, GATAD2a, 
GATAD2b, and HDAC2. Since CHD3 commonly acts in a mutually exclusive manner 
with CHD4, RBBP7 and RBBP4 act redundantly, and an additional component of the 
NuRD complex, MBD3 has been suggested to be dispensable for transcription factor 
recruitment (e.g., by hunchback)(Kehle et al., 1998), we have therefore identified all the 
components required for a functional NuRD complex. We confirmed the interaction of 
TBX5 with multiple members of the NuRD complex in cardiac extracts (Figure A3.1c). 
Taken together these data show TBX5 interacts with components of the NuRD complex 
in heart tissue.  
  To further define the relationship between TBX5 and the NuRD complex, we 
generated mice heterozygous null for Tbx5 and a central component of the NuRD 
complex, Mta1 (Figure A3.2, Supplemental Figure SA3.3). At E13.5, Mta1+/- mice have 
no apparent cardiac defects (Figure A3.2c), whereas Tbx5+/- mice exhibit previously 
described cardiac defects, including ASD, ventricular septal defects (VSD) and 
atrioventricular septal defects (AVSDs) (also known as common atrioventricular canal 
(CAVC) defects (Fig. A3.2d) (Basson et al., 1994; Basson et al., 1999; Bruneau et al., 
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1999; Bruneau et al., 2001; Baban et al., 2014). Tbx5+/-; Mta1+/- heterozygous null 
embryos demonstrated a higher frequency of AVSDs than either heterozygote alone 
(p<0.03) (Figure A3.2e, Supplemental Figure SA3.3d). Taken together these results 
demonstrate TBX5 and MTA1 genetically interact. 
The finding that TBX5 and components of the NuRD complex interact 
biochemically and genetically led us to hypothesize that TBX5 can function to repress 
aberrant gene expression in the heart. To test this hypothesis, we determined the gene 
targets of TBX5 repression. To this end, we performed RNA-seq analysis from E9.5 wild 
type and Tbx5-/- hearts to determine genes differentially expressed between wild type 
and Tbx5 null hearts (Figure A3.3a, Supplemental Table SA3.2). We overlaid TBX5 
ChIP-seq data (He et al., 2011) with genes upregulated in the Tbx5 null heart. From this 
analysis, we identified 928 genes that are potentially repressed by TBX5 (Supplemental 
Table SA3.3). 
To validate the genes putatively repressed by TBX5, we rank ordered the 928 
genes based on relative change in expression between wild type and Tbx5-/- hearts and 
the number of reads in the ChIP-seq data set. From this list, we cloned the top 15 of the 
ChIP peak sequence elements from 14 genes and performed transcriptional assays 
(Figure A3.3b-m, Supplemental Figure SA3.4). Of the candidate genes tested, 11 were 
repressed by TBX5. This set of genes could be divided into two categories: Casz1, 
Fgf11, Gad1, Kcne3, Kctd16, Nxph4, Plekha2, and Sncb are expressed in neural 
lineages23, while Casz1, Col20a1, Fgf11, Gad1, Klf4, Mef2b, and Plekha2 are 
expressed in a divergent subset of cancers (Liu et al., 2011; Huang et al., 2013; Kimura 
et al., 2013; Ying et al., 2013; Hu et al., 2015). Together these data demonstrate that 
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TBX5 functions as a transcriptional repressor and acts in vivo to repress the ectopic 
expression of neural and cancer related genes in the heart.  
To gain insight into the mechanisms of TBX5-NuRD mediated repression, we 
mapped the protein interaction domains of TBX5 and MTA1 and the catalytic core 
component of the NuRD complex, CHD4 (Supplemental Figure A3.5). We found an N-
terminal CHD4 region was required for interaction with TBX5 (Supplemental Figure 
SA3.5c), while a C-terminal TBX5 region was necessary and sufficient for interaction 
with MTA1 and CHD4 (amino acids 238-340) (Figure A3.4a, Supplemental Figure 
SA3.5d,e). We find this hitherto uncharacterized region to be highly conserved across 
48 TBX5 orthologues (Supplemental Figure SA3.6), and have shown that this domain is 
predicted to form a Coil followed by an α-Helix (Figure A3.4b). We have termed this 
structural-functional region of TBX5 the NuRD interaction domain (TBX5NID).  
The majority of TBX5 mutations associated with CHD are located within the T-
box with most leading to a loss of TBX5 DNA binding or non-sense mediated decay 
(Fan et al., 2003b; Fan et al., 2003a; Mori and Bruneau, 2004). In addition, there exists 
a subset of CHD mutations that lie in the C-terminus of TBX5, outside the T-box, and 
the resulting forms of TBX5 are stable and bind DNA. The molecular basis for these 
CHD-associated mutations however, has been entirely unknown. We found TBX5 CHD-
associated mis-sense mutations in the C-terminal region of TBX5 align to the TBX5NID; 
TBX5S252I, TBX5S261C, TBX5V263M, TBX5K266R, and TBX5Q292R (Heinritz et al., 2005). We 
further show that these single TBX5 mis-sense mutations align along a single 
interaction surface of the TBX5NID α-Helix (Figure A3.4c). Thus, we hypothesized the 
CHD mis-sense mutations in the TBX5NID disrupt the TBX5-CHD4 interaction. 
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We tested the prediction that TBX5 mis-sense mutations in the TBX5NID alter the 
TBX5-NuRD association. Three single mis-sense mutations within the TBX5NID 
(TBX5S261C, TBX5V263M, and TBX5K266R) abolished the interaction between TBX5 and 
both CHD4 and MTA1, and an additional two other CHD single mis-sense mutations 
(TBX5S252I and TBX5Q292R) reduced the interaction (Figure A3.4d). These results show 
that disruption of the TBX5-NuRD complex in vivo leads to cardiac abnormalities 
associated with HOS.  
Having demonstrated the TBX5-NuRD interaction is disrupted in CHD-associated 
mutations in the NID, we queried if repression of our TBX5 target genes was NuRD 
dependent. We performed transcriptional assays and observed of our targets repressed 
by TBX5, Kctd16 and Mef2b fail to be repressed by TBX5 CHD associated mutation 
TBX5S261C (Figure A3.4e-f). Moreover, TBX5S261C failed to repress transcription of 
multiple elements of the Mef2b gene (Supplemental Figure SA3.7a-b). Taken together, 
with results showing that we were able to ChIP CHD4 in the presence of TBX5 to these 
elements (Supplemental Figure SA3.7c-d), these results imply the TBX5-NuRD complex 
is required to repress inappropriate gene expression in the heart and further suggest a 
subset of CHD mutants leads to the mis-expression of genes including Mef2b in the 
developing heart. 
 Analysis of TBX5 orthologues demonstrates there is a complete conservation of 
the TBX5NID amino acids mutated in TBX5-associated CHD in animals with a septated 
heart (TBX5S261, TBX5V263, TBX5K266) (Figure A3.4g). In contrast, orthologues of TBX5 
in vertebrates that lack a septated heart have amino acid substitutions at positions we 
show ablate the TBX5-NuRD interaction (Figure A3.4d). Taken together, this data 
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suggests the TBX5-NuRD interaction arose coincident with cardiac atrial septation. This 
hypothesis is further supported by our observations that Tbx5+/-; Mta1+/- compound 
heterozygous mice have a higher frequency of AVSDs than either heterozygote alone 
(Supplemental Figure SA3.3d). AVSDs have been reported in 18 HOS patients, and 10 
have been characterized to date (Kehle et al., 1998). Of these, 6 of the mutations lead 
to the introduction of a stop codon before the TBX5NID and one mis-sense mutation 
maps within the TBX5NID and ablates the TBX5-NuRD interaction (Figure A3.4d). Thus, 
we find a phenotypic correlation between those patients displaying AVSD and the 
genotype of those TBX5 patient mutations lacking or altering the TBX5NID.  
 
DISCUSSION 
 Our results demonstrate a functional requirement for an interaction between 
TBX5 and components of the NuRD complex. Our observation that only a subset of 
TBX5-repressed target genes failed to be repressed by the TBX5 HOS mutation 
TBX5S261C (Figure A3.4e-f, Supplemental Figure SA3.8), strongly implies TBX5 
functions in both a NuRD-dependent and NuRD-independent manner. Moreover, since 
we do not detect an alteration in cardiac genes in TBX5 null heart tissue, these data 
further suggest that the loss of the TBX5-NuRD interaction is not associated with a cell 
fate switch but rather demonstrate that the TBX5-NuRD interaction functions to prevent 
the expression of genes incompatible with normal heart development. 
Our studies demonstrate that a proteomic based approach coupled with protein 
modeling provides a powerful predictive strategy in prioritizing patient mutations. This 
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type of approach should be applicable to the analysis of any protein in any cell or tissue 
type. The power of such an approach is underscored by recent high through-put 
sequencing studies that have led to the identification of a vast number of somatic 
mutations in coding regions of potential disease causing genes. However, exploiting 
such large data sets has proved problematic in that it is not been possible to prioritize 
which mutations are natural occurring, non-disease associated variants and which are 
disease causing. Results presented here demonstrate a novel proteomic-modeling 
based strategy that can lend itself to prioritizing mis-sense mutation and moreover, 
present a potential means to predict the disease associated phenotypes with specific 
mutations. 
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Figure A3.1. TBX5 interacts with the NuRD complex.  
(a) Overview of the isolation and characterization of the endogenous cardiac TBX5 
interactome. (b) Transcriptional TBX5 interaction network. Network nodes, labeled with 
mouse gene symbols, are candidate direct or indirect TBX5 interactions identified from 
affinity enrichment of biotinylated TBX5. Network edges represent known and/or 
predicted functional interactions in the STRING database. Edge thickness reflects the 
combined STRING evidence score for each binary relationship. Thicker edges 
represent increased interaction evidence. Selected transcriptional complexes within the 
network are highlighted in red dashed boxes. (c) Immnuo-isolation of endogenous 
TBX5Avi from cardiac nuclei confirms interaction of TBX5 with endogenous components 
of the NuRD complex.  
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Figure A3.2. TBX5 and the NuRD complex genetically interact.  
Histology staining (Hematoxylin and Eosin) of heart tissue at E13.5 (a) Low 
magnification of a wild type heart. (b) High magnification of a wild type, (c) Mta1+/- , (d) 
Tbx5+/- and, (e) heterozygous null Tbx5+/-; Mta1+/ heart. Note that the Tbx5+/-; Mta1+/ 
hearts exhibited cardiac defects including ASD (asterisk) and AVSD (arrow). Cardiac 
defects are characterized and quantified in Supplemental Fig. 3. as = atrial septum, ivs 
= intervectricular septum, la = left atrium, lv = left ventricle, mv = mitral valve, ra = right 
atrium, rv = right ventricle, tv = tricuspid valve. 
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Figure A3.3. TBX5 functions to represses neural and cancer genes in cardiac 
tissue. 
(a) Schematic overlay between genes upregulated in RNA-seq between wild type and 
Tbx5-/- heart tissue and TBX5 ChIP-seq data20 reveals 928 genes that are both 
upregulated in a Tbx5-/- null and bound by TBX5. (b) Summary of fold change (RNA-
seq) and ChIP-seq peak values of the 15 top rank ordered genes. (c-m) Gene reporter 
elements cloned from potential TBX5 targets in the presence or absence of TBX5. 
Transcriptional assays of target genes show TBX5 acts as a transcriptional repressor in 
11 of 15 elements tested (additional data in Supplemental Fig. 4). Genes defined as 
neural are shown in red, expressed in cancer as blue, or both as purple. * p< 0.05 *** p 
< 0.001. 
  
240 
 
 
 
  
241 
 
Figure A3.4. Congenital heart disease associated mutations of TBX5 disrupt 
TBX5-NuRD complex activity. 
(a) Schematic of human TBX5 protein showing location of a subset of CHD associated 
mis-sense mutations. NID= NuRD interacting domain (aa 238-340). (b) Structural 
rendering of the TBX5NID shows the TBX5NID is comprised of a Coil region followed an 
-Helix. (c) CHD associated mis-sense mutations align along a single surface of the -
Helix and are predicted to disrupt protein-protein interactions (representative aa 
TBX5S261, TBX5V263, and TBX5K266 residues shown in dark blue). (d) IP of V5-tagged 
CHD associated mis-sense mutations of TBX5 probed for CHD4 and MTA1. (e, f) 
Transcription of the regulatory regions of TBX5 target genes in response to wild type 
TBX5 or TBX5S261C. Additional gene targets shown in Supplemental Fig. 4 and 
Supplemental Fig. 8. (g) Phylogenetic comparison of TBX5 orthologues with boot-strap 
values. Sequence of core amino acid residues required for the TBX5-NuRD interaction 
are shown to the right. * p< 0.05 *** p < 0.001. 
  
242 
 
 
  
243 
 
Supplemental Figure A3.1. Generation of the Tbx5Avi knock-in mouse. 
(a) (Top) The Tbx5-Avi targeting cassette contains the biotin acceptor peptide (Avi) 
fused in frame to the terminal coding exon of Tbx5. Neo-neomycin resistance gene. 
PGK- phosphoglycerate kinase-1 promoter. Amp-Ampicillan resistance gene. Exons 
colored brown represent untranslated exons (5’ and 3’ UTR). Exons colored orange 
represent T-box DNA binding domain. Exons colored green represent the nuclear 
localization signal. Exons colored pink represent the activation domain. (Middle) 
Schematic of the Tbx5 recombined locus (Tbx5Avi-Neo) upon homologous recombination. 
(Bottom) Schematic of the Tbx5 locus upon introduction of Cre (Tbx5Avi). (b) Southern 
blot of positive embryonic stem cell clone confirms homologous recombination. (c) 
Southern blot of F2 mice confirms removal of Neo cassette upon introduction of Cre. 
Samples were run on the same gel but were noncontiguous. (d) RT-PCR analysis of 
Tbx5Avi/+ adult hearts demonstrates presence of Tbx5Avi mRNA. 
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Supplemental Figure A3.2. Transcription interaction network assembled by 
STRING analysis.  
Sixty mouse genes corresponding to TBX5 candidate interactions as identified by the 
gene ontology function of transcription were uploaded to the STRING database 
(www.string-db.org). STRING functional relationships were evaluated with default 
settings with text mining disabled. Forty proteins were clustered in a single network, 
reflecting a minimum combined STRING score of > 0.4 (medium confidence) between 
each binary relationship (left). This network was imported to Cytoscape for further 
processing (see Fig. 1). The remaining 20 nodes with scores < 0.4 are illustrated as 
disconnected (right).  
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Supplemental Figure A3.3. TBX5 and the NuRD complex genetically interact.  
Histology staining (Hematoxylin and Eosin) of (a) Mta1+/-, (b) Tbx5+/- and, (c) Tbx5+/-; 
Mta1+/- mice at E13.5. (d) Quantification of cardiac defects seen in all mice. Both chi-
squared and Fisher’s exact test show that the cardiac defects seen in Tbx5+/-; Mta1+/- 
are significant as compared to wild type and Tbx5+/-.  
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Supplemental Figure A3.4. Transcriptional targets not repressed by TBX5. 
(a-d) Gene reporter elements cloned from potential TBX5 targets in the presence or 
absence of TBX5. *** p < 0.001. 
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Supplemental Figure A3.5. The TBX5NID is necessary and sufficient for interaction 
of TBX5 with CHD4.  
(a) Schematic of CHD4 deletion constructs. Phd= Plant homeo domain. (b) Schematic 
of TBX5 deletion constructs. NLS = Nuclear Localization Signal. AD = Activation 
domain. (c) IP of full-length TBX5Avi-V5 with GFP-tagged CHD4 deletions reveals that 
CHD4 interacts with TBX5 via sequences in the N-terminus of CHD4. (d, e) IP of CHD4 
with a TBX5Avi-V5 deletion series demonstrates TBX5 sequences aa 238-340 are both 
necessary and sufficient for interaction with CHD4. This region has been termed the 
NuRD interaction domain. 
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Supplemental Figure A3.6. Sequence alignment of the TBX5NID from 48 TBX5 
ortholgues.  
Height of letters is relative conservation at that residue. 
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Supplemental Figure A3.7. The TBX5/NuRD complex binds to neural and cancer 
genes in vivo.  
(a) TBX5 candidate reporter elements in the presence or absence of wild type TBX5 or 
TBX5S261C. (b) Schematic of ChIP primer locations on Kctd16 element. (c) ChIP of 
CHD4 from cells co-transfected with Kctd16-Luciferase and TBX5. *** p < 0.001. 
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Supplemental Figure A3.8. Targets repressed by TBX5 in a NuRD independent 
manner.  
(a-i) TBX5-repressed gene reporter elements and in the co-transfected with wild type 
TBX5 or TBX5S261C. Genes sorted into neural (red), cancer (blue), or both (purple). * p< 
0.05 *** p < 0.001. 
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Supplemental Table A3.1. Gene-ontology analysis of candidate interactions from 
TBX5 complexes 
 
Supplemental Table A3.2. Genes differentially expressed in E9.5 Tbx5 null hearts 
by RNA-Seq Analysis 
 
Supplemental Table A3.3. Genes potentially repressed by TBX5 
Supplemental Table A3.4. Genotyping primers for Tbx5Avi/Avi; Rosa26BirA/BirA mice. 
Genotyping Primers Sequence 
Wild type Tbx5 F: CGGCGTGCCCAGGACCCTGT 
R: GGCACAGGTCAGCCTTTAGC 
Tbx5Avi F: CGGCGTGCCCAGGACCCTGT 
R: GCGCGCCTTCGTGCCATTCGA 
Sox2-Cre F: GTCCCCTTCTCCATCTCCAG  
R: GCAAACGGACAGAAGCATTT 
Neo F: AGGATCTCCTGTCATCTCACCTT 
R: CTAGAGAATTGATCCCCTCAGAAG 
Presence of BirA F: TTACGCAAGCTGGGTGCAGA 
R: TTACGCAAGCTGGGTGCAGA 
Absence of BirA F: GTGTAACTGTGGACAGAGGAG 
R: GAACTTGATGTGTAGACCAGG 
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Supplemental Table A3.5.  TBX5 target gene primers for transcriptional assays. 
ChIP cloning PCR Primers Sequence 
Casz1-1 F: ATCGGGTACCTGTCCCTTTCTTCTGTCCCA 
R: ATCGGGTACCAGGCATAAGATCGCTGGAAA 
Casz1-2 F: ATCGGGTACCACCATCCATCCTCGTGTAGC 
R: ATCGGCTAGCGCCAAAAACAGTGGCCTAAA 
Col20a1 F: ATCGGCTAGCATCGAGTGTGTCAGCTGTGG 
R: ATCGAAGCTTCCGTGGTGCTGTGTTCTTAC 
Fbxl20 F: GATCACGCGTGGCCCAAGGAATGGGTACT 
R: GATCACGCGTCCACAGTCGCCTCTATCGTC 
Fgf8 F: CGAGGCTAGCCCAGCTCCCTCCTTCCTTTA 
R: CGAGGGTACCGGCAGCTTTCTGTCTTGGTT 
Fgf11 F: GCACAGATCTGGGACTCCCTAACTGTCGTACC 
R: GCACACGCGTCCGCTGGAGCTAGTCAGG 
Gad1 F: CGAGGGTACCCACTGGAATTCCTACCGTGA 
R: CGAGGCTAGCCAAGGCGTTCTGGTCTAAGG 
Kcne3 F: CGCTACGCGTGTGCCACACAGCTACAATAA 
R: CGCTCTCGAGTCCGGTGAACACTGCAATAA 
Kcnn2 F: GATCGGTACCCTGGTCTCCCTGCAGCTTTA 
R: GATCGCTACGGTTGTCCTGGCTCTGTTGCT 
Kctd16 F: AGGACGCGTTGCTTGTGCAAACTCCAGAC 
R: GACCAGATCTAGGCAGGGCGACAGATAGAT 
Klf4 F: ATCGACGCGTCTTGGCGTGAGGAACTCTCT 
R: ATCGAGATCTCGCTCAAATGGGCCTCTA 
Mef2b-1 F: CGAGGTACCTCTTCTCTCGGACGGACCTA 
R: CGAGGCTAGCCACACACACTCACGGCTCTC 
Mef2b-2 F: CGAGGCTAGCCTGCACAGGGACCCACAG 
R: CGAGGCTAGCCTGCACAGGGACCCACAG 
Mef2b-3 F: CGAGGGTACCGCGTGCGATCACCATAACT 
R: CGAGGCTAGCAGGGGCTGCGATGTAGGT 
Nxph-4 F: CGAGGGTACCGCTTGCAGAAGGGTATCTGG 
R: CGAGGCTAGCTAAGCCTCCAGGCATTCAAC 
Plekha2 F: GATCGGTACCTAACTTGGAACCGACCTACG 
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R: GATCGCTAGCTTTCACACCTGAGCGAACTG 
Sncb F: CACGGGTACCTCCCTCCACTGCCTCCAC 
R: CAGCGCTAGCGCTCCAGGGTCCTCCTAGTC 
 
 
Supplemental Table A3.6.  Site directed mutagenesis primer pairs. Amino acid 
changes are represented in bold. 
S252I F: GATGTCTCGGATGCAAATTAAAGAGTATCCTGTGGTTC 
R: GAACCACAGGATACTCTTTAATTTGCATCCGAGACATC 
S261C F: GTATCCTGTGGTTCCCAGGTCGACAGTGAGGCACAAAG 
R: CTTTGTGCCTCACTGTCGACCTGGGAACCACAGGATAC 
V263M F: GGTTCCCAGGAGCACAATGAGGCACAAAGTCACCTCC 
R: GGAGGTGACTTTGTGCCTCATTGTGCTCCTGGGAACC 
K266R F: GAGCACAGTGAGGCACAGAGTCACCTCCAACCACAGC 
R: GCTGTGGTTGGAGGTGACTCTGTGCCTCACTGTGCTC 
Q292R F: CAATTTAGGGTCCCAGTACCGGTGTGAGAATGGTGTC 
R: GACACCATTCTCACACCGGTACTGGGACCCTAAATTG 
 
  
254 
 
Supplemental Table A3.7.  Kctd16 intron 1 ChIP-PCR primer sequences. 
Kctd16 intron 1-1 F: CAAACTCCAGACCACAGGCT 
R: GACAGGTTGCCAGCACTGA 
Kctd16 intron 1-2 F: TCAGTGCTGGCAACCTGTC 
R: GAGCAGTGCAGGCAAGAAAC 
Kctd16 intron 1-3 F: GTTTCTTGCCTGCACTGCT 
R: GAAGGAAAAGCAGCCGGGAA 
Kctd16 intron 1-4 F: TGCTTTTCCTTCCCACCTGG 
R: GGCAGGGCGACAGATAGATG 
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